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A. Introduction*
Metal complexes with open coordination sites have found wide use in molecular 
recognition. They serve as binding sites in the development of chemosensors,1 to study 
metalloenzyme function in bioinorganic chemistry2 or direct supramolecular self-
assembly.3 Lewis-acidic metal complexes can target a large variety of Lewis-basic 
functional groups, which makes them very suitable for the design of synthetic receptors. 
Coordination to metal ions occurs typically with large enthalpies compared to hydrogen 
bond formation, salt-bridges or dipole-dipole interactions. This gives the opportunity to 
study molecular recognition and self-assembly in solvents competing for binding, such as 
water, using coordinatively unsaturated metal complexes as binding sites. A single 
coordinative bond from a guest to a metal-complex host may provide sufficient binding 
energy to result in stable and defined aggregates at micromolar concentrations in water. 
Typically, to achieve tight binding in such environment using weaker intermolecular 
interactions, multiple interactions and large receptor structures are necessary to exclude 
competing solvents.4 However, not all coordinatively unsaturated metal complexes are 
suitable binding sites for molecular recognition of guest molecules. The coordinative bond 
between metal complex and bound guest should be strong, but not too tight. Binding 
affinity and binding kinetics, the on- and off-rates of the ligand, should still allow 
reversibility to keep the important features of molecular recognition, such as self-assembly 
to the thermodynamically most favored structure, dynamic of supramolecular aggregates 
and displacement of a bound guest by a better ligand. Metal complexes, which bind ligands 
at their open coordination sites with milli- to micromolar affinity and rates in the 
millisecond time range or faster are most suitable for self-assembly and molecular 
recognition processes at the laboratory time scale.  
The complementarity of shape and binding sites usually determines the binding selectivity 
of host molecules using hydrogen bonds or electrostatic interactions. This applies equally 
to the small number of oligonuclear metal complex receptors reported until now. However, 
even a single reversible bond between metal complex and ligand shows intrinsic selectivity 
towards the nature of the ligand exceeding its simple Lewis-basicity. The Lewis-basicity of 
a ligand correlates to the hydrogen bond donor or acceptor ability in hydrogen bond 
 
* This introduction is part of a published review: Kruppa, M.; Walenzyk, T.; König, B. 
Chem. Rev. 2005, under revision. 
receptor binding. The strength of the coordinative bond depends additionally on the nature 
of the metal ion and the Lewis basic ligand atom as predicted by the HSAB principle. Such 
selectivity is well documented in metal ion complexation, e.g. by the preferential binding 
of imidodiacetato transition metal complexes to imidazole or pyridine nitrogen atoms. The 
selectivity is useful for receptor design in molecular recognition. 
An obvious prerequisite for a metal complex to serve as binding site is its stability. The 
metal ion should be coordinated thermodynamically and kinetically tight. A reversibly 
bound Lewis-basic guest should not displace the original ligand from the metal ion. This 
calls for multidentate and/or macrocyclic primary ligands for metal ion binding, and indeed 
all reported examples of reversible coordination of a guest to a metal ion-binding site in 
molecular recognition use such ligands. 
Scheme 1. Principle of a coordinatively unsaturated metal complex as binding site for the 
reversible coordination of a Lewis-basic guest molecule 
 
Scope and Limitations 
This introduction will summarise the use of reversible coordination to metal complexes in 
molecular recognition. To be included, the stable metal complex of a primary ligand and a 
transition metal ion must posses unoccupied coordination sites and bind reversibly to a 
complex Lewis-basic guest. The primary ligands at the unsaturated metal complex used as 
binding sites define the scope of this survey. Figure 1 gives the general ligand types that 
are discussed. For each ligand type the discussion is about  
• the typical stability constants of their transition metal complexes,  
• solid state structures from the Cambridge structural data base, in which the primary 
ligand-metal complex coordinates an additional complex ligand,  
• reversible guest binding of the metal complex in homogeneous solution, and 
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• binding processes of metal complexes immobilised on solid supports, such as 
polymers or gold. 
The discussion excludes the solid-state structures and reversible coordination in solution 
the binding of simple inorganic ligands, such a halides or sulfate ions. The purpose of this 
introduction is to provide material supporting the design of functionalised metal complexes 
as synthetic receptors for complex guests, such as peptides, amino acids, heterocycles or 
nucleobases. The range of functional groups covered, which interact with metal 
complexes, is therefore limited to relevant ones for this purpose, such as carboxylate, 
phosphate, aromatic amines, diamines, imines or thiols. 
In addition, complexes with bipyridines or terpyridines as primary ligand are excluded 
from this introduction, because the few examples in which such complexes are solely used 
as metallo-binding sites are difficult to distinguish from the vast majority of applications of 
this complexes in photochemistry and photophysics. The key references for the use of 
bipyridine and terpyridine complexes as binding sites in molecular recognition by Anslyn5, 
6 and others7 are given. 
Porphyrin metal complexes as host binding sites are not covered in this introduction. 
Hamilton8 very successfully used them for protein surface binding. Kral and Schmidtchen9 
reported sugar binding by porphyrin sandwich complexes. In these examples, the large 
hydrophobic porphyrin surface is significant for the binding process in water. The 
formation of a reversible coordinative bond to the central metal ion of the porphyrin ligand 
is ineffectual for the process. Functionalised porphyrin hosts were widely used for guest 
binding. Sanders reported macrocyclic zinc(II) porphyrins and their use as synthetic 
enzymes directing and catalyzing Diels Alder reactions.10 Neutral zinc(II) porphyrin 
reversibly coordinates pyridine derivatives as additional ligand in dichloromethane 
solution. Synthetic porphyrin-based receptors for amino acids11 or nucleobases12 are 
known, but their binding ability is usually restricted to non-competing solvents, such as 
dichloromethane or chloroform. Neutral porphyrin complexes of divalent metal ions, such 
as zinc(II), show only little Lewis-acidity and therefore weak coordination ability of 
additional ligands. Studies using trivalent porphyrin metal complexes as defined hosts 
reversibly coordinating guest molecules are limited.13 The use of porphyrin complexes in 
composite materials or self-assembled aggregates in material science is well documented,14 
but outside the scope of this introduction. 
 
Overall, this introduction† provides a survey of reversible coordination to unsaturated 
metal complexes used in molecular recognition limited to the most important ligand 
classes used so far. The selection of the ligands is defined by the ability of their 
corresponding transition metal complexes to reversibly and tightly bind Lewis-basic guest 
molecules in competing solvents, such as water. This renders the selected complexes 
suitable as potential metal binding sites for synthetic receptors applicable in chemical 
biology or biotechnology, where their use would be most advantageous. 
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Figure 1. Acyclic general ligand types of transition metal binding sites for molecular 
recognition covered in this introduction. 
1. Iminodiacetato (IDA) Complexes 
Heintz first reported the iminodiacetato ligand (IDA)15 in 1862. Since then it has been 
widely used as a chelating ligand for various metal ions, e.g. Cu(II), Ni(II), Zn(II), Co(III), 
Fe(III), Al(III) and Cr(III).16, , , , ,17 18 19 20 21 Table 1 summarises the metal ion binding constants 
of some typical complexes. Complexes with ligand to transition metal ion stoichiometries 
of 1:1 and 2:1 are typical. Metal ion binding constants, thermodynamic and kinetic 
stability are usually very high. Depending on the coordination number of the transition 
metal ion, complexation with the tridentate IDA ligand leaves coordination sites open for 
reversible ligand binding. Therefore, unsaturated IDA complexes qualify perfectly as 
binding sites for molecular recognition of Lewis-basic guests.  
                                                 
† The chapter about azamacrocycles (contained in the published review) can be found in 
the dissertation of Dr. T. Walenzyk 
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Table 1. Overview of binding constants of different metal ions to IDA22
Ion Equilibrium log K 
Cr3+ ML/M.L 
ML2/M.L2
10.9 
21.4 
Co2+ ML/M.L 
ML2/M.L2
6.54 
11.95 
Ni2+ ML/M.L 
ML2/M.L2
8.3 
14.5 
Cu2+ ML/M.L 
ML2/M.L2
10.56 
16.4 
Fe3+ ML/M.L 
ML2/ML.L 
10.72 
9.42 
Zn2+ ML/M.L 
ML2/M.L2
7.15 
12.4 
 
1.1 Structures of IDA Complexes in Solid State 
In the following, we will discuss the solid-state structure of some typical IDA complexes, 
which have coordinated additional Lewis-basic guests. 
1.1.1 Cu(II) Complexes 
A large number of Cu(II)-IDA complexes have been reported and structurally 
characterised. Cu(II) complexes of IDA ([Cu(IDA)(H2O)2]) form polymeric structures in 
the solid state.16,20 The Cu(II) ion coordination geometry is a distorted octahedron.  
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Figure 2. A fragment of polymeric [Cu(IDA)(H2O)2]n.  
A large variety of complexes with IDA,23, , , , , ,24 25 26 27 28 29 N-IDA30, , 2631  or C-IDA25, 32 
derivatives as primary chelating agent and imidazoles30,23,24,25,26 as an additional ligand 
have been studied. The investigation of their structures in the solid state gave several 
interesting correlations: In compounds prepared from equimolar amounts of Cu(II)/IDA/N-
heterocyclic donor, the Cu(II) exhibits a distorted pyramidal coordination (type 4+1) or, in 
some cases, an octahedral coordination geometry (type 4+2 or 4+1+1) is shown.26 The IDA 
or IDA derivative acts as a terdentate ligand with mer-chelation. In contrast, all known 
mixed-ligand complexes having a 1:1:2 Cu(II)/IDA/N-heterocyclic donor ratio show an 
elongated octahedral Cu(II) coordination with the IDA ligand as a fac-terdentate chelate. 
 
F
t
6igure 3. Structure of compound [Cu(MID
he solid state.  
   
A)(ImH)] and [Cu(IDA)[MeImH)(H2O)2]26 in 
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1.1.2 Other Transition Metal IDA Complexes with additional Ligand in 
the Solid State 
The large number of solid-state structures known of transition metal complexes that bear 
an additional typically weaker bound ligand prohibits their discussion in detail. Therefore, 
table 2 summarises all structures found in the Cambridge structural database where an IDA 
transition metal complex coordinates an additional complex ligand. Noticeable is the 
ability of IDA complexes to bind additional N-heterocyclic ligands, in particular imidazole 
and pyridine. The summarised information may guide the design of functionalised IDA 
complexes as chemosensors, for self-assembly or other purposes. 
Table 2. References of X-ray structure analyses selected from the Cambridge structural database of transition metal IDA complexes coordinating an 
additional complex ligand (M = transition metal – IDA complex) 
Metal Ions Additional 
Ligand Cu(II)        Ni(II) Zn(II) Fe(III) Co(III) Cr(III) Mn(II) Ru(II)
O O
MM
R
 
R=Me33    
R=Me34
R=Ph35
R=CH2OH36
R=Ph-OH, CH2 -CH=CH237
R=Me33 R=Me38
R=Me39
R=Ph40
M
NRN
 
R=H25,26,32,41
R=Me 
       
M
NHN
NHN
 
See ref.41, 42
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MNHN
NHN
NNH
 
 
See ref.43
      
N
NH
M
 
See ref.20
       
N
N
CONH2
M
 
See ref.44
       
M
NN
RR
 
R=H28,29,32,45
R=Me46
R=H47
      
M
N
N
 
See ref.32,46
      
See ref.48
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M
N
H
N
H2N
 
See ref.49
       
M
O
N
N N
N
 
See ref.50
       
M
S
N N
S
NH2 NH2
 
       
See ref.51
M
H2N
N2H  
       
See ref.52
NH
MNH2 NH2
 
    
  
See ref. See ref.53 54
N
N
M
M  
See ref.55      
  
NN MM
 
    
  
See ref.  56
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N N
NH2N
NH
M
 
See ref.57  
     
See ref.56
N N
NH2NH
N
M
 
See ref.57,58   
     
HN N
NH2N
N
M
M
+
 
See ref.59   
     
N O
NH2
M  
See ref.60   
     
N
N
H
NH2
O
O
M  
   
   
See ref.61 See ref.62
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1.2 Recognition Processes in Solution 
1.2.1 Peptide and Protein Binding by IDA Transition Metal Complexes 
The affinity of IDA complexes to histidine residues is well documented in the solid state 
and in solution. Its main application is protein purification using metal ion affinity 
chromatography (IMAC) (see chapter 1.3.1). Some examples for peptide and protein 
binding in homogeneous solution are known. 
1.2.1.1 Coordination of two Hexapeptides to Cu(II) and Pd(II) Models of 
Metal Chelation site on IMAC resins 
To improve protein purification methods based on immobilised metal ion affinity 
chromatography (IMAC) (see chapter 1.3.1) a deeper understanding of the interaction 
between protein and metal complex is required. A polyhistidine tail (Hisn=2 to 6) is 
introduced by standard methods of molecular biology on the protein side. This creates 
affinity to an IMAC column.63, ,64 65 By varying the amino acid sequence in the fused tail to 
SPHHGG, milder eluation conditions of tagged proteins were achieved.66,67
The coordination of proteins or the affinity tag region to immobilised Cu(II)-IMAC 
binding sites is difficult to study by direct physical methods. Therefore, Shepherd 
investigated which amino acids or side-chain donors atoms of SPHHGG and HHHHHH 
peptide sequences coordinate to the metal ion.68 The diamagnetic, square-planar 
[PdII(mida)] chelate (mida2- = methyliminodiacetate) was used as a soluble model for an 
IMAC binding site to approximate the distorted tetragonal Cu(II)-IDA coordination 
geometry. The investigation of the binding motif by 1H-NMR measurements assumed 
equilibrium (1). 
 
[PdII(mida)(D2O)] + SPHHGG [PdII(mida)(SPHHGG)] + D2O (1) 
 
EPR spectra and pH dependence of UV/Vis spectra of [Cu(mida)(SPHHGG)] and 
[Cu(mida)(HHHHHH)] provided additional details. From the data, a binding model with a 
three-point contact of the protein-affinity tags to the Cu(II)-IMAC column at pH 7 was 
derived. 
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Figure 4. Geometry of investigated Cu(II) complexes. 
1.2.1.2 Recognition of Flexible Peptides by IDA Complexes in Water 
Since 2000, the group of Mallik reported IDA metal complexes capable of binding strongly 
to histidine patterns of flexible peptides in water.69 To achieve strong and selective binding 
the geometry of the IDA complex and the target histidine pattern need to be 
complementary. 
To demonstrate their concept Mallik designed and synthesised water-soluble peptides with 
three histidine moieties at particular distances apart (12–16 Å). This distance corresponds 
to the inter-histidine distances (His1, His7, and His12 or 14) on the surface of the protein 
carbonic anhydrase. Figure 5 shows the structures of the peptides. 
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Figure 5. Structures of the histidine-containing peptides used in the binding studies. 
From molecular modeling, the distance between the imidazole groups of the histidines was 
estimated to increase by approximately 4 Å when the peptide length increased by a glycine 
unit. The peptide 8 was designed to probe the role of flexibility in the recognition process 
(the inter-histidine distance for 8 was estimated to vary from ∼ 18 to ∼ 23 Å). Peptide 6 
bears a hydrophobic methyl group, while 7 has a hydrophilic amide moiety in the side 
chain to study the effect of hydrophobicity on the recognition process. The monohistidine 
peptides 3 and 2 served as the controls for recognition studies. 
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They designed five Cu(II) complexes (figure 6) as binding sites for these studies with 
distances between the Cu(II) ions estimated to be ∼ 12 Å for 10, ∼ 16 Å for 11, and ∼ 14–
18 Å for 12 and 13. The complex 9 with one Cu(II) ion serves as a control. 
 
X XX
X
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N
H
X
N
H
X
O O
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X
O
OO
O
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X
X =
N(CH2CO2-)2Cu2+
9
10
11 12
13  
Figure 6. Structures of the metal complexes used in the recognition studies. 
Using isothermal titration microcalorimetry (ITC) the binding constant (Kst), reaction 
stoichiometry (n), and enthalpy change (∆H) of the recognition process was determined. A 
solution of metal complex (0.1 – 0.5 mM) in the ITC cell was titrated with a peptide (0.80 
– 5.0 mM) both dissolved in 25 mM HEPES buffer at pH 7.0 and 25 °C. 
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Figure 7. Binding constants of the model peptides with the metal complexes. 
With the distance-matched peptide 5, complex 12 showed a stronger binding affinity (Kst = 
1.19⋅106 M-1) than with a shorter peptide (4, Kst = 104,400 ± 22,800 M-1) or a longer 
peptide (8, Kst = 243,600 ± 24,500 M-1). A hydrophobic side chain on peptide 6 had a 
devastating effect on the affinity for the metal complexes, due to unfavorable entropy 
changes. Introduction of a hydrophilic side chain on peptide 7 also led to large entropy 
losses and consequently decreased the affinity for the metal complexes. For all of the 
systems tested, the metal-ion-free ligands showed no measurable interaction by ITC under 
the same experimental conditions. 
1.2.1.3 Protein Surface Recognition by a Designed Metal Complex 
Extending the results from small peptide model compounds Mallik et al. were able to 
selectively bind to peptides and proteins by recognising unique patterns of surface-exposed 
histidines.70
The target protein was carbonic anhydrase (CA, bovine erythrocyte). CA displays six 
histidines on the surface (1, 7, 12, 14, 61, and 93). The distances separating the histidines 
1, 7, 14 (or 12) are 13 ± 2 Å, 16 ± 2 Å, and 17 ± 2 Å respectively. Three other proteins 
were used as controls (chicken egg albumin, horse skeletal muscle myoglobin, and chicken 
egg lysozyme). Chicken egg albumin (CEA) has the same number of solvent-exposed 
histidines as CA (22, 23, 329, 332, 363, 371), but the pattern is different. Myoglobin (Mb) 
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has seven histidines on the surface (36, 48, 81, 97, 113, 116, 119), but with different 
distribution. Lysozyme has only one histidine (15) exposed on the surface. All of these 
proteins (target and controls) are known to interact with transition metal ions and 
complexes through the surface-exposed histidines.71 In addition to the already mentioned 
complexes 9 – 13, interactions with cyclen 14 were also tested by ITC. 
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Figure 9. Binding constants of the metal complexes with the proteins HEPES buffer, 
25 mM, pH = 7.0, 25 °C). 
Comparison of the binding constants indicated that complex 11 is very selective for CA 
compared to CEA (300:1); with myoglobin, the selectivity is moderate (20:1). For 
myoglobin, two of the cupric ions of 11 may simultaneously bind to two histidine residues 
on the protein surface (His 113 and 116 or 119). This leads to a lower selectivity of 11 in 
distinguishing CA from myoglobin. To demonstrate selective binding of 11 to the target 
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protein, a mixture of CA and complex 9 ([CA] = 100 µM; [9] = 100 µM) was titrated with 
11 ([11] = 0–500 µM). No change in the binding constant was observed for 11. On the 
other hand, when a mixture of CA and 11 ([CA] = 100 µM; [11] = 100 µM) was titrated 
with 9 ([9] = 0–1 mM), no binding was detected. A mixture of the tested proteins (100 µM 
each) was titrated with complex 11 to obtain an unchanged affinity of 11 towards CA 
(280000 M-1). If CA was omitted from the protein mixture, only very weak binding 
(K < 1000 M-1) was detected. 
1.2.1.4 Conjugation of poor Inhibitors with Surface Binding Groups 
To convert a poor inhibitor of carbonic anhydrase into a good inhibitor, surface-histidine 
coordination was used to increase its affinity.72
 
 
Figure 10. Surface-assisted enhancement in the binding of an inhibitor. The inhibitor binds 
at the active site pocket and to a surface-exposed His residue of the enzyme. 
Benzene sulfonamide, a rather weak inhibitor for carbonic anhydrase (Kd = 120 µM), was 
converted to a very good inhibitor for the enzyme (Kd = 130 nM) as a result of this 
conjugation. For proof-of-concept five Cu(II)-complexes (figure 11) were designed and 
synthesised. 
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Figure 11. Structures of tested compounds. 
The length of the spacer separating the benzene sulfonamide group from IDA was varied 
in these complexes. Benzene sulfonamide 20 and the di-Cu(II) complex 21 (lacking the 
benzene sulfonamide moiety) were used as controls for these studies. The binding 
constants of the complexes with carbonic anhydrase (bovine erythrocyte) were determined 
with isothermal titration calorimetry (25 mM HEPES buffer, pH = 7.0). 
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Table 3. Binding parameters of the complexes with carbonic anhydrase 
Compound Binding constant 
[L⋅mol-1] 
Enthalpy  
[kcal⋅mol-1] 
Complex 15 (4.6 ± 0.07) ⋅ 106 -26.4 ± 0.8 
Complex 16 (1.9 ± 0.03) ⋅ 105 -51.7 ± 5.8 
Complex 17 (7.5 ± 0.1) ⋅ 106 -36.9 ± 4.2 
Complex 18 (5.4 ± 0.02) ⋅ 105 -30.3 ± 2.6 
Complex 19 (4.3 ± 0.03) ⋅ 105 -45.5 ± 2.2 
Control 20 (9.0 ± 0.1) ⋅ 103 -31.2 ± 1.6 
Control 21 (22.8 ± 1.3) ⋅ 103 -129.0 ± 3.2 
 
Affinities of the conjugates were considerably higher compared to the controls. Complex 
17 showed the highest affinity for the enzyme, three orders of magnitude higher compared 
to the controls. The similar binding constants for complex 15 (one Cu(II) ion) and 17 (two 
Cu(II) ions) may indicate that one cupric ion binds to one histidine on the surface of the 
protein. 
1.2.1.5 Combination of Cu(II)-IDA and Crown Ether Binding Site 
To amplify crown ether – ammonium ion binding in water König et al. prepared a peptide 
binding luminescenting crown ether, which contains a pendant Cu(II)-IDA complex.73
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Figure 12. The luminescenting benzo-crown ether 22. 
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No response of the emission properties is observed for 22 if treated with KSCN or 
nBuNH3Cl in buffered aqueous solution (50 mM HEPES, pH 7.5, 1 c = 10-5 mol/L, up to 
1000 equiv. ammonium ion), even with large excess of the salts. The aqueous solvent 
competes with the crown ether for the cation binding and the ammonium-crown ether 
interaction is intercepted. The situation changes if the dipeptide His-Lys-OMe is added to a 
solution of 22. Coordination of the N-terminal His to the Cu(II)-IDA complex of 22 makes 
the crown ether-ammonium ion binding intramolecularly and much more favorable. 
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Figure 13. Proposed mode of binding of 22 and His-Lys-OMe. 
Titration of 22 with His-Lys-OMe in HEPES buffer (50 mM, pH 7.5) resulted in a 1:1 
complex as shown by a Job’s plot analysis. With a binding constant of log K = 4.22 ± 0.05 
compound 22 binds the ammonium group of His-Lys-OMe with high affinity in buffered 
water. The emission intensity change of 22 in the presence of His-Lys-OMe can even be 
observed with the naked eye (see figure 14). No emission response is detected under the 
same conditions with the N-terminal acylated dipeptide Ac-His-Lys-OMe, which proves 
the importance of an N-terminal His for the overall binding process. 
 
 
 
 
 
 
 
     (I)                  (II) 
Figure 14. Emission intensity changes of solutions of 22 in buffered water in the presence 
of His-Lys-OMe (II) and without (I). 
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The use of His-OMe resulted in a 2:1 stoichiometry for the His-OMe–22 aggregate. After 
binding of one His-OMe to Cu(II)-IDA one coordination site remains, which can 
accommodate the imidazole moiety of a second His-OMe while its ammonium group is 
bound by the crown ether, leading to an increased emission intensity. The overall binding 
constant of His-OMe to 22 was determined to be log K = 3.8 ± 0.1. The binding motif 
allows the selective detection of N-terminal His groups, which is illustrated by the binding 
of tripeptide His-Gly-Gly. This peptide binds to 22 with the same 2:1 stoichiometry as 
observed for histidine and an overall affinity of log K = 3.71 ± 0.05. In an additional 
binding experiment it could be shown that the designed receptor 22 can selective detect the 
amino acid His among 20 natural α-amino acids. 
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Figure 15. Response of the emission intensity of 22 to the presence of 20 natural α-amino 
acids in aqueous buffered solution (50 mM HEPES, pH 7.5). (Tyr is not soluble in HEPES 
buffer, and the indole emission of Trp interferes with the emission of 22). 
1.2.2 Carbohydrate Recognition in Water 
Several attempts to recognise carbohydrates selectively by means of synthetic receptors 
based on hydrogen bonding, charged interactions, or boronic acids have been made.74,75 
These suitable forces for sugar binding in apolar organic media become far less attractive 
in aqueous media.76 Using metal coordination Striegler et al.77 built up ternary ligand 
Cu(II) complexes for sugar binding in aqueous solutions. In order to find a suitable metal 
complex for selective binding of various carbohydrates (glucose 24, galactose 25, mannose 
26, or maltose 27) they investigated several bi- and tridendate Cu(II) complexes (figure 
16). 
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Figure 16. Structures of the Cu(II) complexes 23, 28-33. 
The Cu(II) complexes from tridentate N- and N,O-ligands [(diethylenetriamine)copper(II)] 
dinitrate [CuDIEN]-(NO3)2 23, [(triazacyclononane)copper(II)] dichloride [Cu(TACN)]Cl2 
28, and N-[{(2-hydroxyethyl)ethylenediamine}copper(II)] dichloride CuHEN 29, 
coordinate hexoses 24-27 in identical stoichiometries. In contrast, decomposition of 
[(ethylenediamine)copper(II)]sulfate 30, [(phenanthroline)-copper(II)] dinitrate 31, 
copper(II)iminodiacetic acid 32, and copper(II)pyridinedicarboxylic acid 33 occurs in 
alkaline solution (pH > 10.4), which prevents the observation of complex formation with 
the investigated sugars. Since strong binding of carbohydrates requires highly alkaline 
pHs, only Cu(II) complexes which are stable under these conditions are useful. Complex 
[Cu(styDIEN)](HCOO)2 34, a potential binding site for molecular imprinted devices was 
also examined. 
Cis-diol fragments are expected to lead to higher binding affinities than trans-diol motifs.78 
The binding constants of the 1:1 complexes of 23, 29, and 34 with 24-27 (scheme 2) were 
determined according to the method of Rose and Drago.79
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Scheme 2. Complex formation of [Cu(styDIEN)](HCOO)2 34 with 24-27 at pH = 12.40 
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Table 4. Apparent binding constants (pK11) for ternary complexes formed from 23, 29, and 
34 with 24-27 
 23 29 34 
Compd. pK11  pK11  pK11  
24 3.73 ± 0.12 3.37 ± 0.31 3.61 ± 0.17 
25 3.70 ± 0.09 3.41 ± 0.43 3.64 ± 0.12 
26 3.68 ± 0.12 3.05 ± 0.41 3.38 ± 0.19 
27 3.75 ± 0.12 3.41 ± 0.26 3.62 ± 0.09 
 
The ternary complexes formed from 24, 25, and 27 with 23, 29, or 34 show similar 
apparent binding constants, while those formed with 26 are a little lower. Striegler et al. 
attributed this to an rearrangement of the ligand–Cu(II)–mannose complex when complex 
formation with a cis-1,2-diol occurs at C2 and C3 instead of the preferred chelation by the 
hydroxyl groups at C1 and C2. 
 
 24 
1.3 Recognition Processes on Solid Surfaces 
1.3.1 Immobilised metal ion affinity chromatography (IMAC) 
Immobilised metal ion affinity chromatography (IMAC) is a widely used technique. It is a 
separation and purification method based on interfacial interactions between biopolymers 
in solution and metal ions immobilised on a solid support. The cross-linked polymer is 
hydrophilic. Introduced in 1975 by Porath and coworkers this purification method is 
presently one of the most popular methods for purification of recombinant proteins.80
Scheme 3. Schematic principle of the IMAC technique81
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This interesting method of reversible coordination of His-tagged proteins to IDA metal 
complexes typically of Ni(II) or Cu(II) led to a huge number of review articles over the last 
decades.82 Due to this comprehensive coverage of the topic and its specific application, we 
will not discuss the IMAC technique in detail in this review and refer the interested reader 
to the cited literature. 
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1.3.2 Molecular Imprinting 
As demonstrated in chapter 1.3.1 the design of synthetic molecules capable of recognising 
chemical entities in a specific and predictable manner is of great fundamental and practical 
importance. The principal paradigm of the molecular design of such materials involves the 
preorganisation of binding sites of the host system (receptor) around complementary 
binding sites of the guest molecule (substrate).83 Wulff and coworkers developed an 
approach to substrate-selective polymers.84 This technique of template polymerisation, also 
known as molecular imprinting, has been used to prepare polymeric materials for 
applications in molecular recognition and chromatographic separations. Template 
polymerisation produces cross-linked polymers containing functional groups strategically 
arranged in the polymer matrix. Arnold et al. report a variation of this template 
polymerisation technique to synthesise rigid macroporous polymers containing (Cu(II)-
IDA) complexes.85,86
Scheme 4. Polymerisation recipe and workup of templated chelating polymers 
N(CH2COO)2Cu
(II)
Cu(II)
N
N
N
N
N(CH2COO)2
Cu
Cu
EDGMA cross-linker
CH3OH, 65°C
AIBN
(i)   Aq CH3OH,
(ii)  Triazacyclononane
(iii) EDTA
CuCl2
 
 
For initial studies of template polymerisation using metal ion complexes a set of model 
templates was developed. Each of these templates 34-40 bears imidazole functionalities 
with slightly different arrangements. Compounds 41 and 42 are structural analogs of 
compounds 35 and 36 that contain no imidazole ligands for coordination of the metal ions. 
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Figure 17. Set of imidazole templates 35-39 and structurally related pyrroles 41 and 42. 
In order to incorporate Cu(II) into the polymer at positions corresponding to the imidazole 
ligands of the templates, individual template-monomer assemblies were polymerised in the 
presence of a large excess of cross-linker. A control polymer with a random distribution of 
copper ions (P-1) was also prepared using the monofunctional ligand 1-benzylimidazole 
(40). 
Table 5. Polymerisation and characterisation of metal-complexing polymers 
recovery of polymer 
code 
template used 
(mmol/g) 
Cu(II) in 
polymer 
(mmol/g) 
Cu(II) 
(mmol/g) 
template (mmol/g) 
P-1 40 (0.51) 0.52 0.48 0.49 
P-2 35 (0.26) 0.52 0.47 0.26 
P-3 36 (0.27) 0.53 0.49 0.26 
P-4 37(0.25) 0.54 0.50 0.23 
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To determine some of the factors that influence the ability of the templated polymers to 
discriminate template from nontemplate molecules, individual and competitive binding 
was studied. Experiments with the nontemplated polymer (P-1) were used to distinguish 
non-specific metal ion binding from specific coordination. 
Table 6. Substrate binding by templated and nontemplated polymers under saturation 
rebinding conditions 
entry polymer substrate substrate bound 
(mmol/g) 
1 P-1 35 0.46 
2 P-1 36 0.44 
3 P-1 37 0.45 
4 P-1 38 0.44 
5 P-2 35 0.33 
6 P-2 36 0.22 
7 P-2 37 0.19 
8 P-2 38 0.18 
9 P-3 35 0.17 
10 P-3 36 0.24 
11 P-4 37 0.20 
12 P-4 38 0.24 
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Table 7. Selectivity of templated and nontemplated polymers during competitive rebinding 
of bis(imidazole) substrates 
entry polymer substrates relative selectivity during 
rebinding 
1 P-1 35 + 36 α35/36 = 1.02 
2 P-2 35 + 36 α35/36 = 1.17 
3 P-2 35 + 37 α35/37 = 1.35 
4 P-2 35 + 38 α35/38 = 1.32 
5 P-3 35 + 36 α36/35 = 1.15 
6 P-4 35 + 37 α37/35 = 1.22 
 
As shown in table 6, this random polymer binds nearly equal amounts of the four different 
bis(imidazole) substrates 35-38. P-1 also exhibits no selectivity in a competitive binding 
experiment. In contrast, polymers prepared in the presence of a bis(imidazole) template 
show preferences for their own templates in both saturation and competitive rebinding 
experiments. The larger the structural differences between the substrates, the more 
pronounced are the selectivities. In the competitive rebinding experiments, P-2 shows a 
small but measurable selectivity for its own template over the close structural analog 36, 
which differs only in the orientation of the imidazole groups. (35 and 36 are in fact so 
similar that it is impossible to separate them by RP-HPLC). The separation factor increases 
to above 1.3 when the polymer is used to distinguish template 35 from substrates 37 and 
38, which have imidazole groups with larger distances. 
Molecular imprinted polymers can also be used as selective adsorbents. However, 
chromatographic separation with these polymers showed the need to optimise the 
imprinting process. The relatively high degree of crosslinking needed to capture a specific 
arrangement of functional monomers in the solid polymer prevents the diffusion of 
substrates in the particles, which leads to band spreading and poor peak resolution. Access 
of very large substrates to binding sites can thus be severely impeded. 
One approach to overcome these problems is to graft the monomer-template assemblies 
and a crosslinker onto a reactive support with the desired physico-mechanical 
properties.87,88 Arnold and his group has investigated poly(trimethylpropane 
trimethacrylate) (TRIM, 45) as a reactive surface for template polymerisation.89
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Figure 18. Monomers used for molecular imprinting. 
During the polymerisation, it is necessary that the monomer-template assembly is held 
together by strong metal-to-ligand interactions. Unfortunately, very strong interactions 
with the template can interfere with the material’s subsequent chromatographic 
performance. Tightly bound substrates experience very long retention times and excessive 
band spreading. Replacing the metal ion used during imprinting (Cu(II)) by others better 
suited for the chromatographic separation [i.e. Zn(II)] yields adsorbents capable of 
separating closely related bis-imidazole substrates. This “bait-and-switch” approach can 
significantly enhance the performance of molecular imprinted materials. 
Chromatographic separation experiments with bis-imidazoles (35-37, 40, 41) showed the 
expected results. Retention of the imidazole-containing compounds on materials loaded 
with Cu(II) was so strong that no peaks were observed during isocratic elution. Substrate 
retention times were greatly reduced when the Cu(II) ions were replaced with Zn(II). 
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Table 8. Capacity factors (k´) and chromatographic separation factors (αi,j) for imidazole 
and substrates 37-40 on polymer-coated silica (LiChroshere 1000) prepared using 37-40 as 
templates 
Substrate Material prepared using: 
 37 38 39 40 
 k'í (α37,i) k'í (α38,i) k'í (α39,i) k'í (α40,i) 
Imidazole 0.75 1.16 0.69 8.1 1.5 5.8 1.7 6.6 
37 0.87 - 0.69 8.1 1.7 5.1 1.8 6.3 
38 2.9 0.30 5.6 - 6.6 1.4 7.7 1.5 
39 2.6 0.33 3.5 1.6 8.7 - 6.3 1.8 
40 2.7 0.32 1.5 3.9 2.9 3.0 11.3 - 
Elution volumes (Ve) were measured on 50 x 4.6 mm I.D. columns, 0.5 ml/min 100% 
methanol, 65 °C, with a sample size of 10µl of 0.4 mM solution. The mobile phase 
contained zinc acetate in the following concentrations: experiments on 37-templated 
material, 50 mM; 38-templated material, 50 mM; 39-templated material, 40 mM; 40-
templated material, 30 mM. k´= (Ve-Vo)/Vo, αi,j = (Ve-Vo)i/(Ve-Vo)j 
 
The material, which was prepared with the monodentate coordinating template 37, retains 
the three bis-imidazole substrates 38, 39, and 40 to very similar extents. The binding sites 
in this “random” material have no basis to discriminate among the compounds. When the 
polymer-coated silica was prepared using bis-imidazole 38, 39, or 40, as the template, the 
template was always the most strongly retained analyte. 
In 1997, the same group reported an approach to preparing stereoselective ligand-exchange 
supports using molecular imprinting.90 Several aliphatic and aromatic amino acids were 
investigated in order to evaluate the role of the side group in stereodifferentiation. 
Comparison with an achiral monomer based on iminodiacetate showed that the 
enantioselectivity of the adsorbent arises from the chirality of recognition sites created 
during polymerisation. 
Scheme 5. Source of enantioselectivity in imprinted ligand-exchange materials. Molecular 
imprinting with L-Phe gives a cavity that is selective for L-Phe. (a) The L-isomer can 
simultaneously chelate to a metal ion and fit into the shape-selective cavity. (c) Rebinding 
of the D-isomer is hindered because chelation of the metal ion by the D-isomer is sterically 
unfavorable. (b) Alternately, if the molecule fits into the cavity, it cannot chelate Cu(II). 
This idealised picture of the origin of enantioselectivity is probably only true for a small 
fraction of the binding sites. 
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1.3.3 Metal Chelating Lipids 
As the specific targeting of proteins to interfaces is important for applications in 
biomedicine and to study protein interactions in biological membranes Arnold et al. 
prepared chelating amphiphiles.91 For targeting proteins to monolayer and bilayer 
assemblies, they synthesised a lipid with an IDA moiety in the head group (46). When 
loaded with Cu(II), small quantities of this IDA-lipid in monolayers and liposomes of 
distearoyl phosphatidylcholine (DSPC) effectively bind a small histidine-rich protein, 
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myoglobin. Horse heart myoglobin contains 11 histidines, of which at least four can 
coordinate to Cu(II)-IDA.92
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Figure 19. Cu(II)-IDA-lipid 46. 
The binding studies focus on myoglobin interacting with monolayers and vesicles of DSPC 
and IDA-lipid 46 containing Cu(II) or Ca(II). Because imidazole is not a good ligand for 
Ca(II) (Ka = 1.2 M-1),93 this divalent ion provides a noncoordinating surface for 
comparison. Monolayer surface pressure-area (π-A) isotherms, measurements of protein 
binding to liposomes, and ESR analyses of Cu(II)-containing liposomes in the presence of 
unmodified and diethyl pyrocarbonate (DEPC)-modified protein were used to examine the 
lipid – protein interactions. The results indicated that myoglobin is binding to these 
artificial membrane assemblies. The binding is significantly enhanced by coordination of 
surface histidines to Cu(II) ions immobilised at the membrane surface (Ka > 106 M-1). 
One year later in 1995, the same group synthesised a new IDA-lipid unit.94 In addition to 
the targeting function, it is also desirable to have the capability to directly probe molecular 
redistribution or assembly that accompanies protein binding. Thus the new IDA-lipid 47 
(PSIDA) incorporated a fluorescent pyrene label in the lipid tail. 
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Figure 20. Fluorescent IDA-lipid 47. 
These emitting probes of the lipid membrane are sensitive to protein binding and 
recognition of lipid components. In the course of studying ligand-induced reorganisation of 
the fluorescent lipid 47 in membrane assemblies, Arnold and his group observed that metal 
ion binding can strongly affect the ratio of the excimer to monomer emission intensities. 
The pyrene-labeled IDA lipid also serves as a membrane “receptor mimic” in that binding 
of external ligands can induce its reorganisation in the membrane and change its 
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fluorescence properties.95,96 Using these properties of the modified lipid, they show that a 
small globular protein, the soluble domain of cytochrome b5, can be targeted with high 
affinity to PSIDA-containing lipid monolayers via metal coordination to a six-histidine 
peptide appended to the protein’s C-terminus (6-His cyt b5). The poly(histidine) fusion 
peptide and metal-chelating IDA lipid comprise an effective and versatile system for 
targeting proteins to lipid assemblies. 
 
Figure 21. Fluorescence micrographs of fluorescein labeled 6-His cyt b5 in the presence of 
metal-chelating lipid monolayers spread on a buffered subphase (20 mM MOPS, 100 mM 
NaCl, pH 7.5) at π = 25mN/m. (A) 10% PSIDA-Ni(II), (B) 10% PSIDA, no metal, (C) 
30% PSIDA-Ni(II), (D) 30% PSIDA, no metal, (E) 100% PSIDA-Ni(II), and (F) 100% 
PSIDA, no metal. 
In 1997 Arnold et al.97 reported the use of such metal-chelating lipids in the application of 
2D protein crystallisation. A 2D protein crystallisation requires the immobilisation and 
orientation of a protein at the monolayer surface in high concentration, without loss of 
mobility.98 This mobility is supplied largely by the lipid monolayer. Crystallisation is 
generally performed using fluid-phase monolayers. For targeting proteins to the interface, 
various classes of interactions have been employed. In most cases, specific ligands have 
been used to promote crystallisation. In each instance, a unique lipid containing the 
appropriate affinity ligand was required. Using the concept of targeting proteins through 
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coordination of amino acid side chains to lipid-bound metal ions the same metal-
containing lipid can be used to bind to a large variety of peptides. For this purpose lipid 48 
was specifically designed for 2D crystallisation. 
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Figure 22. Metal chelating lipid 48. 
Unsaturated oleyl tails are utilized to provide the required monolayer fluidity. The utility 
of this lipid for 2D protein crystallisation is demonstrated using the tetrameric protein 
streptavidin. Fluorescence microscopy is used to confirm and further characterise the 
streptavidin crystallisation process. 
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2. Nitrilotriacetato (NTA) Complexes 
2.1 Structures 
First published in the same year as the IDA ligand, nitrilotriacetic acid (NTA) has been 
widely used as a chelate for more than 60 metal ions.99 Most common are NTA complexes 
of Al(III),100 Cu(II),101 Cd(II),102 Ni(II),103 Zn(II),104 Cr(II and III),105 Fe(II and III)106 and 
Co(II and III).107 Table 9 summarises the metal ion binding affinity for some typical NTA 
complexes. 
Table 9. Overview of binding constants of different metals towards NTA22 measured at 
20 °C (* = 25 °C)
Ion Equilibrium log K 
Fe2+ ML/M.L 
ML2/M.L2
8.33* 
12.8*
Co2+ ML/M.L 
ML2/M.L2
10.38 
14.33 
Ni2+ ML/M.L 
ML2/M.L2
11.5 
16.32 
Cu2+ ML/M.L 
ML2/M.L2
12.94 
17.42 
Fe3+ ML/M.L 
ML2/M.L2
15.9 
24.3*
Cd2+ ML/M.L 
ML2/M.L2
9.78 
14.39 
Zn2+ ML/M.L 
ML2/M.L2
10.66 
14.24 
Al3+ ML/M.L 11.4 
 
2.1.1 Cu(II) complexes 
The higher stability of the NTA complexes in comparison to the corresponding IDA 
analogues is due to the additional coordinating ligand site. Carboxylate donor groups and 
the central nitrogen atom provide the tetradentate chelation. The chelation of a Cu(II) ion 
leads to the formation of three five-membered rings.108
 
Figure 23. Structure of the Cu-NTA chelate in the solid state. 108
The two remaining coordination sites on the copper ion can bind to Lewis-basic donor 
atoms.109 Figure 24 shows two Cu(II)-NTA complexes and a trans-1,2-bis(4-
pyridyl)ethylene (bpe) as bridging ligand. 
 
 
Figure 24. X-ray structure of [Cu2(nta)2(bpe)]2- (b).  
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2.1.2 Ni(II) complexes 
Ni(II)-NTA complexes were used to coordinate nucleobases as additional Lewis basic 
ligands.110 The crystal structures of co-crystals of Ni(II)-NTA and adenine or cytosine 
demonstrate the potential of NTA complexes to form aggregates with such biologically 
interesting ligands. However, the X-ray structure reveals that hydrogen bonds and not a 
reversible coordination stabilise the aggregate of nucleobase and metal complex. 
 
 
 
Figure 25. Molecular structure of [Ni(nta)(H2O)2]⋅(cytosinium)⋅2 H2O in the crystal. 
2.1.3 Zn(II) complexes 
The structure of the Na[Zn(NTA)(H2O)] is isomorphous with the Na[Cu(NTA)(H2O)] 
discussed above.111 The structure consists of an intricate network of ligand-bridged 
coordination complexes. Two coordination sites, which remain vacant after NTA 
coordination of the Zn(II) ion are occupied by non-chelating O atoms from other 
[Zn(NTA)]- ions. 
 
Figure 26. Structure of the Na[Zn(NTA)(H2O)] complex in the crystal. 
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2.1.4 Cr(III) complexes 
Chelating Cr(III) metal ions by NTA leads to different species in solution, depending on 
the pH.112 Solutions of pH 5.5 result in the formation of Cs2[Cr(nta)2(µ-OH)2]⋅4H2O, while 
solutions at pH 1 give [Cr(nta)(H2O)2] and at pH 5-6 [Cr(nta)(H2O)(OH)]- is obtained. A 
similar complex is formed when acetate is added (figure 27).113
 
 
Figure 27. Molecular structure of the dimeric unit in K2[Cr(nta)(OH)(acetato-
O,O)Cr(nta)]⋅4H2O in the solid state.113 
The best investigated ligand for Cr(III)-NTA is imidazole.114 The crystal structure of figure 
28 shows two imidazole residues coordinating to the Cr(III) ion. 
 
Figure 28. Crystal structure of Cr(III)-NTA coordinating additional imidazole groups.  
 39
2.1.5 Fe(III) complexes 
A more oxophilic metal complex is obtained with Fe(III) ions as chelated metal ion with 
NTA. The octahedral coordination geometry of the complexes is similar to structures 
obtained with other metal ions.115
 
 
Figure 29. Structure of [Fe(nta)Cl2][pyH]2 in the solid state.116
The oxophilic character of these Fe(III)-NTA complexes is illustrated by their ability to 
bind to β-keto-carboxylates. The antibiotic ciprofloxacin coordinates to the iron center by 
its carboxy and keto oxygen atoms. 
 
 
Figure 30. Structure of [Fe(cip)(nta)] (cip = ciprofloxacin) in the solid state.117
 40 
2.1.6 Co(III) complexes 
NTA metal complexes with Co(III) ions have been investigated in detail. Crystal structures 
with NTA acting as a tridentate ligand,118 tetradentate NTA ligand,119 oxo-bridged Co(III)-
NTA complexes,120 complexed carbonate ions (see figure 31)121 and complexed amino 
acids (see figure 32)122 have been reported. 
 
 
Figure 31. Structure of the [Co(nta)(CO3)]2- anion in the solid state. 
 
 
Figure 32. Structure of trans(N)-[Co(bcmpa)((R)-phe)]- anion in the solid state. 
Overall, the reported crystal structure analyses of NTA complexes with Cu(II), Cr(III), 
Zn(II), Co(III) or Fe(II) ions, which coordinate additional ligands, show similar 
coordination geometries for the metal ion and the NTA ligand.  
2.1.7 NTA complexes in solid state (tabulated) 
Table 10 summarises all X-ray structures registered at the Cambridge Crystallographic 
Database according to the selection criteria previously mentioned.  
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Table 10. References of X-ray structure analyses selected from the Cambridge structural 
database of transition metal NTA complexes coordinating an additional complex ligand (M 
= transition metal – NTA complex) 
Metal Ions Additional 
Ligand Cu(II) Ni(II) Co(III) Fe(III) Cr(III) 
O O
MM  
    See ref.  
OO
O O
M
 
   See ref.   
M'
OO
O O
M
 
  See ref.123   
M
O
O
 
   See ref.124  
O
O O
M  
  See ref.    
O
O O
MM  
   See ref.125  
NH N M
 
    See ref.  
N
NH+
NH2
N
N
H
M
 
 See ref.     
M
NH2
NH2  
  See ref.126   
M
NH2
N
Et Et  
  See ref.    
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M
NH2
NH2  
  See ref.127   
N
N
M
M
 
See ref.128     
N
M
N
M
 
See ref.      
N
N
M
N
N
M
 
See ref.129     
M'M
NN
NN
 
    See ref.130
M
N
N
 
   See ref.131  
M
NH2
O O
R
 
  R=Gly, Leu, Phe, Trp    
M
N
H
NH
O
O
N
O
O
 
  See ref.132   
M
NO
F N
N
H
O
 
   See ref.   
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2.2 Recognition Processes in Solution 
2.2.1 Interactions of Acids, Amino Acids and their Esters with Divalent 
Metal NTA Complexes 
Angelici et al. studied the interactions of complexes of divalent metal ions and 
quadridentate ligands with amino acids and their esters.133 Divalent ions used for these 
experiments are manganese, cobalt, nickel, copper, zinc and lead. Binding constants of 
amino acids to these metal complexes were determined using potentiometric 
measurements. Titration data of stoichiometric mixtures of [Cu(NTA)]- and Gly or EtVal 
were fitted to the equilibrium shown in scheme 6, which involves the formation of a Cu(II) 
hydroxo species. The titration data show that hydroxo complex formation occurs only by 
the displacement of the acid or ester (E). 
Scheme 6. Binding equilibrium between ester (E), hydroxo anion and [Cu(NTA)]-
Cu(NTA)-
OH-                E 
E + Cu(NTA)(OH)2-
+ +
Cu(NTA)(E)- + OH-
KOH Kf
Kd
 
 
Kd = [MZOH2-][E]/[MZE-][OH-] = KOH/Kf, where Kf  is the formation constant of the acid 
or ester with [Cu(NTA)]-.134 Similar experiments were carried out with the other metal 
ions; table 11 summarises the resulting data. 
Table 11. Aggregate formation constants of [M(NTA)]- with glycine and ethyl valinate at 
25 °C 
M2+ Log KfEtVal Log KfGly
Mn 2.39 ± 0.02 2.24 ± 0.005 
Co 1.88 ± 0.014 3.65 ± 0.014 
Ni 2.03 ± 0.011 4.95 ± 0.011 
Cu 2.88 ± 0.002 5.46 ± 0.008 
Zn 1.58 ± 0.08 3.64 ± 0.007 
Pb 1.55 ± 0.10 1.93 ± 0.009 
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The assumption was made that only a mono ester complex is formed with a 1:1 ratio of 
[M(NTA)]- and the ester. This is supported for copper ions by the observation that only a 
mono amine complex is observed with [Cu(NTA)]- even in the presence of a 50-fold 
excess of ammonia. Measurements with other metal ions did not indicate the formation of 
bis-ester complexes under the experimental conditions. The authors do not report species 
distribution plots, therefore the pH at which complete aggregate formation occurs in 
solution remains unclear. 
Table 12. Aggregate formation constants of [Cu(NTA)]- with amino acids and their esters 
at 25 °C (log standard deviation <0.01) 
Acid pKa Log Kf Ester pKa Log Kf
Gly 2.35 
9.78 
 
5.44 
Me 
Et 
n-Bu 
7.62 
7.68 
7.78 
3.06 
3.15 
3.33 
Ala 2.34 
9.87 
 
5.42 
 
Et 
 
7.91 
 
3.10 
Phe 1.83 
9.13 
 
4.99 
 
Et 
 
7.12 
 
2.77 
Leu 2.36 
9.60 
 
5.35 
 
Et 
 
7.64 
 
2.79 
Val 2.32 
9.62 
 
5.10 
 
Et 
 
7.75 
 
2.88 
β-Ala 3.55 
10.35 
 
4.56 
 
Et 
 
9.13 
 
3.65 
His 1.85 
6.04 
9.12 
4.16 (monodentate) 
 
5.73 (bidentate) 
 
Me 
 
7.23 
3.98 
 
4.90 
 
The coordination of His and MeHis to [Cu(NTA)]- leads to more complex equilibria, as 
these ligands are potentially tridentate. Cu(II)-His systems contain mixtures of species in 
which His is coordinated either as anion or in its zwitterionic form.135
Blakney et al. measured the binding constants of Gly to Cd(II)- and Zn(II)-NTA using 
NMR techniques.136 The results confirm previously reported data from potentiometric 
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titrations. In 2003 Crumbliss et al. reported ternary complexes of Fe(NTA) with phosphate 
and acetohydroxamic acid.137 The investigated overall reaction is shown in equation 1, 
where Fe(NTA)(aq)m- and HxPO4n- represent the various hydrolyzed and protonated forms of 
the reactants, depending on pH. 
 
  Fe(NTA)(aq)m- + HxPO4n- ? Fe(NTA)HxPO4(aq) p-   (1) 
 
The kinetics of the complex formation was followed using UV-spectroscopy and the same 
reaction was carried out with acetohydroxamic acid replacing phosphate. 
2.2.2 Hexahistidine-Tag-Mediated Fluorescent Labeling with (Ni(II): 
Nitrilotriacetic Acid)n – Fluorochrome Conjugates138
Structural and mechanistic characterisation of proteins by fluorescence resonance energy 
transfer (FRET) requires the ability to incorporate fluorescent probes at specific, defined 
sites. Proteins lacking these specific sites need to be modified. One strategy involves use of 
the “hexahistidine tag“139 – i.e., the amino acid sequence His6 – to target site-specific 
fluorescent labeling. The hexahistidine tag is known to interact tightly with transition-
metal complexes, including Ni(II):nitrilotriacetic acid (Ni(II):NTA). The hexahistidine tag 
can be introduced at protein termini or internal sites by using standard molecular-biology 
procedures. These tags should interact tightly with (Ni(II):NTA)n-fluorochrome conjugates 
(figure 33). 
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Figure 33. Schematic representation of the mode of interaction of 49a or 49b with the 
hexahistidine tag. 
To test these hypotheses Kapanidis et al. synthesised derivatives of the widely used 
cyanine fluorochromes Cy3 and Cy5. Fluorescence anisotropy experiments established that 
49a and 49b exhibit high affinity for the hexahistidine tag (KD = 1.0 µM for 49a; KD = 
0.4 µM for 49b). Thus, titration of 49a and 49b with an otherwise identical protein lacking 
a hexahistidine tag results in little or no increase in fluorescence anisotropy. FRET 
experiments confirm that 49a and 49b exhibit high affinity and high specificity for the 
hexahistidine tag (KD = 0.9 µM for 49a; KD = 0.3 µM for 49b; specificity >95%). 
2.2.3 Arginine Carrier Peptide Bearing Ni(II) NTA 
The ability to bind very tightly to poly-His-tag proteins via NTA complexes stimulated 
Futaki et al. to combine this function with a carrier peptide, which is able to invade living 
cells.140 Octaargnine was used as such a peptide and was linked to a NTA based chelator. 
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O
O
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O
O
O
N
H
GRRRRRRRR-Ac
50  
Figure 34. Arginine carrier peptide (R8-NTA-Ni(II), 50) with binding site for His-tagged 
proteins. 
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Covalent cross-linking between the cargo proteins and the carrier peptide is necessary for 
the cellular introduction. The histidine-tagged enhanced green fluorescent protein (H6-
EGFP) forms a noncovalent complex with the carrier peptide. The interactions (KD = 
4.2⋅10-7 M) are strong enough that the protein penetrates into cells. Internalisation of the 
H6-EGFP was monitored by laser confocal microscopy after 3 h incubation of the protein 
with HeLa cells at 37 °C. Significant internalisation of H6-EGFP was observed when the 
cells were treated with H6-EGFP (10 µM) in the presence of R8-NTA-Ni(II) (50 µM). 
 
 
Figure 35. Confocal microscopic observation of the HeLa cells treated with R8-NTA-
Ni(II)/H6-EGFP for 3 h. 
2.3 Recognition on Surfaces 
2.3.1 Immobilised Metal Ion Affinity Chromatography (IMAC) 
Immobilised metal ion affinity chromatography (IMAC) on resins coupled with chelating 
agents is widely used to purify proteins containing exposed histidine and cysteine side 
chains. Recent reviews cover applications of the technique and studies thoroughly (see 
references cited at the 1.3.1. IDA IMAC chapter), so that we exclude this application from 
this overview. 
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2.3.2 Immobilisation of Ni(II)-NTA on Microtiter Plates 
Paborsky et al. describe the application of a NTA derivative, N,N-
bis[carboxymethyl]lysine (BCML), which can be coupled by simple amide chemistry to 
carboxyl groups on commercially available microtiter plates coated with maleic 
anhydride.141
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Figure 36. Immobilisation of proteins on microtiter plates derivatised with N,N-
bis[carboxymethyl]lysine (BCML). Two adjacent histidine residues in a protein containing 
a 6His tag bind in bidentate fashion (B) to a BCML-derived plate (A). 
The NTA modified plate was charged with Ni(II) ions and used to capture either 
recombinant IL8 or recombinant sTF, both engineered to contain 6His tags. The amount of 
each protein captured by the Ni(II)-NTA plate was measured by sandwich ELISA. To 
determine the specificity of the Ni(II)-NTA plate for proteins containing 6His tags, the 
capture of IL8-6His was compared with native IL8 (lacking a 6His tag) and the capture of 
6His-sTF was compared with FLAG-sTF. The IL8-6His was bound by the Ni(II)-NTA 
plate in a dose-dependent manner, reaching saturation at approximately 5 nM. In contrast, 
the native IL8 did not bind the plate, indicating that the binding was specifically through 
the six histidine residues. Results comparing 6His-sTF and sTF lacking the 6His tag were 
similar. 
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Figure 37. Specificity of Ni(II)-NTA plate for 6His-containing proteins. Purified IL8-6His 
(dots) or native IL8 (triangle) was added to the Ni(II)-NTA ELISA plate and binding was 
detected.  
2.3.3 Molecular Imprinting of Ni(II)-NTA Complexes 
The preparation of molecular imprinted polymers (MIPs) selective for amino acids and 
small peptides has been limited to traditional imprinting formulations, such as 
polyacrylates. Methacrylic acid is the functional monomer in organic solvents. Hart et al. 
developed a polymerisable acrylamide functionalised NTA ligand.142 By incorporating a 
Ni(II) – NTA complex into the polymer they provided a “handle” to bind peptides 
containing N-terminal His residues in water. The ligand occupies four positions in the 
octahedral coordination sphere of NiII leaving the remaining two for selective binding of 
His. The polymerisable methacrylamide – NTA – Ni(II) mixed complex was prepared by 
combining aqueous solutions of NTA monomer with NiSO4. The pre-polymerisation 
template complex was then formed by addition of the N-terminal histidine peptide His-Ala. 
Copolymerisation of this complex (5 mol%) with N,N’-ethylenebisacrylamide as cross-
linking monomer (82 mol%) and acrylamide (13 mol%) provided a pale blue monolith.  
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Scheme 7. Schematic representation of the peptide imprinting process 
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The polymer-bound NTA – Ni(II) complex in the absence of peptide is pale green. Upon 
binding an N-terminal histidine peptide, the color changes to pale blue. This change lends 
itself to a colorimetric assay of binding of peptides to these materials. Binding isotherms 
were obtained for the template peptide (His-Ala) as well as three other peptide sequences. 
 
 
His-Ala 
His-Ala-Phe 
His-Phe 
Ala-Phe 
Figure 38. Binding isotherms for the rebinding peptides in aqueous solution to a polymer 
prepared using His-Ala as the template peptide. 
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It is clear from the binding data that the (His-Ala)-imprinted polymer has a significantly 
higher capacity for the template peptide over other sequences examined. Non-histidine 
containing peptides have almost no affinity for the polymer. 
2.3.4 Immobilisation on Gold Surfaces143
Surface plasmon resonance (SPR) is a useful technique for measuring the kinetics of 
association and dissociation of ligands from proteins in aqueous solution.144 Varieties of 
techniques have been used to immobilise proteins on silver or gold films for studies using 
SPR.144,145 Whitesides et al. developed procedures to modify the surface of gold films by 
formation of self-assembled monolayers (SAMs) of alkanethiolates.146 They describe the 
generation of a SAM functionalised with the Ni(II)-NTA group. Using this way to 
immobilise proteins wearing a stretch of His-tags, a surface was created, that would 
specifically immobilise a protein of interest while resisting non-specific binding of other 
proteins. Therefore, the requirement for non-specific, covalent modification of the protein 
was avoided. 
 
Scheme 8. Procedure for immobilising proteins on surfaces to test for the ability of 
immobilised proteins to interact with ligands in solution 
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After the His-tag receptor is bound to the modified gold-surface, interactions between the 
receptor and a ligand in solution could be studied by SPR. A similar approach was used by 
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Hoggett et al. to measure the interaction between E. Coli core form of bacterial RNA and 
immobilised His-tagged form of σ70 factor.147 Vogel and co-workers demonstrated the 
reversible binding of an anti-lysozyme Fab fragment modified with a C-terminal 
hexahistidine extension on similar gold-surfaces.148 The apparent dissociation constants 
were determined using SPR and IR-spectroscopy and showed that the immobilisation did 
not affect the secondary structure of the protein.  
Using gold particles as a label for bound Ni(II)-NTA to a His-tag attached to a protein, 
Powell et al. report the construction of Ni(II)-NTA groups fixed on a gold particle.149 For 
detection using electron microscopy, it provides a high-resolution site-specific label. With 
metal enhancement (e.g., silver), the signal was detectable in the light microscope or by the 
naked eye.  
The Ni(II)-NTA His-Tag approach has been used in several examples to create strong 
intermolecular interactions. However, how strong is the coordination bond between a 
histidine tag and Ni(II)-NTA? This question asked Samorì et al. in 2000.150 To give an 
answer they simulated the process involved in the Ni(II)-NTA protein separation 
techniques by reproducing the approach, binding, stretching and unbinding under external 
forces between individual His tags and individual Ni(II)-NTA chelating groups in a single-
molecule experiment with the scanning force microscope (SFM, see scheme 9). 
Scheme 9. Sketch of the approach, binding, stretching, and unbinding of a) a His-tagged 
protein (p) under the flow inside an affinity chromatography column or on a biosensor 
surface and b) a His-tagged peptide covalently bound to an SFM tip in an approach and 
retraction cycle. 
 
A n-His-tagged peptide (n = 2 or 6), HCys-(Gly)6-(His)n-OH, was covalently attached on 
its Cys end to a gold-coated SFM tip. The tip was brought into proximity to a substrate 
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having exposed Ni(II)-NTA groups covalently bound trough carboxymethylated dextran 
linkers, which were attached to a gold surface bearing an alkane C18 chain. Whenever the 
n x His-tag of the peptide formed a chelate with a Ni(II)-NTA group, a molecular bridge 
was established between the tip and the substrate. The tip was subsequently retracted at a 
constant pulling velocity until the bridge broke. The probability of binding events 
increased from 28 % for 2 x His-tag to 42 % for a 6 x His-tag. Most of the unbinding traces 
exhibited a single rupture: the distribution of the forces was very broad and peaked at 
about 500 pN for the 6 x His-tag and about 300 pN for the 2 x His-tag. 
 
 
Figure 39. Histogram of the distribution (n, number of events) of all the unbinding forces 
(F) recorded with the Ni(II)-NTA-functionalised substrate and a) the 2xHis-tag and b) the 
6xHis-tag. 
2.3.5 Electropolymerisation of NTA-Complexes 
The electrosynthesis of polymers is one of the known methods that allow the reproducible 
and precise functionalisation of conductive microsurfaces of complex geometry by organic 
molecules. Gondran et al. successfully synthesised and electro polymerised a NTA 
derivative bound to a poly(pyrrole) film.151 The ability of this polymer to bind Cu(II) was 
investigated using cyclic voltametry. 
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Scheme 10. Schematic representation of the reversible immobilisation of His-tagged 
biomolecules to an electrogenerated poly(pyrrole)-NTA film 
 
 
To examine the potential affinity of the metal-poly film for histidine tagged proteins, two 
platinum electrodes containing the chelating polymer with coordinated Cu(II) ions were 
soaked in 0.1 M phosphate buffer, one in the presence of His-tagged glucose oxidase (his-
GOX, 0.1 mg/mL) and the other in the presence of regular glucose oxidase (GOX, 
0.1 mg/mL). In the presence of oxygen, this enzyme catalyzes the oxidation of glucose 
with the concomitant production of H2O2. Its activity can be monitored via the 
electrochemical oxidation of H2O2. Using this technique, the electrode coated with his-
GOX resulted in markedly higher maximum current density (jmax, determined at glucose 
saturating conditions) than the electrode incubated with GOX. 
2.3.6 Metal Chelating Lipids 
To link lipid technology to the concept of fusion proteins, Tampé et al. synthesised lipid 
molecules, which contain NTA as a metal chelator head-group able to bind electron donor 
groups such as imidazole or histidine.152  The synthesis was carried out with two different 
amphipatic molecules, a phospholipid (DPPE, 51), and a dioctadecylamine (DODA, 52). 
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Figure 40. Two NTA-lipids.  
The lipids were characterised chemically and physically by FTIR spectroscopy, mass 
spectroscopy, and film balance experiments. Both, NTA-lipids, NTA-DPPE and NTA-
DODA spread at the air/water interface. The addition of Ni(II) resulted in complexed 
Ni(II)-NTA-DODA, which spreads at the air/water interface. Added imidazole interacts 
specifically with the metal-complexes on the lipid surface. 
Scheme 11. Schematic illustration of complex formation and imidazole binding to Ni(II)-
NTA-DODA at the lipid surface 
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Addition of EDTA, which has a higher binding affinity for the Ni(II) ions than NTA, 
reverses the binding event. Therefore, the immobilisation of any bound ligand can be 
disrupted under mild conditions. In 1995, the same group was able to immobilise 
fluorescence-labeled histidine-tagged biomolecules.153 The two-dimensional organisation 
is visualised by epifluorescence microscopy and film balance-studies. 
 
Figure 41. Lateral organisation and pattern formation of histidine-tagged peptides 
(6 nmol) at a Ni(II)-NTA-DOPA/DMPC (1:1) monolayer (10 nmol). 
Similar lipid surfaces have been used to grow two-dimensional crystals and to determine 
structures of various His-tagged proteins.154 This method of surface modifications using 
lipid bound metal complexes inspired Nolan et al. to modify microspheres by the 
formation of self-assembled bilayer membranes where the metal chelators have lateral 
mobility. Interactions on this surface were studied by flow cytometry. 
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Figure 42. Self-assembled bilayers consisting of Ni(II)-NTA-DOGS (Ni(II)-1,2-dioleoyl-
sn-glycero-3-[(N(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl]) and egg phos-
phatidylcholine (PC) on the surface of silica microspheres that confer lateral mobility to 
the captured His-tagged protein.  
2.3.7 NTA-Modified Magnetic Nanoparticles 
Trying to develop a simpler and more versatile platform for protein purification than 
IMAC, Xu et al. invented surface-modified magnetic nanoparticles as the binder, carrier 
and anchor for histidine-tagged proteins.155 Using NTA to attach to FePt magnetic 
nanoparticles covalently, they developed a simple procedure to obtain pure proteins 
directly from the mixture of lysed cells within 10 min. 
Scheme 12. The surface-modified magnetic nanoparticles selectively bind to histidine-
tagged proteins in a cell lysate) I: 6His tagged protein; II: other proteins; III: cell debris; 
IV: colloid contaminants) 
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Scheme 13. Synthesis of NTA-modified magnetic nanoparticles ((I) AcOCl, Zn, 85-90 %; 
(II) NHS, DCC; (III) NaHCO3, 40-46 %; (IV) H2NNH2, AcOH, 88-90 %; (V) FePt (3-
4 nm); and (VI) NiCl2⋅6H2O and buffer) 
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The procedure to use particles, such as 58, for protein separation consists of three simple 
steps: (1) adding 58 into the suspension of the lysed cells and shaking for 5 min, (2) using 
a small magnet to attract the nanoparticles to the wall of the vial and washing them with 
deionised water to remove the residual protein solution, and (3) using concentrated 
imidazole solution to wash the nanoparticles to yield pure proteins. After releasing the 
proteins, washing with EDTA, buffer, and NiCl2⋅6H2O solution, 58 can be recovered and 
reused. 
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2.3.8 Immobilisation on Quartz Surfaces 
Vogel et al. reversibly immobilised His-tagged proteins on quartz in an oriented manner 
while their function is preserved.156 The chelator NTA is covalently bound to the 
hydrophilic quartz surface and subsequently loaded with the divalent metal cation (e.g. 
Ni(II)). Additional electron-donating groups such as histidine residues subsequently fill the 
free coordination sites of the chelator-metal complex. The binding of the protein to the 
NTA is highly specific with reasonable affinities and in addition is fully reversible upon 
addition of a competitive ligand, reprotonation of the histidine residue, or removal of the 
metal ion via EDTA complexation (figure 43). Binding and removal from the surface of 
the modified quartz is visualised using green fluorescent protein in real-time 
measurements. 
 
 
Figure 43. Schematic representation of the binding of a His-tagged protein to the quartz 
surface. 
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3. Bis(2-pyridylmethyl)-amine (BPA, DPA, BISPMA, 
DIPICA, BISPICAM)157 Complexes 
3.1 Structures of BPA Complexes 
In bis(2-pyridylmethyl)-amine (BPA) ligands the carboxylic acid functionalities of IDA 
are replaced by pyridines. First reported in 1964 by Kabzinska, this ligand and derivatives 
of it are used for complexation of over 50 different metal ions.158 Most emphasis was put 
on the investigation of coordination compounds with Cu(II),159 Zn(II)160 and Fe(III) 
ions.161  
Table 13. Selected binding constants of some important types of BPA complexes 22
Ion Equilibrium log K 
Co2+ ML/M.L 
ML2/M.L2
7.74 
13.05 
Ni2+ ML/M.L 
ML2/M.L2
8.7 
16.60 
Cu2+ ML/M.L 
ML2/M.L2
14.4 
19.0 
Zn2+ ML/M.L 
ML2/M.L2
7.57 
11.93 
Cd2+ ML/M.L 
ML2/M.L2
6.44 
11.74 
 
3.1.1 Cu(II) Complexes 
The Cu(II)-BPA complex [Cu(bpa)Cl2] was structurally examined by Choi et al..162 In this 
compound the Cu(II) ion is coordinated by three nitrogen atoms of the BPA ligand and two 
chlorine anions in a distorted square-pyramidal environment. The basal plane is defined by 
the N(1), N(2), N(3) and Cl(2) atoms. 
 
 
Figure 44. An ORTEP view of [Cu(bpa)Cl2] in the crystal with the atomic numbering 
scheme (30% probability ellipsoids shown). 
Beside complexes with a 1:1 stoichiometry, Cu(II)-BPA coordination compounds with 2:1 
stoichiometry are known, which have no vacant coordination sites and are therefore not 
discussed here.163 The 1:1 complex can be used to bind additional electron donating 
groups. Murakami et al. reported X-ray structures, which show picolinate (figure 45) and 
α-amino acids, like L-Phe (figure 46), coordinated to the Cu(II)-BPA complex.164  
 
 
Figure 45. ORTEP drawing of [Cu(bpa)(pic)]PF6⋅H2O. 
 62 
 
Figure 46. Structure of [Cu(bpa)(L-Phe)]ClO4 in the solid state. 
A better understanding of the redox reactions between the metal center and the pterin 
cofactor in phenylalanine hydroxylase led Yamauchi and coworkers to examine the binding 
of pterin-6-carboxylate (ptc, as a cofactor model) to [Cu(bpa)(ptc)]⋅H2O⋅CH3OH.165 The 
studies showed the Cu(II) binding modes of oxidised and reduced pterins. The redox 
activitiy of the examined [Cu(bpa)]2+ - tetradropterin systems was influenced by the 
complex structure. 
3.1.2 Zn(II) Complexes 
The structure of [Zn(bpa)(H2O)2](ClO4)2 shows a distorted octahedral coordinated 
Zn(II).166 This geometry results from the three nitrogen donor groups of the chelating 
ligand BPA and the additional two water molecules. 
 
 
Figure 47. ORTEP drawing of the crystal structure of [Zn(bpa)(H2O)2]2+. 
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In contrast to this structure Wirbser et al. reported a pentacoordinated Zn(II) structure. 
[Zn(bpa)Cl2] shows a trigonal bipyramidal coordination geometry in the solid state.167
 
 
Figure 48. Structures of [Zn(bpa)Cl2] in the crystal. 
As the BPA ligand uses only three coordination sites of an octahedral coordinating Zn(II) 
ion, [Zn(bpa)2]2+ complexes with a 2:1 ligand to metal ion stoichiometry are known. 168 
One of the ions which can additionally bind to [Zn(bpa)]2+ complexes are phosphates. In a 
more complicated structure Vahrenkamp et al. reported the first crystal structure of a 
phosphate - Zn(II)-BPA complex.169  
 
 
Figure 49. Structure of the complex (BPA⋅Zn)3(TolOPO3)2]HPO4 (tolyl groups omitted for 
clarity) in the solid state. 
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The ability of [Zn(bpa)]2+ to bind phosphate is discussed in the chapter of recognition 
processes in solution (Chapter 5.2.2) in detail. 
Crystal structures of [Fe(bpa)Cl3] (figure 50)170 and [Fe(bpa)2(BF4)2]171 show similar 
structures with the metal ion in an octahedral coordination. 
Figure 50. ORTEP view of [Fe(bpa)Cl3] in the solid state. 
Table 14 summarises all X-ray structures registered in the Cambridge Crystallographic 
Database according to the selection criteria previously mentioned. 
3.1.4 BPA Complexes in Solid State (tabulated) 
3.1.3 Fe(III) Complexes 
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Table 14. References of X-ray structure analyses selected from the Cambridge structural database of transition metal BPA complexes coordinating 
an additional complex ligand (M = transition metal – BPA complex) 
Metal Ions Additional 
Ligand Zn(II)        Cu(II) Fe(III) Ni(II) Co(III) Mn(II) Cr(III) Re(II)
R
O O
MM  
R=Me172,173
R=Me172, ,174 175
R = Et  
 
R=Me161,172
R=Et172,176
R=Hex177
R=(CH2)3-Ph178
R=CH2-Cl179
R=Ph180
R=Me173,175
R=Et  
R=Me181
R=Me182
R=Et183
R=Ph182,184
R=Me185
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O
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pTol
M
 
       
See ref.186
M
O
O
O
 
See ref.172,,187  See ref.172,187
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See ref.192
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See ref. 195
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       See ref.159,164
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       See ref.164
N O
O
M  
       See ref.164
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       See ref.165
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3.2 Recognition Processes in Solution 
3.2.1 Surface Recognition of α-helical peptides in aqueous solution 
Hamachi et al. used the [Zn(bpa)]2+-based coordination chemistry for the design of 
artificial receptors in aqueous solution.212,213 A Zn(II) bispicolylamine complex is 
employed as a binding site for histidine residues because of its good affinity in aqueous 
solution. Five dinuclear Zn(II)-BPA complexes including meta- or para-xylene, 9,10-
dimethylanthracene and 3,3´- or 4,4´-dimethylbiphenyl as a linker were prepared. Two 
mononuclear Zn(II) complexes based on benzyl-BPA or 9-anthrylmethyl-BPA were used 
for comparison. The target molecules for binding are four helical model peptides with one 
or two His located on one side of the α-helix (shown in figure 51). 
Bpa BpaBpa
BpaBpa
BpaBpaBpa
Bpa Bpa
BpaBpa
N
NN Zn
O2NO
    Bpa =                                                 
Zn(Bpa)-Bzl                                    Zn(Bpa)-pXyl                                   Zn(Bpa)-mXyl
Zn(Bpa)-9-Anth                         Zn(Bpa)-9,10-Anth                                Zn(Bpa)-3,3'-Biph
Zn(Bpa)-4,4'-Biph
                                     1          5         10       15
peptide (H-16)         Ac-AEAAAKEAAAKEAAAHA-NH2       i
peptide (H-12,16)    Ac-AEAAAKEAAAKHAAAHA-NH2       i,i+4
peptide (H-9,16)      Ac-AEAAAKEAHAKEAAAHA-NH2       i,i+7
peptide (H-5,16)      Ac-AEAAHKEAAAKEAAAHA-NH2       i,i+11
 
Figure 51. Molecular structures of [Zn(bpa)]2+-based receptors and their target peptide 
sequences. 
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For the rapid screening of the affinity of these Zn(II)-BPA based receptors to the four 
peptides, the receptor-induced conformational change of the peptides was examined by 
circular dichroism spectroscopy. 
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H-19 H-12,16 H-9,16 H-5,16
peptide
[ θ]
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q/[
θ] 0
eq
Zn
Zn(Bpa)-Bzl
Zn(Bpa)-pXyl
Zn(Bpa)-mXyl
Zn(Bpa)-9,10-Anth
Zn(Bpa)-3,3'-Biph
Zn(Bpa)-4,4'-Biph
 
Figure 52. Changes of θ values at 222 nm upon addition of 5 equiv. of [Zn(bpa)]2+-based 
receptors to the corresponding peptides. [Peptide] = 50 µM in 10 mM borate buffer (pH 
8.0) at 10°C. 
It is apparent that helicity significantly increases upon receptor addition for peptides 
having two His residues, but not for the mono-His peptide. The helical conformation of H-
12,16 peptide, is selectively stabilised by Zn(BPA)-9,10-anthracene. For the H-9,16 
peptide, Zn(BPA)-pXyl, Zn(BPA)-9,10-Anth, and Zn(BPA)-4,4´-Biph show similar 
effects. In the case of H-5,16 peptide, Zn(BPA)-4,4´-Biph selectively induces a helical 
conformation. Neither Zn(II)-cations nor a Zn(BPA)-Bzl mononuclear receptor effectively 
induces a conformational change of the peptides. 
The Job’s plot based on CD measurements shows its maximum at 0.5 of the molar fraction 
of the receptor (inset of figure 53). Consistently, ESI-TOF mass spectroscopy, under 
identical conditions, displayed a 1:1 complex between the receptor and the peptide as a 
major species.  
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Figure 53. CD titration curve of H-12,16 peptide with Zn(BPA)-9,10-Anth. The error 
limits were derived from three titration experiments. Inset: Job’s plot of this combination 
(the total concentration is 100 µM). 
Thus, the binding stoichiometry was determined to be 1:1 ratio and the CD titration curve, 
which obeys a typical saturation behavior (figure 53), plotted at 222 nm gave a binding 
constant (Kass) of 103.9 M-1. Similar titration curves and Job’s plots were obtained for other 
combinations and the affinity constants are summarised in table 15. All receptor - peptide 
combinations selected by screening have an affinity in the range of 104.0 to 105.0 L/mol. 
Table 15. Binding constants of the Zn (BPA) molecules with various peptides 
Peptide Receptor Kass (M-1) 
H-12,16 Zn(BPA)-9,10-Anth (8.5 ± 2.7)⋅103
H-9,16 Zn(BPA)-9,10-Anth (1.3 ± 0.7)⋅104
H-9,16 Zn(BPA)-pXyl (2.5 ± 0.7)⋅104
H-9,16 Zn(BPA)-4,4´-Biph (2.5 ± 0.4)⋅104
H-5,16 Zn(BPA)-4,4´-Biph (3.9 ± 0.6)⋅104
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Scheme 14. Schematic representation of side chain selective peptide recognition by a 
[Zn(bpa)]2+-based receptor 
 
 
3.2.2 Artificial receptors for phosphorylated peptides 
Hamachi and his group have used [Zn(bpa)]2+ based receptors to selectively bind 
phosphorylated peptides and ATP.213, 214,215 Anthracene derivatives having two Zn(II)-
BPA moieties selectively coordinate phosphorylated amino acids and signal the binding by 
a change in emission. When phosphorylated tyrosine (p-Tyr) was added to the aqueous 
solution of the dinuclear compound 59, Hamachi et al. observed a significant increase of 
emission of the anthracene chromophore (figure 55). 
(NO3 )4-.
NNN N
NN
Zn
2+
Zn
2+
NN
N
NN
N
Zn
2+ Zn
2+
(NO3 )4-.
N
N
N
Zn
2+
.(NO3 )2-
59 60
61  
Figure 54. Emitting mono- and dinuclear Zn(II) complexes. 
 74 
 
Figure 55. Emission changes of compound 59 (10µM) upon addition of p-Tyr: [p-Tyr] = 
0, 1.0, 3.0, 5.0, 10, 30, 50 µM from the lowest to the top trace. The spectra were measured 
in 10 mM HEPES buffer (pH 7.2) at 20°C, λex = 380 nm. 
These receptors strongly bind and fluorometrically sense phosphorylated species such as 
phosphate and p-Tyr in the range of 10-6-10-5 M in a neutral aqueous solution. No 
fluorescent response is induced by other anions, such as sulfate, nitrate, acetate, and 
chloride. Job’s plot analyses of the binding of these receptor and p-Tyr reveal a 1:1 
stoichiometry (inset of figure 56). 
 
Figure 56. Relative emission response of compound 59 to the anion concentration 
(log[anion]): phosphate (•), p-Tyr (■), chloride (ο), acetate (◊), sulfate (∆), nitrate (∇), 
carbonate ( ), azide (x). λex = 380 nm. Inset: Job’s plot of compound 59 (= 1) and p-Tyr. 
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NMR studies suggested that two Zn (BPA) sites equally contribute to the phosphate ion 
binding. Cocrystal structures of the complex with phenyl phosphate support this expected 
coordination geometry.202 
 
Figure 57. ORTEP drawing of the complex of 59 with phenyl phosphate. 
Based on these results, Hamachi subsequently examined the sensing ability of these 
receptors towards phosphorylated peptides in aqueous solution. Three kinds of 
phosphorylated peptides (peptide-a, -b, -c) and a non-phosphorylated peptide (peptide-d, 
scheme 15) for comparison were used to investigate receptor binding. 
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Scheme 15. (Top) Amino acid sequences of the phosphorylated peptides and (bottom) 
schematic depiction of the interaction of receptor 59, 60 with a phosphorylated peptide 
 
Peptide a: Glu-Glu-Glu-Ile-pTyr-Glu-Glu-Phe-Asp 
Peptide b: Arg-Arg-Phe-Gly-pSer-Ile-Arg-Arg-Phe 
Peptide c: Lys-Ser-Gly-pTyr-Leu-Ser-Ser-Glu 
Peptide d: Glu-Glu-Glu-Ile-Tyr-Glu-Glu-Phe-Asp 
 
 
 
The fluorescence intensity of 59 significantly increases by addition of less than 1 µM of 
peptide-a. The binding is remarkably strong with the affinity of 107 M-1. A photograph of 
the fluorescence change of the receptor 59 upon addition of peptide-a is shown in figure 
58. 
 
 
Figure 58. Increased emission of the receptor 59 in the presence of phosphorylated 
peptide-a (middle); the solution of 59 only (left); 59 in the presence of non-phosphorylated 
peptide-d (right). 
Apparently, the blue fluorescence is greatly intensified by the phosphorylated peptide-a, 
whereas the non-phosphorylated peptide-d does not induce a fluorescence change. Such 
visualisations stimulated the same group to immobilise the artificial receptors  59 and 61 in 
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a gel matrix without loss of their binding capability displayed in solution.216 The binding 
constant in the gel is 3-fold smaller compared to homogeneous solution. Therefore, the 
previously observed discrimination between phosphorylated and non-phosphorylated 
peptides is still valid. For rapid sensing, the hydrogel was miniaturised and arranged into 
an array on a glass support. 
Scheme 16. Preparation scheme of a semi – wet sensor array (1 is the monomer of the 
hydrogel) 
 
 
This chip was used for receptor screening as shown in figure 59. Variations of receptors, 
pH, metal salts, and presence of phosphorylated peptide could be screened on one chip. 
 
 
Figure 59. Images of sensing patterns of a semi-wet chemosensor chip containing 
(80 µM), (b) CG-2 (Ca(II) probe) (50 µM) in the presence of various metal cations,
SNARF-1 (pH probe) (100 µM) at various pHs. (d) An image of an integrated mo
recognition hydrogel chip for mixed solution assay. 
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(a) 59 
 or (c) 
lecular 
The receptor 59 based detection system for phosphorylated peptides was also used to 
detect the presence of phosphorylated peptides in SDS-Page gel electrophoresis.217
Other groups synthesised modified BPA-ligands to bind to phosphates.218, , 219 220 Here, two 
[Zn(bpa)]2+ binding units and additional hydroxy coordination was used for anion binding.   
Scheme 17. Structure of BPA-ligand used for complexation experiments 
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The solution binding processes were investigated by potentiometric titration. The species 
distribution plot shows the Zn2L3+ phenylphosphate aggregate as the only species between 
pH 5 and 8. This compound is present in the solid state as found by X-ray structure 
analysis. 
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Figure 60. Species distribution diagram of 62 (1 mmol dm-3) in the presence of Zn(II) ion 
(2 mmol dm-3) and phenyl phosphate2- (1 mmol dm-3) as a function of pH in aqueous 
solution at 25 °C with I = 0.10. Free ligand is a total of metal-free ligand species (HL⋅nH+). 
 
 
Figure 61. Crystal structure of p-nitrophenyl phosphate2--bound di-Zn(II) complex. 
Kim et al. designed a receptor for AMP binding based on BPA ligands.219 Using a 4-
methyl-phenyl group as linker to bridge the BPA ligands they created a binuclear complex 
with similar structure as the compound from Koike. 
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Scheme 18. Schematic representation of the AMP chemosensor 
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Sensing AMP is achieved by displacement of pyrocatechol violet. The AMP binding is 
monitored by the amount of free pyrocatechol violet in solution. The binding was 
investigated spectrophotometrically and by isothermal titration calorimetry. 
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Figure 62. The ITC plot for the titration of [Zn2(H-bpmp)]3+ (0.5 mM) with AMP (5 mM) 
in aqueous HEPES buffer pH 7.0 at 30 °C. 
Using a similar approach Smith et al. reported a indicator displacement system for 
fluorescent detection of phosphate oxyanions under physiological conditions.221 Hong and 
coworkers reported a fluorescent PPi (pyrophosphate, P2O74-) sensor based on a 
naphthalene-BPA system, which shows high sensitivity and selectivity over a wide pH 
range for PPi ions relative to other anions, including ATP and ADP.  The presence of PPi is 
signaled by changes in the emission intensity of the luminescent receptor. 
 
Zn
2+
Zn
2+ NN O N
N
N
N
63  
Figure 63. Structure of Hongs PP1 sensor 63. 
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Upon addition of PPi, a six-fold increase of the emission intensity is noted. Added ATP 
leads to a twofold increase of emission intensity. 
The binding mode for PPi-63 is illustrated in scheme 19, which is based on previous work 
involving a structurally similar sensor and its X-ray crystal structure.   
Scheme 19. Proposed mechanism for the complexation of sensor 63 with PPi and ATP 
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The observed selectivity for PPi over ATP can be understood from the structure of the 
guest and the charge density of four O-P oxygen atoms of the guest involved in the 
complexation. The total anionic charge density of the four O-P oxygen atoms involved in 
the complexation of ATP with 63 is smaller than that of the four O-P oxygen atoms of PPi. 
Therefore, the binding affinity of ATP is reduced drastically, and observed fluorescence 
changes are smaller relative to PPi binding. 
3.3 Recognition Processes on Solid Surfaces 
3.3.1 Sensors for Phosphatidylserine-containing Membranes 
Using the sensor metal complex 59 from Hamachi, the group of Smith showed its use to 
detect the presence of anionic phospholipids, particularly phosphatidylserine (PS), on the 
surface of vesicles and cells.222 However, the excitation wavelength is in the UV range and 
therefore not compatible with the lasers in most flow cytometers. This prompted Smith and 
co-workers to design a second generation of sensors.223
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Figure 64. Coordination complexes 64-67 as potential PS sensors. 
The titration experiments involved addition of unilamellar vesicles composed of 1:1 
POPC:POPS, 1:1 POPC:POPA, 1:1 POPC:POPG, or 100 % POPC to a 1 µM solution of 
64 or 65. 
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Formula for R Phospholipid
-H POPA 
-CH2CH2N(CH3)3+ POPC 
-CH2CH(NH3+)COO- POPS 
-CH2CH(OH)CH2OH POPG 
 
Figure 65. Head group structure of common phospholipids. 
The resulting isotherms fit to a 1:1 binding model, which allowed calculation of apparent 
phospholipid binding constants. As the sensors were not expected to bind the zwitterionic 
POPC head group, this titration was performed as a control to determine specificity of the 
sensors for anionic PS.  
Table 16. Sensor/phospholipid binding constants (Ka) 
Sensor Ka x 104 (M-1)a
 100 % POPC 1:1 
POPC:POPS 
1:1 
POPC:POPG 
1:1 
POPC:POPA 
64 <1 23.3±1.7 14.2±3.8 11±6.0 
65 <1 5.3±2.0 2.0±0.5 2.0±0.3 
66 <1b 11.5±5.5 - - 
67 <1b 7.7±3.3 - - 
a Values are average of at least three independent measurements. 
b Values are average of two independent measurements. 
 
The effect of only one Zn(II)-BPA unit in the sensor structure was evaluated using control 
compounds 66 and 67. Vesicles composed of 100 % POPC or 1:1 POPC:POPS were added 
to a 1 µM solution of 66 or 67. The emission of butyl-linked sensor 66 with 1:1 
POPC:POPS is about two times that observed with 100% POPC vesicles, whereas the 
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intensity ratio with TEO-linked sensor 67 is about five. Thus, it is clear that the 
hydrophilic TEO-linker is more useful for detecting PS-containing membranes over PC-
only membranes. The emission of sensor 65 with two [Zn(bpa)]2+ units is significantly 
higher than that obtained with 67, indicating that the second [Zn(bpa)]2+ unit increases the 
interactions that produce a stronger response to PS-containing membranes. 
The PS sensitivity of sensor 65 was investigated in additional titration experiments with 
POPC vesicles enriched with various amounts POPS. A solution of 65 (1 µM) was titrated 
with vesicles composed of POPC and 0-50 % POPS. Sensor 65 can readily detect the 
presence of bilayer membranes containing 5 % PS. 
Table 17. Sensor 65/phospholipid binding constants (Ka) for vesicles with varying PS 
content 
 95:5 
POPC:POPS 
90:10 
POPC:POPS 
80:20 
POPC:POPS 
50:50 
POPC:POPS 
Ka x 104 (M-1)a 1.0±0.3 2.2±0.5 5.7±0.5 5.3±2.0 
a Values are average of at least three independent measurements. 
Scheme 20. Sensing of PS-containing membranes. PS is represented with filled head 
group, PC is unfilled head group 
 
Until now, no surface-immobilised BPA complexes and their use in molecular recognition 
have been reported. 
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4. Tris(2-pyridylmethyl)-amine (TPA, TMPA) Complexes 
4.1 Structures of TPA Complexes 
Substitution of the carboxylic acid functionalities of NTA by pyridine leads to the TPA 
ligand. Da Mota first reported the ligand in 1969 and a large number of derivatives have 
been used for complexation of metal ions.224 Beside Ni(II)225 and Co(III)226 complexes, 
most reports cover investigations of Cu(II),227 Zn(II)228 and Fe(III) ion complexation.229  
Table 18. Overview of typical binding constants of different metal ions to the TPA 
ligand22
Ion Equilibrium log K 
Co2+ ML/M.L 11.4 
Ni2+ ML/M.L 14.5 
Cu2+ ML/M.L 16.2 
Zn2+ ML/M.L 11.0 
Fe2+ ML/M.L 8.7 
 
4.1.1 Cu(II) Complexes 
The structure of the Cu(II) complex of TPA was reported by Karlin et al..230 Indicated by 
the similar Cu(II)-N bond lengths and bond angles the copper ion is found in a trigonal 
bipyramidal coordination geometry. 
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Figure 66. ORTEP drawing of [Cu(tpa)(Cl)]+. 
These copper complexes have the ability to bind additional phosphate ions, which is 
illustrated by a structure of the 1:1 complex of [Cu(tpa)]2+ and BNPP (= bis(p-nitrophenyl) 
phosphate).231
 
 
Figure 67. ORTEP diagram (50% probability ellipsoids) of the cationic portion of 
[Cu(tpa)(BNPP)]ClO4. Hydrogen atoms are omitted for clarity. 
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4.1.2 Zn(II) Complexes 
 
The crystal structure of [Zn(tpa)Cl]ClO4 shows the ligand maintaining a helical twist in 
which the dihedral angle between the plane of each pyridine ring and the axis of the M-
N(11) bond is between 12 and 22 °.232  
 
 
Figure 68. ORTEP diagram (30% probability ellipsoids) of the cationic portion of 
[Zn(tpa)Cl]ClO4. 
Thus, the overall shape of the cationic portion of the molecule resembles a propeller. The 
complex is potentially chiral. In the crystal, the compounds are found as racemate with 
their mirror images. Similar to the Cu(II) complex the analogous Zn(II) complex binds to 
BNPP.233
 
Figure 69. An ORTEP drawing (40% probability drawing) of the cationic portion of 
[Zn(tpa)(BNPP)]ClO4. 
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Adams et al. also reported a 2:1 complex of [Zn(tpa)]2+ and BNPP.234 The ability of this 
metal complex to bind imidazole is demonstrated by the structure of the 2:1 complexation 
of [Zn(tpa)]2+ and deprotonated imidazole.235 Each of the two zinc atoms is 
pentacoordinated by four nitrogen atoms from TPA and one nitrogen atom from bridging 
imidazolate ligand in an approximately trigonal bipyramidal structure. The distance 
between the two zinc atoms in the Zn-Im-Zn moiety is 6.078 Å. 
 
 
Figure 70. Cationic structure of [(tpa)Zn(im)Zn(tpa)]3+. 
4.1.3 Fe(III) Complexes 
Fe(III) complexes of TPA were found to crystallise as an oxo-bridged dimer.236
 
 
 
Figure 71. ORTEP diagram of the dinuclear cation in [{Fe(tpa)(H2O)}2O]-
(ClO4)4⋅3H2O⋅0.25CH3CH2OH. 
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Next to complexes with diphenylphosphates,238 and acetates,239 structures with natural 
amino acids and dipeptides were investigated (figure 73).240
Figure 73. ORTEP drawing of the complex cation in [Fe2(µ-O)(µ-L-alanyl-L-
alanine)(tpa)2](ClO4)4⋅2CH3CN⋅C4H9OH. 
Figure 72. Ellipsoid plot of the cation in [Fe(tpa)(dtc)]ClO4⋅0.25 MeOH. 
 
Table 19 summarises all X-ray structures registered at the Cambridge Crystallographic 
Database according to the selection criteria previously mentioned. 
4.1.4 TPA Complexes in Solid State (tabulated) 
An interesting substrate which can bind to these Fe(III)-TPA complexes is dithiolate 1,2-
benzenethiol (= H2dtc) (figure 72).237  
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Table 19. References of X-ray structure analyses selected from the Cambridge structural database of transition metal TPA complexes coordinating 
an additional complex ligand (M = transition metal – TPA complex) 
Metal Ions Additional 
Ligand Zn(II)        Cu(II) Fe(III) Ni(II) Co(III) Mn(II) Cr(III) Ru(II)
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4.2 Recognition Processes in Solution 
4.2.1 Recognition of Cysteines 
Holwerda and co-workers examined the complexation of [Cu(tpa)]2+ with cysteine.266 An 
intense, symmetric absorption band with λmax at 396 nm was observed upon mixing 
cysteine with [Cu(tpa)]2+ throughout the pH range 4.0 - 6.0. Stopped-flow studies at 396 
nm indicated that complexation was complete within the mixing time (3 ms), even at low 
cysteine concentrations. Excellent linear (Ae - Ao)-1 vs. [Cys]-1 correlations were found 
within the pH range 3.99-5.80, indicating the exclusive formation of a 1:1 cysteine-
[Cu(tpa)]2+ adduct. The formation constant (Kf) was calculated to be Kf = (1.21 ± 
0.06)⋅102 M-1. The pH dependence of Kf is consistent with the formation of a thiolate 
sulfur-Cu(II) bond: 
 
Cys-SH + Cu(tpa)2+ [(tpa)Cu-S-Cys]+ + H+
4.2.2 Phosphate Recognition in Solution 
As known from X-ray structures [Zn(tpa)]2+ has the ability to bind to phosphates.233,234 In 
2003 Mareque Rivas et al. reported 31P{1H} NMR titration experiments of dibenzyl 
phosphate (= dbp) with [Zn(tpa)]2+ in D2O at pD 7.4.  The addition of increasing amounts 
of the Zn(II) complex to solutions of DBP caused a progressive upfield shift of the 31P 
signal relative to free DBP. During these studies, other ligands with additional amino 
groups were used.  
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Figure 74. TPA ligands with additional amino groups.267
The additional electron donating amino groups do not participate in metal complexation, 
but form hydrogen bonds to the coordinated phosphate ion as confirmed by the X-ray 
structure of [Zn(bpapa)]2+ (bpapa is a tpa with one additional amino groups; see figure 74). 
 
 
Figure 75. A thermal ellipsoid plot of [(bpapa)Zn(µ-η2-DBP)2Zn(bpapa)]2+. 
Supported by this additional interaction, the binding of the phosphate ion to the BPAPA-
complex is stronger than the binding to the TPA-complex. This effect was also observed 
during binding studies of phenylphosphate (PP2-) to the metal complexes 69 and 70.268
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Scheme 21. Changes of the proton chemical shift of H6 of 69 (1mM in D2O) (ο) and 70 
(1mM in D2O) (•) upon addition of increasing amounts of PP at pH 7 ± 0.1 (50 mM 
HEPES) 
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A similar system was used to bind phosphate ions, supported by additional interactions to 
guanidinium moieties.269 The chemosensor developed in this study takes advantage of an 
indicator-displacement assay comprised of metallo-host 71 and 5(6)-carboxyfluorescein. 
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Scheme 22. Assembly for phosphate ion detection using an indicator-displacement assay 
 
 
71
 
Upon addition of aliquots of 71 to a solution of 5(6)-carboxyfluorescein, binding proceeds 
in a 1:1 stoichiometry with a color change from yellow to light orange. Added aliquots of a 
phosphate solution reverts the light orange color of the host-dye complex into the yellow 
color of free dye in solution. This indicates that the phosphate ion displaces the dye from 
the host cavity. 
4.3 Recognition Processes on Solid Surfaces 
Until now, no applications are reported using immobilised TPA-complexes for binding of 
guest molecules on supporting surfaces. 
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B. Main Part 
1. Investigation of Metal Complex – Amino Acid Side 
Chain Interactions by Potentiometric Titrationi
This chapter deals with the application of potentiometric titrations as a screening method 
for interactions of metal complexes with additional substrates related to side chains of 
amino acids.ii The resulting data was analysed by a computer program (HyperQuad2000) 
to determine every equilibrium constant involved in the titration experiment.iii
                                                 
i Kruppa, M.; Frank, D.; Leffler-Schuster, H.; König, B. Inorg Chem. 2005, under revision. 
ii All potentiometric titrations were performed by H. Leffler-Schuster. 
iii Data analysis was carried out by D. Frank as reported in his Zulassungsarbeit. 
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1.1 Introduction 
In 1975 Porath published a new type of chromatography which was first called "metal 
chelate chromatography", but later termed "immobilised metal (ion) affinity 
chromatography" (IMAC).1 The technique uses the different affinity of proteins to metal 
complexes immobilised on a chromatographic support.2
To find suitable metal complexes for this purification method it is necessary to know how 
strong metal ions are bound to a chelate (problem of metal leaching3). This information can 
be obtained using potentiometric titration of desired metal and chelate.4 IDA and NTA 
complexes are well investigated in this respect.5,6 But next to the binding between metal 
and immobilised chelate the interactions of substrate and metal complex are essential for 
the use in chelating purification methods. Weak binding will not generate a good 
separation. Very strong interactions will block all binding sites. Potentiometric titration can 
reveal equilibria between metal complexes and additional ligands.7 The binding of amino 
acids towards different metal complexes was investigated,8 but in most of the data the α-
amine and Carboxylate amino acid functional group are used to chelate the metal complex. 
Working with peptide or proteins, these binding processes are not relevant. C-terminal 
Carboxylate and N-terminal amine of one protein will not chelate a metal complex. The 
support of additional side chain functionalities is essential for a binding event. The 
histidine-tag strategy, in which several imidazole side chains and the N-terminal amino 
group reversibly coordinate to a metal complex, demonstrates this impressively. To 
understand which side chains of natural amino acids are suitable for metal coordination 
potentiometric titration may provide information. 
We report here the use of potentiometric titration to screen interactions between several 
metal complexes (figure 76) and functional groups of amino acid side chains. In addition to 
the well investigated IMAC metal complexes 72-75 we focus our investigation on M(II) 
cyclen complexes 76-79. 
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Figure 76. Structures of metal complexes 72-79 investigated in this study. 
We represent typical amino acids side chain functional groups by butyl amine (Lsy), acetic 
acid (Glu, Asp), ethanol (Ser, Thr), ethane thiole (Cys), imidazole (His), N-ethylguanidine 
hydrogenchloride (Arg), phenol (Tyr) and disodium phenylphosphate (phosphorylated 
Tyr). The investigation of each metal complex – substrate combination consists of three 
experiments. In two initial potentiometric titrations, we examine the properties of substrate 
and metal complex separately. The obtained pKs values for substrate and metal complex 
are then used to analyse the titration curve of a 1:1 mixture of substrate and metal complex. 
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1.2 Results and Discussion 
First, the substances resembling the side chain functional groups of natural amino acids 
(with exception of amide and thioether) were titrated, to determine their pKa values for our 
experimental conditions. Table20 summarises the results and compares with literature 
reported values. 
Table 20. Determination of pKa values for the different functional group  
Compound Deprotonation reaction(s) pKa (this work) 
pKa (Lit.) 
butylamine But-NH3+ / But-NH2 + H+ 11.3 10.66
di-Sodium- 
phenylphosphate a
RPO4H2 / RPO4H-+ H+ 1.0 0.89
 RPO4H- / RPO42--+ H+ 6.2 6.210
acetic acid HAc / Ac- + H+ 4.7 4.76
ethanol EtOH / EtO- + H+ b 15.96
ethanthiole EtSH / EtS- + H+ 13.2 10.1 – 11.311
imidazolea ImH2+ / ImH + H+ 7.3 7.06
 ImH / Im- + H+ b 14.46
N-ethylguanidine-
hydrogenchloride RNH3
+ / RNH2 + H+ b 13.412
phenol PhOH / PhO- + H+ 10.2 10.0 6
a 1 eq HClO4 for each protonation step was added 
b Determination of pKa value not possible using TEAOH 
 
The potentiometric titration of the metal complexes 72-79 was used to determine the pKa 
values of the deprotonation of coordinated water molecule(s). In cases of 74 and 75 an 
initial deprotonation of the third carbonic acid is taking place before the required NTA 
complex is formed. 
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Table 21. Potentiometric Titration of metal complexes investigated in this study 
Metal complex Deprotonation reaction(s) pKa 
Cu(II)-IDA (72) [Cu(ida)(H2O)3] / [Cu(ida)(OH)(H2O)2]- + H+ 9.0 
Ni(II)-IDA (73) [Ni(ida)(H2O)3] / [Ni(ida)(OH)(H2O)2]- + H+ 9.8 
Cu(II)-NTA 
(74) [Cu(ntaH)(H2O)3] / [Cu(nta)(H2O)2]
- + H+ 2.1 
 [Cu(nta)(H2O)2]- / [Cu(nta)(OH)(H2O)]2- + H+ 9.9 
 [Cu(nta)(H2O)(OH)]- / [Cu(nta)(OH)2]3- + H+ 12.8 
Ni(II)-NTA 
(75) [Ni(ntaH)(H2O)3] / [Ni(nta)(H2O)2]
- + H+ 2.1 
 [Ni(nta)(H2O)2]- / [Ni(nta)(OH)(H2O)]2- + H+ 13.8 
Cu(II)-Cyc (76) [Cu(cyc)(H2O)]2+ / [Cu(cyc)(OH)]+ + H+ 12.9 
Ni(II)-Cyc (77) [Ni(cyc)(H2O)]2+ / [Ni(cyc)(OH)]+ + H+ 12.5 
Zn(II)-Cyc (78) [Zn(cyc)(H2O)]2+ / [Zn(cyc)(OH)]+ + H+ 8.1 
Cd(II)-Cyc (79) [Cd(cyc)(H2O)]2+ / [Cd(cyc)(OH)]+ + H+ 11.2 
 
The potentiometric titrations to identify interactionsbetween a functional group and a metal 
complex were carried out at a constant 1:1 substrate to metal complex ratio. Variation of 
the ratio was not expected to yield extra information, and was not attempted. 
 
M(II)-IDA Titration 
As an already established system for poly-His-tag binder M(II)-IDA complexes were used 
to verify the screening method. Cu(II)- and Ni(II)-IDA complexes are known to have the 
highest affinity towards histidines.2 Figure 77 shows the affinities of all tested substrates 
towards these metal complexes 72 and 73. As expected, among all tested compounds only 
imidazole showed significant binding affinity to the metal complexes. 
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Figure 77. Potentiometric screening results for Cu(II)-IDA 72 and Ni(II)-IDA 73 
complexes. 
All other experiments showing no binding event were analysed by two independent 
equilibria already known from the separate titration experiments. The pKa values fit very 
well to the data obtained and summarised in table 20 and table 21. 
The equilibria shown in scheme 23 were used to analyse the potentiometric data. The 
initial deprotonation step (pKa1 values can be found in table 21) is followed by a 1:1 
complexation of imidazole and M(II)-IDA13 (pKa2 (72) = 13.0, pKa2 (73) = 12.9). 
Scheme 23. Deprotonation and binding equilibria used to fit potentiometric titration data 
of imidazole in the presence of 72 or 73 
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Figure 78. Species distribution plots of 72 (left) and 73 (right) in the presence of 
imidazole. 
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The species distribution plots of 72 and 73 are similar. The increase in deprotonated 
[Cu(ida)(H2O)2(OH)]- is more continuous with increasing basicity, while the Ni(II) 
complex is deprotonated very slowly until a pH of 9.5. Similar characteristics are observed 
for the aggregate formed between metal complex and imidazole. At the end of titration (pH 
13) both imidazole-metal complex aggregates represent nearly 85 % of the complexes 
species. 
 
M(II)-NTA Titration 
In the last decade NTA complexes were used more frequently than IDA complex for 
immobilisation of His-tagged proteins. Possessing an additional Carboxylate function for 
metal complexation, the binding between chelate and metal ion is tighter.14
In the same way as shown for IDA, the NTA complexes 74 and 75 were used in a 
potentiometric screening experiment. Figure 79 illustrates the affinities of all tested 
substrates to the metal complexes 74 and 75. Among all tested compounds only imidazole 
showed affinity to the metal complexes. 
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Figure 79. Potentiometric screening results for Cu(II)-NTA 74 and Ni(II)-NTA 75 
complexes. 
Similar to the titration of the M(II)-IDA complexes, data from titrations without binding 
process were analysed by two independent deprotonation equilibria of substrate and metal 
complex. The pKa values derived fit very well to the previously obtained data in table 20 
and table 21. 
The first reaction taking place is a proton transfer and takes place after mixing imidazole 
with 74 or 75. Imidazole is protonated and the NTA complex is formed (scheme 24). 
Starting the potentiometric titration, imidazole is deprotonated again. The equilibria used 
for analysis of the obtained data are shown in scheme 24.  pKa1  values are listed in table 
21. The deprotonation of the formed imidazole-M(II)-NTA complex is only observed for 
titration of 74 (pKa2 = 13.8). 
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Scheme 24. Deprotonation and binding equilibria assumed to fit potentiometric titration 
data of imidazole in the presence of 74 or 75 
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Figure 80. Species distribution plots of 74 (left) and 75 (right) in the presence of 
imidazole. 
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Comparing the binding between imidazole and 74 with the interactions between imidazole 
and 75 some differences are observed. The interactions of 75 and imidazole is stronger 
compared to the Cu(II) complex. While the binding to the Ni(II) complex starts around pH 
6, the Cu(II) complex starts interacting with imidazole only after reaching pH 8. 
 
M(II) Cyclen Titration 
The previous chapters demonstrated the ability of potentiometric screening to identify 
substrate-metal complex interactions. Cyclen complexes are known to show high affinities 
towards several functional groups, like phosphates or imides.15,16 Potentiometric 
measurements were used to find unknown interactions between side chain functionalities 
of natural amino acids and these M(II)-cyclen complexes. Figure 81 shows the affinities of 
the examined substrates to the cyclen complexes 76-79.  In addition to the previously 
described interactions of phosphates and Zn(II)-cyclen 78 the measurement reveal, that 
imidazole is binding to Zn(II)-cyclen 78 and Cd(II)-cyclen 79. 
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Figure 81. Potentiometric screening results for Cu(II)-cyclen 76, Ni(II)-cyclen 77, Zn(II)-
cyclen 78, and Cd(II)-cyclen 79 complexes. 
All other titrations resulted just in the independent deprotonation of two compounds in 
solution. Scheme 25 illustrates the assumed equilibria for potentiometric data fitting of the 
titration of Zn(II)-cyclen in the presence of di-sodium phenylphosphate. Phenylphosphate 
and water coordinated to 78 show protonation equilibria with pKa values of 6.0 and 8.4, 
resp. 
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Scheme 25. Equilibira assumed in the titration of 78 in the presence of phenylphosphate 
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Figure 82. Potentiometric titration data (left)of a 1:1 mixture of 78 and phenylphosphate 
(black dots are experimental data; red line is the calculated fitting) and species distribution 
plot (right). 
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The distribution plot of the interaction between 78 and phenylphosphate shows that 
binding starts at around pH 9 and at pH 11 approx. 70 % of 78 is coordinated by 
phenylphosphate. Analysing the potentiometric titration of 78 and imidazole resulted in 
more complex equilibria. Initial one imidazole coordinates to one cyclen. At around pH 9.5 
this imidazole is deprotonated, promoted by the Lewis acidic metal complex. The 
negatively charged imidazole now attracts a second Zn(II)-cyclen complex and forms a 2:1 
Zn(II)-cyclen – imidazole aggregate. 
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Scheme 26. Deprotonation and binding equilibria of 78 and imidazole 
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igure 83. Potentiometric titration data (left) of a 1:1 mixture of 78 and imidazole (black 
The titration experiment of an equimolar mixture of 79 and imidazole resulted in very 
dots are experimental data; red line is the calculated fitting) and species distribution plot 
(right). 
simple deprotonation-binding equilibrium and is shown in scheme 27. 
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Scheme 27. Deprotonation and binding equilibrium of 79 and imidazole 
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Figure 84. Potentiometric titration data (left) of a 1:1 mixture of 79 and imidazole (black 
dots are experimental data; red line is the calculated fitting) and species distribution plot 
(right). 
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1.3 Conclusion 
Based on potentiometric titration data it was possible to prove substrate-metal-complex 
interactions in aqueous solution. In addition to already known interactions of M(II)-
IDA/M(II)-NTA and imidazole binding of imidazole to M(II)-cyclen was discovered. 
Cd(II)-cyclen showed imidazole binding and Zn(II)-cyclen binds to imidazole and 
phosphate. The newly identified metal complex to amino acid side chain functional group 
interactions, and the excluded interactions, may help to develop and optimise new IMAC 
polymers for protein purification. 
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1.4 Experimental Section 
1.4.1 Instruments and general techniques 
 
Melting points (mp) were determined with a Büchi SMP 20 and are uncorrected. 
 
IR-spectra were recorded with a Bio-Rad FTS 2000 MX FT-IR and Bio-Rad FT-IR FTS 
155. 
 
NMR: Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 K), Bruker Avance 
400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), Bruker Avance 300 (1H: 300.1 MHz, 
13C: 75.5 MHz, T = 300 K). The chemical shifts are reported in δ [ppm] relative external 
standards (solvent residual peak). The spectra were analysed by first order, the coupling 
constants are in Hertz [Hz]. Characterisation of the signals: s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, bs = broad singlet, dd = double doublet, dt = double 
triplet, ddd = double double doublet. Integration is determined as the relative number of 
atoms. Error of reported values: chemical shift: 0.01 ppm for 1H-NMR, 0.1 ppm for 13C -
NMR; Coupling constants: 0.1 Hz. The used solvent is reported for each spectrum. 
 
MS-Spectra: Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD), Finnigan MAT 
TSQ 7000 (ESI). Xenon serves as the ionisation gas for FAB.  
 
X-Ray: Data collections were performed at 173 (± 1) K with graphite-monochromated 
Mo-Kα radiation (λ = 0.71073 Å) on a STOE-IPDS diffractometer. The structures of the 
compounds were solved by direct methods SIR97 and refined by full-matrix least-squares 
on F2 using SHELXL-97. 
 
Optical rotation was measured on a Perkin Elmer Polarimeter 241 with sodium lamp at 
589 nm in a specified solvent. 
 
Elemental Analysis: Microanalytical Laboratory of the University of Regensburg. 
 
Thin layer chromatography (TLC) was performed on aluminia plates coated with silica 
gel (Merck silica gel 60 F 254, layer thickness 0.2 mm). Visualisation was accomplished 
by UV-light (λ = 254 nm) and ninhydrine in EtOH. 
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 Column chromatography was performed on silica gel (70-230 mesh) from Merck. 
 
General Material. TEAOH (Merck), TEAP (Fluka), mono sodium phthalate (Merck), 
perchloric acid (60%, Merck), Iminodiacetic acid (IDA) (Fluka), Cu2(CO3)(OH)2 (Alfa 
Aesar), NiCO3⋅2NiOH(OH)2⋅4H2O (Alfa Aesar), nitirilotriacetic acid (Fluka), cyclen 
(Schering), copper(II) perchlorate hexahydrate (Alfa Aesar), nickel(II) perchlorate 
hexahydrate (Alfa Aesar), zinc(II) perchlorate hexahydrate (Alfa Aesar), cadmium(II) 
perchlorate hexahydrate (Alfa Aesar), ethanol (Merck), acetic acid (100%, Merck), phenol 
(Merck), imidazole (Fluka), butylamine (Fluka), N-ethylguanidine hydorgenchloride 
(Vocado), and di-soidum phenyl phosphate (Fluka) were bought and used without further 
purification. 
 
Potentiometric Titrations. All titrations were performed under N2 atmosphere with a 
computer controlled pH-meter (pH 3000, WTW) and dosimat (Dosimat 665, Metrohm). 
For all titrations 0.1 M perchloric acid and 0.1 M tetraethylammonium hydroxide 
(TEAOH) in water containing tetraethylammonium perchlorate (TEAP) to maintain an 
ionic strength of I = 0.1 were used. TEAOH solutions were calibrated with mono sodium 
phthalate. A titration of perchloric acid with TEAOH solution was used for calibration and 
to determine log Kw. The Irving-factor (AI) was determined according to pHmeasurement = 
pHreal + AI. All measurements were performed at 25 °C. Data analysis was performed on a 
computer using Hyperquad2000 (Version 2.1, P. Gans). 
 
X-Ray Data 
[Cu(ida)(H2O)2] (72) 
C4CuH9NO6, Mr = 230.66, blue translucent prism, orthorhombic, Space group P b c a, a = 
10.2310(7) Å, b = 10.4043(7) Å, c = 13.6500(12) Å, α = β = γ = 90, Z = 8, V = 
1452.99(19) Å3, Dx = 2.109 mg/m3, µ = 2.999 mm-1, F(000) = 936, Crystal size 0.60 x 0.20 
x 0.20 mm, θ-range for data collections 2.98 to 25.86 °, Index ranges –12 <= h <= 12, -12 
<= k <= 12, -16 <= l <= 16, Reflections collected/unique 18368/1390 [Rint = 0.0287], 
Data/restraints/parameters 1390/1/145, Goodness-of-fit on F2 1.096, Final R indices 
[I>2σ(I)] R1 = 0.0165, wR2 = 0.0488 R indices (all data) R1 = 0.0185, wR2 = 0.0498, 
largest diff. peak and hole 0.306 and -0.418 e. Å-3. 
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H[Ni(nta)(H2O)3] (75) 
C6H12NNiO9, Mr = 299.99, turquoise translucent stick, orthorhombic, Space group P b c a, 
a = 6.5876(4) Å, b = 12.3015(9) Å, c = 27.8271(16) Å, α = β = γ = 90, Z = 8, V = 
2255.0(3) Å3, Dx = 1.884 mg/m3, µ = 1.771 mm-1, F(000) = 1328, Crystal size 0.60 x 0.30 
x 0.10 mm, θ-range for data collections 2.21 to 25.23 °, Index ranges –7 <= h <= 7, -14 <= 
k <= 14, -32 <= l <= 32, Reflections collected/unique 19824/2014 [Rint = 0.0411], 
Data/restraints/parameters 2014/0/223, Goodness-of-fit on F2 1.063, Final R indices 
[I>2σ(I)] R1 = 0.0204, wR2 = 0.0546 R indices (all data) R1 = 0.0215, wR2 = 0.0552, 
largest diff. peak and hole 0.368 and –0.208 e. Å-3. 
 
 
 
[Cu(cyc)](ClO4)2 (76) 
C8Cl2CuH20N4O8, Mr = 433.0, blue stick, orthorhombic, Space group P 21/n, a = 8.9260(8) 
Å, b = 15.0469(10) Å, c = 11.9045(11) Å, α = γ = 90 °, β = 92.904(11), Z = 4, V = 
1596.8(2) Å3, Dx = 1.808 mg/m3, µ = 1.748 mm-1, F(000) = 892, Crystal size 0.48 x 0.06 x 
0.06 mm, θ-range for data collections 2.66 to 25.86 °, Index ranges –10 <= h <= 10, -18 <= 
k <= 18, -14 <= l <= 14, Reflections collected/unique 5937/5941 [Rint = 0.0000], 
Data/restraints/parameters 5941/0/221, Goodness-of-fit on F2 0.851, Final R indices 
[I>2σ(I)] R1 = 0.0407, wR2 = 0.0897 R indices (all data) R1 = 0.0676, wR2 = 0.0955, 
Absolute structure parameter none, largest diff. peak and hole 0.623 and –0.337 e. Å-3. 
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1.4.2 Synthesis 
 
[Cu(ida)(H2O)2] (72):  
Iminodiacetic acid (IDA) (2.40 g, 18.8 mmol) and Cu2(CO3)(OH)2, (2.00 g, 9.0 mmol) 
were dissolved in water (150 mL). The solution was stirred at 60 °C for 2 h. The blue 
suspension formed was cooled to r.t. and filtered. Slowly evaporation of the solvent 
delivered 72 (8.0 mmol, 1.85 g, 89 %) as dark blue crystals.  
mp > 200 °C. – IR (KBr) [cm-1]: ν~  = 3453, 3273, 2932, 1574, 1396. – Elemental analysis 
calcd. (%) for C4CuH9NO6 (230.66): C 20.82, H 3.93, N 6.07; found C 21.04, H 3.69, N 
6.02. 
 
[Ni(ida)(H2O)3] (73): 
Iminodiacetic acid (IDA) (1.00 g, 7.5 mmol) and NiCO3⋅2NiOH(OH)2⋅4H2O (0.94 g, 
2.5 mmol) were dissolved in water (150 mL). The solution was stirred at 60 °C for 2 h. The 
bluish-green suspension formed was cooled to r.t. and filtered. Slowly evaporation of the 
solvent delivered 73 (2.2 mmol, 0.62 g, 88 %) as turquoise crystals. 
mp > 200 °C. – IR (KBr) [cm-1]: ν~  = 3456, 3279, 2935, 1568, 1406. – MS (ESI, 
MeOH/H2O/MeCN/AcOH): m/z (%) = 207 (100) [Ni(ida) + NH4+]. – Elemental analysis 
calcd. (%) for C4H9NiNO6 (225.80): C 21.34, H 4.03, N 6.22; found C 21.12, H 3.88, N 
6.10. 
 
H[Cu(nta)(H2O)3] (74): 
Nitrilotriacetic acid (NTA) (2.00 g, 10.5 mmol) and Cu2(OH)2CO3 (1.16 g, 5.2 mmol) were 
dissolved in MeCN (40 mL). The mixture was refluxed for 3 h and was filtered 
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immediately. The resulting blue solution was evaporated and crystallisation yielded 74 
(9.2 mmol, 2.81 g, 88%) as blue crystals.  
mp > 200 °C. – IR (KBr) [cm-1]: ν~  = 3333, 2943, 2651, 2593, 2362, 1593, 916, 763. – MS 
(ESI, MeOH/H2O/MeCN/AcOH):m/z (%) = 250 (100) [Cu(nta)-], 333 (76 %), [Cu(nta)- + 
2 MeCN]. – Elemental analysis calcd. (%) for C6CuH12NO9 (304.98): C 21.61, H 3.97, N 
4.59; found C 21.65, H 3.50, N 4.20. 
 
H[Ni(nta)(H2O)3] (75): 
Nitrilotriacetic acid (NTA) (5.00 g, 26.2 mmol) and NiCO3⋅2 Ni(OH)2⋅4H2O (3.26 g, 
8.6 mmol) were dissolved in MeCN (150 mL). After refluxing for 1 h the solution was 
concentrated under reduced pressure. The blue-green solid was crystallised in water. 75 
(7.9 mmol, 2.37 g, 92 %) is a green crystalline solid.  
mp > 200 °C. – IR (KBr) [cm-1]: ν~  = 3502 cm-1, 3934, 2724, 988, 912. – MS (ESI, 
MeOH/H2O/MeCN/AcOH): m/z (%) = 246 (100) [Ni(nta)-]. – Elemental analysis calcd. 
(%) for C6H12NNiO9 (299.99): C 24.00, H 4.03, N 4.67; found C 23.72, H 3.82, N 4.32. 
 
[Cu(cyc)](ClO4)2 (76): 
Cyclen (0.70 g, 4.0 mmol) and copper(II) perchlorat-hexahydrate (1.50 g, 4.0 mmol) were 
separately dissolved in MeOH (15 mL) and the solutions combined. The resulting 
suspension is refluxed for 30 min. The precipitating needles were filtered off and the 
filtrate concentrated. The blue amorphous solid was crystallised in methanol. 76 
(3.8 mmol, 1.65 g, 94 %) is a dark blue crystal.  
mp > 200 °C. – IR (KBr) [cm-1]: ν~  = 3285 cm-1, 2938, 2906, 1084, 625. – MS (ESI, 
MeCN): m/z (%) = 117 (24) [Cu(cyc)2+], 138 (100) [Cu(cyc)2+ + MeCN], 158 (44) 
[Cu(cyc)2+ + 2 MeCN], 334 (38) [Cu(cyc)2++ ClO4-], 705 (< 5) [2 Cu(cyc)2+ + 2 ClO4- + Cl-
], 769 (5) [2 Cu(cyc)2++ 3 ClO4-]. – Elemental analysis calcd. (%) for C8Cl2CuH20N4O8 
(433.0): C 22.10, H 4.62, N 12.97; found C 22.17, H 4.62, N 12.97. 
 
[Ni(cyc)](ClO4)2 (77):  
Cyclen (0.49 g, 2.9 mmol) and nickel(II) perchlorat-hexahydrate (1.04 g, 2.9 mmol) were 
separately dissolved in MeOH (15 mL) and the solutions combined. The resulting 
suspension was refluxed for 30 min. The mixture was evaporated to dryness and the 
amorphous solid was crystallised in methanol. 77 (2.6 mmol, 1.10 g, 90 %) is a yellow-
brown solid.  
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mp > 200 °C. – IR (KBr) [cm-1]: ν~  = 3429 cm-1, 3259, 2939, 2888, 1089. – MS (ESI, 
MeOH/H2O/MeCN/AcOH): m/z (%) = 115 (12) [Ni(cyc)2+], 136 (58) [Ni(cyc)2+ + MeCN], 
156 (100) [Ni(cyc)2+ + 2 MeCN], 177 (20) [Ni(cyc)2+ + 3 MeCN], 299 (20) [Ni(cyc)2+ - 
H+], 265 (10) [Ni(cyc)2+ + Cl- ], 289 (28) [Ni(cyc)2+ + CH3COO-], 229 (15) [Ni(cyc)2+ + 
ClO4-]. – Elemental analysis calcd. (%) for C8Cl2H20N4NiO8 (429.92): C 22.35, H 4.69, N 
13.03; found C 21.89, H 4.53, N 12.71. 
 
[Zn(cyc)](ClO4)2 (78): 
Cyclen (0.90 g, 5.4 mmol) and zinc(II) perchlorat-hexahydrate (2.00 g, 5.4 mmol) were 
separately dissolved in MeOH (15 mL) and the solutions combined. The resulting 
suspension was refluxed for 30 min. The mixture was evaporated to dryness and the 
amorphous solid was crystallised in methanol. 78 (2.6 mmol, 1.10 g, 90 %) is a colourless 
crystalline solid.  
mp >200 °C. – IR (KBr) [cm-1]: ν~  = 3429, 3178, 2918, 3259, 2953, 1090. – MS (ESI, 
MeOH/H2O/MeCN/AcOH): m/z (%) = 110 (8) [Zn(cyc)2+], 138 (100) [Zn(cyc)2+ + 
MeCN], 295 (26) [Zn(cyc)2+ + CH3COO-], 335 (58) [Zn(cyc)2+ + ClO4-), 773 (13) 
[2 Zn(cyc)2+ + 3 ClO4-]. – Elemental analysis calcd. (%) for C8Cl2H20N4O8Zn (436.61): C 
22.01, H 4.62, N 12.83; found C 21.76, H 4.80, N 12.65. 
 
[Cd(cyc)](ClO4)2 (79):  
Cyclen (1.64 g, 9.5 mmol) and cadmium(II) perchlorat-hexahydrate (4.00 g, 9.5 mmol) 
were separately dissolved in MeOH (15 mL) and the solutions combined. The resulting 
suspension was refluxed for 30 min. The mixture was evaporated to dryness and the 
amorphous solid was crystallised in methanol. 79 (3.8 mmol, 1.65 g, 94 %) is a colourless 
crystalline solid.  
mp > 200 °C. – IR (KBr) [cm-1]: ν~ = 3499, 3318, 29096, 2864, 1089, 626. – MS (ESI, 
MeCN): m/z (%) = 142 (12) [Cd(cyc)2+], 163 (100) [Cd(cyc)2+ + MeCN], 183 (64) 
[Cd(cyc)2+ + 2 MeCN], 385 (24) [Cd(cyc)2+ + ClO4-], 867 (36) [2 Cd(cyc)2+ + 3 ClO4- ]. – 
Elemental analysis calcd. (%) for C8CdCl2H20N4O8 (484.0): C 19.87, H 4.17, N 11.59; 
found C 19.34, H 4.27, N 11.30. 
 
 136
2. Molecular Recognition using Modular Receptor 
Synthesis 
Most synthetic receptors already published in literature (see introduction) have one thing in 
common: Each receptor is designed for binding to a specific substrate. Therefore, each 
project starts by synthesising a desired receptor using the individual expertise of the 
different research groups. 
However, if the final receptor is divided into single recognition segments, which can be 
linked via standardised reactions, a simple and modular access towards a wide variety of 
synthetic receptors can be achieved (figure 85). 
 
 
 
Figure 85. A substrate (blue) is bound by a synthetic receptor (multi colour) assembled by 
a building block approach. 
One of the best established methods for covalent linking of molecules is the peptide 
coupling. The possibility of orthogonal protection of amines and acids, the simple 
activation of carbonic acids in coupling reactions and the stability of the amide bond are 
reasons for the wide use of this ligation method. Therefore, the linkage of building blocks 
for molecular recognition to extended synthetic receptors should be easily done using 
peptide coupling. 
Building blocks of a receptor construction kit can be separated into different classes (figure 
86). 
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Terminal Recognition units A: 
The receptor molecule is assembled by peptide coupling. For that reason every receptor 
backbone contains a N-terminal and a C-terminal ending which can be addressed by 
terminal recognition units A (chapter 2.1). 
 
Recognition units in the side chain of natural amino acids B: 
To incorporate a recognition unit within the receptor structure, side chains of natural amino 
acids can be used. The recognition units B can be linked to lysines, aspartic acids or 
glutamic acids by peptide coupling. Tyrosines can be addressed by substitution reactions 
(chapter 2.2.1). 
 
Unnatural amino acids with binding sites C: 
Possessing an amine and a carboxylate this building block can be connected like any other 
natural amino acid into a receptor molecule. The side chain of this unnatural amino acid C 
already contains a chelator, which is used for the desired recognition process. Therefore, 
no additional linkage of the binding site (which is necessary for building block B) is 
needed (chapter 2.2.2). 
 
 
 
Figure 86. Terminal recognition units (A); building blocks with side chain functionality 
transferable into a recognition unit (B); receptor building blocks combining amino acid 
functionality and recognition unit (C) (red bars represent the amide bonds). 
The following chapters describe the synthesis and use of different recognition building 
blocks. In many cases natural amino acids serve as the starting material.  
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2.1 Terminal Receptor Building Blocks 
2.1.1 N-terminal Receptor Building Blocks 
N-terminal building blocks are chelators functionalised with an additional carboxylic acid. 
Peptide coupling to the N-terminal end or a lysine side chain allows incorporating them 
into the synthetic receptor chain. 
2.1.1.1 IDA-Building Blocks 
N-terminal IDA building blocks contain two carboxylates (red ellipse), which have to be 
protected orthogonally to the carboxyl group for ligation with the receptor (blue circle). 
Therefore, one main task was the choice of suitable protecting groups. An overview is 
given in table 22. 
Table 22. Possible variations for carbonic acid protection 
N
O
R1
O
O O
R1
O
O
R2n
 
Binding Site Ligation Site
 
 
R1 R2 Cleavage of R2 Cleavage of R1 
Me, Et tBu HCl/Ether or 
TFA/DCM 
LiOH, 
Water/Acetone 
Me, Et Bzl Pd/C, H2 LiOH, 
Water/Acetone 
tBu Bzl Pd/C, H2 HCl/Ether or 
TFA/DCM 
Bzl tBu HCl/Ether or 
TFA/DCM 
Pd/C, H2
 
The deprotection of the recognition unit protecting groups will take place in a 
multifunctional complex receptor compound. Some of the final compounds will not allow 
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all reaction conditions. Therefore, harsh reaction conditions for deprotection must be 
avoided. R1 has to represent a protecting group, which is orthogonal to the total receptor 
synthesis. The cleavage of R2 generates zwitterionic compounds, which are difficult to 
purify. In addition, some of the starting compounds are not easily prepared or are very 
expensive. 
First a synthesis was chosen with methylester protected IDA-units. The carbonic acid for 
ligation towards the receptor molecule was benzyl protected. Via hydrogenolytic cleavage 
of the benzylester, a differentiation between the two types of carbonic acids was possible. 
As shown in scheme 28 80 was obtained in good yields using an alkylation of dimethyl 
iminodiacetate hydrogenchloride. The following deprotection using Pd/C under 10 bar H2-
atmosphere was nearly quantitatively. 
Scheme 28. Synthesis of the N-terminal IDA-receptor 81 
 
NH
O
O
O
O
N
O
O
O
O
O OBr O
O K2CO3
N
O
O
O O
O
OH
+
, KI,
MeCN
92 %
Pd/C, H2,
Ethanol
96 %
80 81  
 
To develop optimal coupling conditions for such kind of terminal receptors, 81 was reacted 
with H-Gly-OBzl. Using EDC/HOBt to create the active ester of 81 it was possible to 
obtain 82 in good yields (scheme 29). The by one glycine unit extended building block 82 
was hydrogenolytical deprotected. 83 can now be used for further coupling reactions in 
receptor synthesis. 
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Scheme 29. Extension of the terminal recognition unit 81 with one glycine unit 
 
N
O
O
O O
N
H
O
O O
Bzl
N
O
O
O O
N
H
O
OH
O
N
O
O
O O
O
OH
H-Gly-OBzl×HOTos,
EDC, HOBt,
DIPEA, DCM
71 %
Pd/C, H2,
Ethanol
91 %
81 82 83
 
These methylester protected recognition unit cannot be used in receptors which are instable 
towards bases. Building blocks with benzylester protected binding sites are needed for 
such receptor synthesis. 84, 85, and 86 were obtained in good to very good yields via 
double alkylation of H-Gly-OtBu, H-β-Ala-OtBu or H-γ-Abu-OtBu with 
benzylbromoacetate respectively. The following deprotection of the tert-butylesters 
yielded in the N-terminal IDA-units 87, 88, and 89 (scheme 30). 
Scheme 30. Synthesis of N-terminal recognition units with benzylester protected IDA-
chelators 
N
O
O
O O
O
O
n
 
NH2
O
O n O
O
Br
N
O
O
O O
O
OH
n
 
+
K2CO3, KI,
MeCN
n = 1
n = 2
n = 3
84
85
86
n = 1
n = 2
n = 3
79 %
100 %
100 %
*HCl
HCl/Et2O
87
88
89
n = 1
n = 2
n = 3
66 %
88 %
86 %
n = 1
n = 2
n = 3
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The advantage of benzylester protecting groups is the easy work up without additional 
purification after hydrogenolytical cleavage. 
If the final receptor molecule is unstable towards hydrogenolytical and basic reaction 
conditions, tert-butylesters can be used to protect the IDA binding site. The deprotection of 
the chelating unit is accomplished at strong acidic conditions. The benzylester-protected 
derivatives of glycine, β-alanine, and γ-aminobutyric acid were converted into the tert-
butyl protected building blocks 90, 91, and 92 respectively using double alkylation of the 
primary amine (scheme 31). The benzylester could be cleaved nearly quantitively to obtain 
the zwitterions 93, 94, and 95 respectively. 
Scheme 31. N-terminal IDA-building blocks with tert-butylester protected binding site 
N
O
O
O O
O
O
n
 
NH2
O
O n O
O
Br
N
O
O
O O
O
OH
n
 
+
86 %
61 %
61 %
n = 1
n = 2
n = 3
90
91
92
n = 1
n = 2
n = 3
K2CO3, KI,
MeCN
93
94
95
n = 1
n = 2
n = 3
93 %
100 %
93 %
n = 1
n = 2
n = 3
Pd/C, H2,
Ethanol
 
 
2.1.1.2 BPA-, Cyclen-, and NTA-Building Blocks 
BPA1- and cyclen-building blocks2 with N-terminal ligation functionality could be 
obtained in similar reactions (scheme 32). Other research groups have already published 
these reactions. 
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Scheme 32. Literature known syntheses of N-terminal cyclen and BPA building blocks 
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n 
N
NN
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O
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R
Cl
N N
N
N O
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n
 
Br
O
O
R
+
+
n = 1-3
R = Me, Et, Bzl
 
 
NTA-recognition units with an additional acid are synthesised using the amino acids 
aspartic and glutamic acid.i
2.1.2 C-terminal Receptor Building Blocks 
Receptor building blocks possessing an additional amine as ligation functionality are 
named C-terminal recognition units. They are used as recognition building blocks, which 
can be linked to the C-terminal end, an aspartic or a glutamic acid of a receptor molecule. 
2.1.2.1 IDA-Building Blocks 
Due to the easy access to mono Boc-protected ethylendiamine 96,3 this diamine was taken 
as a basis for the first receptor synthesis (scheme 33). Using a nucleophilic substitution 
reaction, this amine was converted into the IDA units 97, 98, and 99 with good yields. 
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i Ritter, S. unpublished results. 
Scheme 33. Synthesis of C-terminal building blocks 100 and 101 
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R
O N
N
H
O
R
O
O O
R
O
ON
H
NH2
O
O
K2CO3
+
, KI,
MeCN
R = Bzl
R = Me
R = Et
87 %
72 %
72 %
R = Bzl
R = Me
R = Et
97
98
99
96
 
N
NH2
O
R
O
O O
R
*2HCl
HCl/Et2O
99 %
88 %
R = Bzl
R = Me
R = Bzl
R = Me
100
101  
 
The Boc-group was deprotected in HCl saturated ether with good yields to obtain the 
ammonium chlorides 100 and 101. Peptide coupling with moderate yields resulted in 102. 
One problem of this reaction is the possibility of an intramolecular lactam formation of the 
terminal amine. The cleavage of the Boc-group gave the extended N-terminal receptor 103 
(scheme 34). 
Scheme 34. Peptide coupling of the N-terminal IDA unit 100 
 
N
N
H
O
O
O O
Bzl
O
N
H
Bzl
boc
N
N
H
O
Bzl
O
O O
Bzl
NH2
O
EDC, HOBt,
DIPEA, DCM
Boc-Gly-OH,
64 %
*2HCl
HCl/Et2O
90 %
100
102 103  
 
Mono-Boc-butyldiamine 1044 reacts analogously. The resulting 106 was used for peptide 
coupling with Boc-Gly-OH. A less favourable intramolecular lactamisation of the 
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recognition unit was expected due to the  formation of an eight-membered ring. 
Unfortunately, the yield of the synthesis of 107 increased just a little compared to the 
synthesis of 102(scheme 35). 
Scheme 35. Synthesis of the C-terminal IDA unit 107 
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2.1.2.2 NTA-Building Blocks 
C-terminal NTA-units are accessible using lysine.5 On optimisation of this literature-
known reaction, 109 was obtained in 91 % yield starting from H-Lys(Z)-OH (scheme 36). 
Scheme 36. Optimised synthesis of C-terminal NTA receptor building block 109 
 
OH
N
H
O
O
NH2 O
O
N
HO
NH2
z
NH2
N
O
O
O O
O
O
SOCl2,
MeOH
*HCl
H-Lys(Z)-OH
98 %
1) Ethylbromoacetate,
    K2CO3, MeCN
2) Pd/C, H2,
      EtOH
93 %
108
109  
 
The intensive use of this receptor unit is discussed in chapter 3 in more detail. Necessary 
for the successful incorporation of 109 into receptor molecules is an efficient coupling 
method. In this case, the combination of EDC and HOBt once again gave the best results. 
The sequence of adding the reagents is important for the success of the coupling reaction. 
High yields were only obtained if the active ester was formed under ice cooling before the 
amine was added. The elongation of the receptor by one glycine unit gave 110 in 71 % 
yield. The Boc-deprotection yielded 111 quantitatively (scheme 37). 
In addition to optimising the coupling reaction, it is also essential to adjust the deprotection 
and complexation reaction of the NTA-unit. For this reason, 110 was hydrolysed with 
LiOH in a mixture of acetone/water 3:1 over night at room temperature. The resulting 
lithium carboxylate 112 was used for complexation of Ni(II), which is quantitative. 113 
was used for microcalorimetric titration of the pentapeptide H-His-Leu-Leu-Val-Phe-OMe 
in DMSO (figure 87) to prove the high affinity of this peptide based receptor to terminal 
histidine. 
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Scheme 37. Coupling and complexation of 109 
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Figure 87. Microcalorimetrical titration of 
113 (c = 0.1 mM) and H-His-Leu-Leu-
Val-Phe-OMe (c = 1 mM) in DMSO. 
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2.1.2.3 BPA- and Cyclen-Building Blocks 
C-terminal cyclen building blocks have been already published.6 Analogue Boc-protected 
BPA-units are available using a double alkylation of mono-Boc-protected diamines and 
were published by Nagano et al. and Kim et al. (scheme 38).7
Scheme 38. Synthesis of cyclen and BPA receptor building blocks reported in literature 
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2.1.3 Terminal recognition units with two chelating sites 
As shown in the introduction, receptors having two metal complexes can bind to suitable 
substrates with very high affinities. However, most of these published receptors have no 
additional functionality, which can be used for extension of the receptor molecule. 
In this chapter, the synthesis of terminal recognition units with two chelating arms bearing 
an additional functionality for receptor ligation is reported. 
2.1.3.1 Bidentate IDA-units 
Starting from 3,5-bis-(bromomethyl)-benzoic acid methylester, terminal bidentate IDA 
receptors were synthesised. tert-Butyl- (116)8 and benzyl-protected (115)9 IDA-units were 
introduced in the benzylic position of 114 via nucleophilic substitution. The recognition 
units 117 and 118 were obtained in poor yields. 
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Scheme 39. Synthesis of the IDA-sandwich receptors 117 and 118 
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2.1.3.2 Bidentate BPA-units 
Starting from Hamachi phosphate receptor (see introduction), 114 was substituted with two 
BPA-units. 
Scheme 40. Synthesis of the BPA sandwich receptor 119 
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While the synthesis of 119 was accomplished in good yields, the ester cleavage was not 
successful until now. Vomasta is currently further investigating this molecule.ii
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ii Vomasta, D. Diploma Thesis, University of Regensburg, ongoing. 
2.1.3.3 Bidentate Cyclen-units 
Under identical conditions, the terminal receptor containing two tris-Boc-Cyclen units 120 
were synthesised in good yields. The ester of this molecule was cleaved in good yields 
resulting in 121. Grauer is currently further investigating this carbonic acid.iii Scheme 41 
also shows the synthesis of the bis-Zn(II) complex 122, which was synthesised in good 
yields over two steps. 
Scheme 41. Synthesis of the N-terminal cyclen building block 120 and its conversion to 
the bis-Zn(II)-cyclen complex 122 or to its free acid 121 
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122 was analysed using X-Ray crystallography. Figure 88 shows the structure of the 
compound in the solid-state binding one anion (OH-). 
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iii Grauer, A. Diploma Thesis, University of Regensburg, ongoing. 
 
 
Figure 88. X-Ray structure of 122. 
The ability of this dinuclear complex to bind phosphates was examined by 
microcalorimetric titration and 31P-NMR. 
For this purpose a solution of the Zn(II)-complex 122 (c= 1 mM) in HEPES buffer 
(50 mM, pH 7.5) was titrated with a solution of sodium phenyl phosphate (c= 35 mM). The 
date were analysed assuming a 1:1 binding stoichiometry between substrate and receptor 
(figure 89). 
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N = 0.83 
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∆H = -(109.3 ± 2.2) kcal⋅mol-1
 
∆S = 18.85 kcal⋅mol-1⋅K-1 
 
 
 
Figure 89. Microcalorimetric titration of 122 (c = 1 mM) and phenyl phosphate 
(c = 35 mM) in HEPES buffer (T = 298 K, pH 7.5, 50 mM). 
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The high binding constant demonstrates a strong affinity of phosphate towards 122. 
Therefore, this binding process was examined using 31P-NMR experiments (162.0 MHz, 
D2O, c = 65.5 mM, 294 K). Solution of pure phenyl phosphate (A) and a 1:1 mixture of 
122 and phenyl phosphate (B) were measured and showed a shift of the phosphate signal 
of ∆ppm = -0.91. This fits very well to the chemically induced shift, which was observed 
by Hamachi examining his phosphate receptors. 
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Scheme 42. Schematic depiction of a planned SPRS 
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The first challenge was the synthesis of a C-terminal NTA building block, which contains 
one acid orthogonally protected to the other two remaining acids. Starting from 
commercially available H-Lys(Z)-OBzl, the α-amine was double alkylated with 
ethylbromoacetate resulting in 123. The following hydrogenolytical cleavage of the amino 
and carboxy protecting groups gave the zwitterion 124. This zwitterion was extracted with 
water. Lyophylisation gave 124 in good purity. The necessary Boc-protection did not work 
well and gave 125 in only moderate yields (scheme 43). 
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Scheme 43. Synthesis of a terminal NTA building block 125 with a free carbonic acid for 
SPRS 
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This building block was used for loading of a safety-catch-resin10 (procedure see 
experimental part). This resin allows solid phase synthesis under acidic and basic 
conditions. The cleavage from the resin is possible with NaOH only after initial activation 
of the sulfonamide giving N-methyl acylsulfonamide using iodoacetonitrile. 
The success of the loading experiments was verified by gravimetric analysis and FT-IR 
spectroscopy. Figure 91 shows the changed IR resonance in the region of carbonyl 
vibrations of esters (new peaks at ν~  = 1716 cm-1 and 1747 cm-1) and sulfonamides (new 
peak at ν~  = 1342 cm-1) after resin loading. 
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Figure 91. IR-Spectra of the carbonyl region of unloaded und loaded safety-catch-resin. 
The preloaded resin was used for a simple coupling experiment with Boc-Gly-OH. After 
ester hydrolysis, Ni(II) complexation (the colour of the resin changed to bluish green) and 
cleavage, the receptor molecule 113 was obtained (scheme 44). This compound was 
analysed with mass-spectroscopy and gave nearly the same results as 113 synthesised in 
solution (see scheme37). 
Scheme 44. SPRS with NTA preloaded safety-catch-resin 
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2.2 Receptors as Side Chains of Amino Acids 
In addition to the already discussed terminal receptors, the synthesis of molecular 
recognition building blocks by amino acid side chain functionalisation was aspired. 
Metal chelating units are introduced into the side chains of natural amino acids. One 
possibility is a coupling reaction of the terminal recognition units from the previous 
chapters with aspartic acid, glutamic acid or lysine. This is desirable, if the distance 
between receptor backbone and binding site should be large. For receptors with recognition 
units very close to the receptor backbone, the design of new unnatural amino acids is 
necessary. The following chapters demonstrate such syntheses using Williamson ether 
synthesis and Negishi coupling of iodoalanines. 
2.2.1 Tyrosine based Receptor 
Starting from the natural amino acid tyrosine, the side chain was modified via nucleophilic 
substitution. Starting from the literature known compound 126,11 a Williamson ether 
synthesis was used to attach this protected cyclen 126 to the phenol side chain of Z-Tyr-
OMe in good yields (scheme 45). To prove the ability to form a metal complex out of this 
chelator precursor, the Boc-groups were cleaved quantitatively in TFA/DCM. The 
following complexation reaction with Zn(II) gave the Zn(II) cyclen derivative 128. 
Scheme 45. Williamson ether synthesis of 127 and synthesis of the corresponding Zn(II) 
complex 128 
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2.2.2 Phenylalanine based Receptorsiv
The function of peptides and proteins is strongly correlated with their secondary and 
tertiary structure,12 which is induced by side chain interactions determined through the 
amino acid sequence. Non-proteinogenic amino acids13, ,14 15 and amino acid mimics are 
widely used to define,16 modulate17 or switch18 the structure of peptides, which may result 
in changes of their biological properties. One concept19 to control a peptide structure is the 
inter- or intramolecular formation of a metal complex, whereby parts of the peptide 
function as donor ligands. This requires modified amino acids bearing a strong metal ion 
chelating ligand for stable complex formation for incorporation into a peptide sequence.20 
Different research groups used alkylation reactions of lysine or diaminopropionic acid to 
generate IDA21 or BPA22 chelates directly on protein surfaces.  
As this modification of amino acid side chains is limited to a certain kind of chelates, a 
more general solution to transform natural amino acids into metal ion chelating amino 
acids is desired. 
Jackson already showed that palladium-catalysed coupling of the organozinc compound 
derived from 129 with aryl iodides is a feasible route to derivatives of phenylalanine.23 The 
scope of this reaction is now extended to phenylalanine derivatives bearing p-NH2 (132), p-
NH-Boc (133), and p-Me (131) aryl substituents. The efficient synthesis of the non-natural 
chiral amino acids 134 and 135 having protected IDA and cyclen metal ion chealting 
ligands in their side chain is reported in this chapter. 
Scheme 46. Palladium-catalysed coupling of aryl iodides with 129 
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So far, no Negishi coupling24 reaction has been reported for alkenyl organozinc compounds 
with p-iodoaniline derivatives as reactants. Previous preparations of the unnatural amino 
acid H-p-NH2-Phe-OH and protected derivatives of it used either the reduction of p-
nitrophenyl alanine25 or Staudinger reactions26 of p-azidophenyl alanine. The necessary 
iodide precursors 129a27 and 129b28 were synthesised from commercially available serine. 
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iv Kruppa, M.; Imperato, G.; König, B. Adv. Cat. Synth. 2005, in preparation. 
The corresponding organozinc reagents 130a and 130b were obtained by direct insertion of 
freshly prepared Rieke zinc.29 The alternative method of zinc dust activation by Me3SiCl in 
DMF was not as efficient as the use of Rieke zinc. The disappearance of the black zinc 
indicates the complete conversion by insertion reaction. The quantitative formation of the 
organozinc compounds 130a and 130b was confirmed by quenching the reaction with 
water giving alanine derivatives. 
Scheme 47. Preparation of the organozinc reagents 130a and 130b 
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The reaction conditions of the palladium-catalysed coupling reaction were optimised using 
organozinc reagent 130a and p-iodotoluene and p-iodoaniline as aryl iodides. While p-
iodotoluene gave 66 % yield of the coupling product (table 23, entry 1) using DME as 
solvent with 0.1 eq CuBr⋅SMe2, the more electron rich p-iodoaniline requires a solvent 
mixture of HMPT and THF (1:1) to give 73 % of Z-p-NH2-Phe-OtBu 132 (table 23, entry 
2). To apply the method to the synthesis of metal chelating chiral amino acids, aryl iodide 
substituted protected metal chelates were prepared starting from p-iodobenzyl bromide. 
Methyl imino diacetate and threefold Boc-protected cyclen30 were alkylated in good yield 
giving aryl iodides 136 and 137. 
Scheme 48. Synthesis of aryl iodides 136 and 137 
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Applying the same conditions as used for the coupling of p-iodoaniline, IDA derivative 
134 was obtained in moderate yield of 42 % (table 23, entry 4). Negishi coupling of aryl 
iodide 136 with iodoalanine 130a gave cyclen-modified amino acid 135 in good yield of 
86 % (table 23, entry 5). 
Table 23. Palladium-catalysed synthesis of the phenylalanine derivatives 131-135 
Entry Iodoalanine Ar-I Solvent Yield 
[%] 
Product 
1 130a 
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2.3 Conclusion 
 
The synthesis of C- and N-terminal receptor building blocks could be achieved by simple 
SN2 reactions of mono protected diamines and amino acids. The ligation of these building 
blocks was optimised using the active ester formed out of EDC/HOBt. The synthesis of 
113 showed the deprotection and metal complexation of the binding site. This receptor 
proved high affinity towards a pentapeptide containing a terminal histidine. The binding 
process was examined by microcalorimetrical titration. 
 
Furthermore the synthesis of bidentate recognition units possessing an additional 
carboxylate for receptor ligation yielded the new receptor precursors 117, 118, 119 and 
120. The Zn(II) complex 122 synthesised by Boc-deprotection of 120 showed high affinity 
towards phenylphosphate which was examined by 31P-NMR and microcalorimetrical 
titration. 
 
In a first attempt a solid phase receptor synthesis was performed using a safety-catch resin. 
 
To create binding sites in the side chains of natural amino acids the functionalisation of 
tyrosine was used for cyclen ligation. 
 
The scope of the Negishi cross coupling reaction of organozinc compounds derived from 
chiral amino acids was extended to electron rich iodoanilines as coupling reagents. This 
now allows the direct modification of serine into phenylalanine derivatives bearing metal 
ion chelating ligand in their side chain. This concept was illustrated by the synthesis of the 
amino esters 134 and 135. Such and similar modified chiral amino acids are useful for the 
preparation of peptides labelled with metal complexes as binding sites or probes, for the 
construction of synthetic receptors and hybrid materials having a peptide backbone and 
metal complex functionality. 
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2.4 Experimental Section 
2.4.1 Instruments and general techniques 
See experimental part of chapter 1 (page 131). 
 
X-Ray Data: 
 
94: 
C15H27NO6, Mr = 317.38, colourless translucent plates, orthorhombic, Space group P n a 
21, a = 6.7622(5) Å, b = 10.3093(9) Å, c = 25.479(3) Å, α = β = γ = 90, Z = 4, V = 
1776.2(3) Å3, Dx = 1.185 mg/m3, µ = 0.091 mm-1, F(000) = 688, Crystal size 0.620 x 0.540 
x 0.120 mm, θ-range for data collections 3.12 to 25.81 °, Index ranges -8 <= h <= 8, -12 
<= k <= 12, -31 <= l <= 31, Reflections collected/unique 10900/3388 [Rint = 0.0662], 
Data/restraints/parameters 3388/1/203, Goodness-of-fit on F2 1.035, Final R indices 
[I>2σ(I)] R1 = 0.0419, wR2 = 0.0998 R indices (all data) R1 = 0.0445, wR2 = 0.1017, 
Absolute structure parameter -0.1(8), largest diff. peak and hole 0.298 and -0.161 e. Å-3. 
 
 
 
98: 
C13H24N2O6, Mr = 304.34, colourless translucent prism, monoclinic, Space group P 21/a, a 
= 9.0953(8) Å, b = 19.1113(13) Å, c = 9.7889(9) Å, α = γ = 90 °, β = 109.062(10), Z = 4, 
V = 1608.2(3) Å3, Dx = 1.257 mg/m3, µ = 0.099 mm-1, F(000) = 656, Crystal size 0.400 x 
0.260 x 0.240 mm, θ-range for data collections 2.13 to 25.78 °, Index ranges -11 <= h <= 
11, -23 <= k <= 23, -11 <= l <= 11, Reflections collected/unique 11159/3077 [Rint = 
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0.0674], Data/restraints/parameters 3077/0/194, Goodness-of-fit on F2 0.881, Final R 
indices [I>2σ(I)] R1 = 0.0383, wR2 = 0.0877 R indices (all data) R1 = 0.0637, wR2 = 
0.0948, largest diff. peak and hole 0.195 and -0.193 e. Å-3. 
 
 
 
122: 
C26H49N8O3Zn2 3(ClO4), Mr = 950.86, colourless translucent stick, orthorhombic, Space 
group P b 21 a, a = 12.5672(7) Å, b = 18.5822(10) Å, c = 32.298(3) Å, α = β = γ = 90, Z = 
8, V = 1776.2(3) Å3, Dx = 1.675 mg/m3, µ = 1.562 mm-1, F(000) = 936, Crystal size 0.60 x 
0.20 x 0.12 mm, θ-range for data collections 2.05 to 25.79 °, Index ranges -15 <= h <= 14, 
-21 <= k<= 22, -39 <= l <= 39, Reflections collected/unique 52151/13872 [Rint = 0.0384], 
Data/restraints/parameters 13872/1/979, Goodness-of-fit on F2 0.618, Final R indices 
[I>2σ(I)] R1 = 0.0327, wR2 = 0.0793 R indices (all data) R1 = 0.0519, wR2 = 0.0897, 
Absolute structure parameter -0.009(7), largest diff. peak and hole 2.050 and -0.285 e. Å-3. 
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2.4.2 Synthesis 
108,v and 3,5-Bis-(bromomethyl)-benzoic acid methylestervi were synthesised according to 
literature known procedures. 
 
N
O
O
O
O
O O
 
 
(Benzyloxycarbonylmethyl-methoxycarbonylmethyl-amino)-acetic acid methyl ester (80): 
Dimethyl iminodiacetic acid hydrogenchloride (3.00 g, 15.2 mmol) was dissolved in 
MeCN (40 mL). Benzylbromoacetate (2.38 mL, 15.2 mmol), a spatula tip KI and K2CO3 
(4.20 g, 30.4 mmol) were added to the reaction mixture. The suspension was stirred at 
60 °C for 3 days, filtered, mixed with water (25 mL) and extracted with EtOAc. The 
organic layers were dried over Na2SO4 and concentrated under reduced pressure. The 
crude oil was purified using column chromatography on silica gel (PE:EtOAc = 1:1, Rf = 
0.36). 80 (13.9 mmol, 4.31 g, 92 %) is a colourless oil. 
1H-NMR (300 MHz; [D6]-Acetone): δ = 3.63 (s, 6 H, O-CH3), 3.68 (s, 4 H, CH2-COOMe), 
3.74 (s, 2 H, CH2-COOBzl), 5.14 (s, 2 H, CH2-Ph), 7.31-7.41 (m, 5 H, H-Ar). – 13C-NMR 
(75 MHz; [D6]-Acetone): δ = 30.1, 51.7 (+, 2 C, CH3), 55.0 (–, 2 C, CH2), 55.2 (–, 2 C, 
CH2), 66.5 (–, CH2), 128.3 (+, 2 C, C-Ar), 128.4 (+, C-Ar), 128.6 (+, 2 C, C-Ar), 135.5 
(Cquat, C-Ar), 170.6 (Cquat, COOBzl), 171.2 (Cquat, 2 C, COOMe). – IR (KBr) [cm-1]: ν~ = 
3478, 3032, 2956, 1740, 1004. – MS (CI-MS, NH3): m/z (%) = 310 (100) [MH+], 327 (7) 
[M + NH4+]. – Elemental analysis calcd. (%) for C15H19NO6 (309.32): C 58.25, H 6.19, N 
4.53; found C 58.03, H 6.27, N 4.24. 
                                                 
v Beck-Piotraschke, K.; Jakubke, H.D. Tet. Asym. 1998, 9, 1505. 
vi Kurz, K.; Göbel, M.W. Helvet. Chim. Acta 1996, 79, 1967. 
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(Bis-methoxycarbonylmethyl-amino)-acetic acid (81): 
Literature known compound BRNr: 8055366 but improved synthesis 
80 (1.00 g, 3.2 mmol) was dissolved in EtOH (25 mL) and mixed with a spatula tip 10 % 
Pd/C. The reaction mixture was stirred for 12 h in an autoclave under 10 bar H2 pressure. 
The suspension was filtered using celite and the filtrate concentrated under reduced 
pressure. 81 (3.1 mmol, 682 mg, 96 %) was isolated as a yellowish oil without further 
purification.  
1H-NMR (300 MHz; CDCl3): δ = 3.54 (s, 2 H, CH2), 3.62 (s, 4 H, CH2), 3.76 (s, 6 H, O-
CH3). – MS (CI, NH3): m/z (%) = 237 (23) [M+NH4+], 220 (100) [MH+]. – C8H13NO6 
(219.20). 
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{[(Benzyloxycarbonylmethyl-carbamoyl)-methyl]-methoxycarbonylmethyl-amino}-acetic 
acid methyl ester (82): 
H-Gly-OBzl⋅HOTos (0.32 g, 0.9 mmol) was dissolved in DCM (15 mL) and DIPEA 
(0.48 mL, 2.8 mmol) was added. After 5 min, 81 (0.23 g, 1.0 mmol), EDC (0.20 mL, 
1.2 mmol), and HOBt (0.16 g, 1.2 mmol) were added to the solution. The reaction process 
was monitored by TLC (EtOAc). Once the reaction was completed, the reaction mixture 
was added to water (25 mL) and extracted with DCM. The organic layers were washed 
twice with brine (30 mL each) and dried over Na2SO4. After evaporation of the solvent, the 
crude product was purified by column chromatography on silica gel (EtOAc, Rf = 0.44). 82 
(0.7 mmol, 246 mg, 71 %) is a colourless oil. 
1H-NMR (300 MHz; CDCl3): δ = 3.45 (s, 2 H, CH2), 3.57 (s, 4 H, N-CH2), 3.71 (s, 6 H, O-
CH3), 4.12 (d, 3J = 6.0 Hz, 2 H, CH2-Gly), 5.17 (s, 2 H, CH2-Ph), 7.29-7.40 (m, 5 H, H-
Ar), 8.20 (t, 3J = 5.5 Hz, 1 H, NH). – 13C-NMR (75 MHz; CDCl3): δ = 41.0 (–, CH2), 51.9 
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(+, 2 C, CH3), 55.4 (–, 2 C, CH2), 58.7 (–, CH2), 67.1 (–, CH2), 128.3 (+, 2 C, C-Ar), 128.5 
(+, C-Ar), 128.6 (+, 2 C, C-Ar), 135.3 (Cquat, C-Ar), 169.7 (Cquat, CONH), 171.3 (Cquat, 
COOBzl), 171.6 (Cquat, 2 C, COOMe). – IR (KBr) [cm-1]: ν~ = 3478, 3034, 2946, 2935, 
1742, 1646, 1030. – MS (CI, NH3): m/z (%) = 384 (8) [MNa+], 367 (100) [MH+]. – 
C17H22N2O7 (366.27). 
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[2-(Bis-methoxycarbonylmethyl-amino)-acetylamino]-acetic acid (83): 
82 (0.25 g, 0.7 mmol) was dissolved in EtOH (25 mL) and mixed with a spatula tip 10 % 
Pd/C. The reaction mixture was stirred for 12 h in an autoclave under 10 bar H2 pressure. 
The suspension was filtered using celite and the filtrate concentrated under reduced 
pressure. 83 (0.6 mmol, 169 mg, 91 %) was isolated as a yellowish oil without purification. 
1H-NMR (600 MHz; CDCl3): δ = 3.47 (s, 2 H, CH2), 3.58 (s, 4 H, N-CH2), 3.72 (s, 6 H, O-
CH3), 4.10 (d, 3J = 5.5 Hz, 2 H, CH2-Gly), 8.32 (t, 3J = 5.6 Hz, 1H, NH). – 13C-NMR 
(75 MHz; CDCl3): δ = 41.0 (–, CH2-Gly), 52.0 (+, 2 C, O-CH3), 55.5 (–, 2 C, CH2), 58.5 
(-, CH2), 171.7 (Cquat, 2 C, COOMe), 172.3 (Cquat, COOH), 172.5 (Cquat, CONH). – IR 
(KBr) [cm-1]: ν~ = 3397, 2958, 1738, 1659, 1414. – MS (CI, NH3): m/z (%) = 294 (68) [M 
+ NH4+], 277 (100) [MH+]. – Elemental analysis calcd. (%) for C10H16N2O7 (276.25): C 
43.48, H 5.84, N 10.14; found C 43.81, H 6.07, N 5.49. 
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(Bis-benzyloxycarbonylmethyl-amino)-acetic acid tert-butylester (84): 
H-Gly-OtBu⋅HCl (0.50 g, 3.0 mmol), benzylbromoacetate (1.03 mL, 6.6 mmol), K2CO3 
(1.81 g, 13.1 mmol), and a spatula tip of KI were dissolved in MeCN (25 mL). The 
suspension was stirred at 60 °C for 2 days und monitored via TLC (EtOAc). The finished 
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reaction was filtered, mixed with water (25 mL) and extracted with EtOAc. The organic 
layers were dried over Na2SO4 and evaporated. The crude product was purified using 
column chromatography on silica gel (EtOAc, Rf = 0.84) giving the colourless oil 84 
(2.4 mmol, 1.01 g, 79 %). 
1H-NMR (300 MHz; CDCl3): δ = 1.44 (s, 9 H, CH3), 3.57 (s, 2 H, N-CH2-COOtBu), 3.72 
(s, 4 H, N-CH2-COOBzl), 5.14 (s, 4 H, CH2-Ph), 7.29-7.39 (m, 10 H, H-Ar). – 13C-NMR 
(75 MHz; CDCl3): δ = 28.1 (+, 3 C, CH3), 55.1 (–, 2 C, CH2), 55.8 (–, CH2), 66.4 (–, 2 C, 
CH2), 81.4 (Cquat, C-Boc), 128.3 (+, 6 C, C-Ar), 128.6 (+, 4 C, C-Ar), 135.6 (Cquat, 2 C, C-
Ar), 170.0 (Cquat, COOtBu), 170.8 (Cquat, 2 C, COOBzl). – IR [cm-1]: ν~ = 3455, 3034, 
2978, 1746, 1145. – MS (CI-MS, NH3): m/z (%) = 428 (100) [MH+], 372 (19) [MH+ − 
C4H8]. – Elemental analysis calcd. (%) for C24H29NO6 (427.5): C 67.43, H 6.84, N 3.28; 
found C 66.95, H 6.59, N 3.01. 
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3-(Bis-benzyloxycarbonylmethyl-amino)-propionic acid tert-butylester (85): 
H-β-Ala-OtBu⋅HCl (1.00 g, 5.5 mmol), benzylbromoacetate (1.73 mL, 11.0 mmol), K2CO3 
(3.04 g, 22.0 mmol), and a spatula tip of KI were dissolved in MeCN (30 mL). The 
suspension was stirred at 60 °C for 2 days und monitored by TLC (EtOAc). The finished 
reaction was filtered, mixed with water (25 mL) and extracted with EtOAc. The organic 
layers were dried over Na2SO4 and evaporated. The crude product was purified using 
column chromatography on silica gel (EtOAc, Rf = 0.84) giving the colourless oil 85 
(5.5 mmol, 2.43 g, 100 %). 
1H-NMR (300 MHz; CDCl3): δ = 1.42 (s, 9 H, CH3), 2.41 (t, 3J = 7.3 Hz, 2 H, N-CH2), 
3.05 (t, 3J = 7.3 Hz, 2 H, N-CH2-COOtBu), 3.63 (s, 4 H, N-CH2-COOBzl), 5.13 (s, 4 H, 
CH2-Ph), 7.31-7.39 (m, 10 H, H-Ar). – 13C-NMR (75 MHz; CDCl3): δ = 28.1 (+, 3 C, 
CH3), 34.9 (–, CH2), 50.3 (–, CH2), 55.0 (–, 2 C, CH2), 66.3 (–, 2 C, CH2), 80.5 (Cquat, C-
Boc), 128.3 (+, 6 C, C-Ar), 128.6 (+, 4 C, C-Ar), 135.7 (Cquat, 2 C, C-Ar), 171.1 (Cquat, 
2 C, COOBzl), 171.5 (Cquat, COOtBu). – IR [cm-1]: ν~ = 3445, 3034, 2976, 1730, 1164. – 
 168
MS (CI-MS, NH3): m/z (%) = 442 (100) [MH+]. – Elemental analysis calcd. (%) for 
C25H31NO6 (441.53): C 68.01, H 7.08, N 3.17; found C 67.99, H 7.14, N 3.02. 
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4-(Bis-benzyloxycarbonylmethyl-amino)-butyric acid tert-butylester (86): 
H-γ-Abu-OtBu⋅HCl (0.50 g, 2.6 mmol), benzylbromoacetate (0.88 mL, 5.6 mmol), K2CO3 
(1.55 g, 11.3 mmol), and a spatula tip of KI were dissolved in MeCN (25 mL). The 
suspension was stirred at 60 °C for 2 days und monitored by TLC (EtOAc). The finished 
reaction was filtered, mixed with water (25 mL) and extracted with EtOAc. The organic 
layers were dried over Na2SO4 and evaporated. The crude product was purified using 
column chromatography on silica gel (EtOAc, Rf = 0.83) giving the colourless oil 86 
(2.6 mmol, 1.17 g, 100 %). 
1H-NMR (400 MHz; CDCl3): δ = 1.43 (s, 9 H, HSQC: H(1)), 1.73 (quin, 3J = 7.3 Hz, 2 H, 
HSQC: H(5)), 2.25 (t, 3J = 7.4 Hz, 2 H, HMBC: H(4)), 2.75 (t, 3J = 7.4 Hz, 2 H, HMBC: 
H(6)), 3.60 (s, 4 H, HSQC: H(7)), 5.13 (s, 4 H, HSQC: H(9)), 7.30-7.38 (m, 10 H, H-Ar). – 
13C-NMR (100 MHz; CDCl3; HSQC, HMBC): δ = 23.3 (–, C(5)), 28.1 (+, 3 C, C(1)), 32.9 
(–, C(4)), 53.5 (–, C(6)), 55.0 (–, 2 C, C(7)), 66.3 (–, 2 C, C(9)), 80.1 (Cquat, C(2)), 128.3 
(+, 4 C, C(11)), 128.4 (+, 2 C, C(13)), 128.6 (+, 4 C, C(12)), 135.7 (Cquat, C(10)), 171.1 
(Cquat, 2 C, C(8)), 172.8 (Cquat, C(3)). – IR [cm-1]: ν~ = 3442, 3034, 2974, 1729, 1154. – MS 
(CI-MS, NH3): m/z (%) = 456 (100) [MH+]. – Elemental analysis calcd. (%) for C26H33NO6 
(455.56): C 68.55, H 7.30, N 3.07; found C 68.20, H 7.24, N 2.96. 
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(Bis-benzyloxycarbonylmethyl-amino)-acetic acid hydrogenchloride (87): 
84 (0.39 g, 0.9 mmol) was dissolved in Et2O (10 mL) and HCl/Et2O was added to the 
solution under ice cooling. After 30 min the Et2O was evaporated and the product dried 
under high vacuum. 87 (0.6 mmol, 0.24 g, 66 %) is a colourless very hygroscopic solid. 
1H-NMR (300 MHz; [D6]-DMSO): δ = 3.65 (s, 2 H, CH2-COOH), 3.79 (s, 4 H, CH2-
COOBzl), 5.11 (s, 2 H, CH2-Ph), 7.29-7.41 (s, 10 H, H-Ar), 10.00-11.00 (bs, 2 H, COOH 
+ NH+). – 13C-NMR (75 MHz; [D6]-DMSO): δ = 54.3 (–, 2 C, CH2), 62.7 (–, CH2), 65.5 (-, 
2 C, CH2), 127.3 (+, 6 C, C-Ar), 128.2 (+, 4 C, C-Ar), 135.8 (Cquat, 2 C, C-Ar), 169.7 
(Cquat, 2 C, COOBzl), 171.2 (Cquat, COOH). – IR (KBr) [cm-1]: ν~ = 3385, 2962, 1746, 
1201. – MS (ESI, MeCN/MeOH + 10 mmol/L NH4Ac): m/z (%) = 372 (100) [MH+]. – 
Elemental analysis calcd. (%) for C20H22NO6Cl (407.85) x 2 H2O: C 54.21, H 5.90, N 3.16; 
found C 54.69, H 5.22, N 3.38. 
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3-(Bis-benzyloxycarbonylmethyl-amino)-propionic acid hydrogenchloride (88): 
85 (0.50 g, 1.1 mmol) was dissolved in Et2O (10 mL) and HCl/Et2O was added to the 
solution under ice cooling. After 30 min the Et2O was evaporated and the product dried 
under high vacuum. 88 (1.0 mmol, 0.42 g, 88 %) is a colourless very hygroscopic solid. 
1H-NMR (300 MHz; [D6]-DMSO): δ = 2.70 (t, 3J = 7.3 Hz, 2 H, N-CH2), 3.34 (t, 3J = 
6.7 Hz, 2 H, CH2-COOH), 4.15 (s, 4 H, CH2-COOBzl), 5.19 (s, 2 H, CH2-Ph), 7.31-7.42 
(s, 10 H, H-Ar), 9.00-11.50 (bs, 2 H, COOH + NH+). – 13C-NMR (75 MHz; [D6]-DMSO): 
δ = 30.1 (–, CH2), 50.3 (–, CH2), 54.0 (–, 2 C, CH2), 66.5 (–, 2 C, CH2), 128.2 (+, 4 C, C-
Ar), 128.4 (+, 2 C, C-Ar), 128.8 (+, 4 C, C-Ar), 135.2 (Cquat, C-Ar), 167.5 (Cquat, COOH), 
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171.9 (Cquat, 2 C, COOBzl). – IR (KBr) [cm-1]: ν~ = 3380, 2957, 1740, 1196, 742, 698. – 
MS (ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 386 (100) [MH+]. – Elemental 
analysis calcd. (%) for C21H23NO6 (385.42) + H2O: C 62.52, H 6.25, N 3.47; found C 
62.57, H 6.00, N 3.45. 
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4-(Bis-benzyloxycarbonylmethyl-amino)-butyric acid hydrogenchloride (89): 
86 (0.29 g, 0.7 mmol) was dissolved in Et2O (10 mL) and HCl/Et2O was added to the 
solution under ice cooling. After 30 min the Et2O was evaporated and the product dried 
under high vacuum. 89 (0.6 mmol, 0.24 g, 86 %) is a colourless very hygroscopic solid. 
mp 41-42 °C. – 1H-NMR (300 MHz; [D6]-DMSO): δ = 1.78 (quin, 3J = 7.1 Hz, 2 H, CH2), 
2.27 (t, 3J = 7.3 Hz, 2 H, N-CH2), 3.01-3.13 (m, 2 H, CH2-COOH), 4.01-4.19 (m, 4 H, 
CH2-COOBzl), 5.19 (s, 2 H, CH2-Ph), 7.31-7.42 (s, 10 H, H-Ar). – 13C-NMR (75 MHz; 
[D6]-DMSO): δ = 20.0 (–, CH2), 30.5 (–, CH2), 53.9 (–, CH2), 54.4 (–, 2 C, CH2), 66.5 (–, 
2 C, CH2), 128.1 (+, 4 C, C-Ar), 128.4 (+, 2 C, C-Ar), 128.8 (+, 4 C, C-Ar), 135.2 (Cquat, 
2 C, C-Ar), 167.5 (Cquat, COOH), 171.9 (Cquat, 2 C, COOBzl). – IR (KBr) [cm-1]: ν~ = 
3419, 2957, 1748, 1211, 748, 698. – MS (ESI, MeCN/MeOH): m/z (%) = 400 (100) 
[MH+], 422 (32) [MNa+]. – Elemental analysis calcd. (%) for C22H25NO6 (399.44) + H2O: 
C 63.30, H 6.51, N 3.35; found C 63.32, H 6.09, N 3.47. 
 171
N
7
8
6
9
O
10
O
O O
O
O
5
4
11
3
2
1
 
 
(Bis-tert-butoxycarbonylmethyl-amino)-acetic acid bezylester (90): 
H-Gly-OBzl⋅HOTos (1.00 g, 3.0 mmol) was dissolved in MeCN (25 mL). tert-
Butylbromoacetate (0.96 mL, 6.5 mmol), K2CO3 (1.80 g, 13.0 mmol), and a spatula tip of 
KI were added. The suspension was stirred at 60 °C for 2 days and monitored by TLC 
(EtOAc). After filtration the filtrate was mixed with water (30 mL) and extracted with 
EtOAc. The organic layers were dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified using column chromatography on silica gel 
(EtOAc, Rf = 0.84) yielding 90 (2.5 mmol, 1.00 g, 86 %) as a colourless oil. 
1H-NMR (300 MHz; CDCl3): δ = 1.44 (s, 18 H, CH3), 3.55 (s, 4 H, CH2-COOtBu), 3.70 (s, 
2 H, CH2-COOBzl), 5.16 (s, 2 H, CH2-Ph), 7.31-7.37 (m, 5 H, H-Ar). – 13C-NMR 
(150 MHz; CDCl3; HSQC, HMBC): δ = 28.1 (+, 6 C, C(11)), 55.0 (–, C(7)), 55.9 (–, 2 C, 
C(8)), 66.3 (–, 2 C, C(5)), 81.2 (Cquat, 2 C, C(10)), 128.2 (+, C(1)), 128.2 (+, 2 C, C(2)), 
128.5 (+, 2 C, C(3)), 135.8 (Cquat, C(4)), 170.1 (Cquat, 2 C, C(9)), 170.9 (Cquat, C(6)). – IR 
(KBr) [cm-1]: ν~ = 3445, 2979, 2934, 1733, 1159. – MS (CI-MS, NH3): m/z (%) = 394 
(100) [MH+], 338 (65) [MH+ − C4H8]. – Elemental analysis calcd. (%) for C21H31NO6 
(393.48): C 64.10, H 7.94, N 3.56; found C 63.17, H 7.43, N 3.60. 
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3-(Bis-tert-butoxycarbonylmethyl-amino)-propionic acid benzyl ester (91): 
Literature known compound BRNr: 7314298vii but improved synthesis 
H-β-Ala-OBzl⋅HOTos (2.00 g, 5.7 mmol) was dissolved in MeCN (40 mL). tert-
Butylbromoacetate (1.85 mL, 12.5 mmol), K2CO3 (3.46 g, 25.0 mmol), and a spatula tip of 
                                                 
vii Sunagawa, M.; Matsumura, H.; Sumita, Y.; Nouda, H. J. Antibiot. 1995, 48, 408. 
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KI were added. The suspension was stirred at 60 °C for 2 days and monitored by TLC 
(EtOAc). After filtration the filtrate was mixed with water (30 mL) and extracted with 
EtOAc. The organic layers were dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified using column chromatography on silica gel 
(EtOAc, Rf = 0.84) yielding 91 (3.5 mmol, 1.42 g, 86 %) as a colourless oil. 
1H-NMR (400 MHz; CDCl3): δ = 1.44 (s, 18 H, CH3), 2.58 (t, 3J = 7.2 Hz, 2 H, N-CH2), 
3.07 (t, 3J = 7.4 Hz, 2 H, CH2-COOBzl), 3.44 (s, 4 H, CH2-COOtBu), 5.12 (s, 2 H, CH2-
Ph), 7.28-7.39 (m, 5 H, H-Ar). – 13C-NMR (100 MHz; CDCl3; HSQC, HMBC): δ = 28.2 
(+, 6 C, C(12)), 33.9 (–, C(8)), 50.0 (–, C(7)), 56.0 (–, 2 C, C(9)), 66.2 (–, C(5)), 81.0 
(Cquat, 2 C, C(11)), 128.2 (+, C(1)), 128.2 (+, 2 C, C(2)), 128.5 (+, 2 C, C(3)), 136.0 (Cquat, 
C(4)), 170.6 (Cquat, 2 C, C(10)), 172.1 (Cquat, C(6)). – IR (KBr) [cm-1]: ν~ = 3446, 2977, 
2940, 1738, 1157. – MS (CI-MS, NH3): m/z (%) = 408 (100) [MH+], 352 (8) [MH+ − 
C4H8]. – C22H33NO6 (407.51). 
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4-(Bis-tert-butoxycarbonylmethyl-amino)-butyric acid benzyl ester (92): 
H-γ-Abu-OBzl⋅HOTos (2.00 g, 5.5 mmol) was dissolved in MeCN (40 mL). tert-
Butylbromoacetate (1.78 mL, 12.0 mmol), K2CO3 (3.33 g, 24.1 mmol), and a spatula tip of 
KI were added. The suspension was stirred at 60 °C for 2 days and monitored by TLC 
(EtOAc). After filtration the filtrate was mixed with water (30 mL) and extracted with 
EtOAc. The organic layers were dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified using column chromatography on silica gel 
(EtOAc, Rf = 0.80) yielding 92 (3.5 mmol, 1.42 g, 63 %) as a colourless oil. 
1H-NMR (400 MHz; CDCl3): δ = 1.44 (s, 18 H, HSQC: H(13)), 1.81 (quin, 3J = 7.2 Hz, 
2 H, HSQC: H(8)), 2.45 (t, 3J = 7.4 Hz, 2 H, HMBC: H(7)), 2.74 (t, 3J = 7.1 Hz, 2 H, 
HMBC: H(9)), 3.41 (s, 4 H, HSQC: H(10)), 5.11 (s, 2 H, HSQC: H(5)), 7.28-7.38 (m, 5 H, 
H-Ar). – 13C-NMR (100 MHz; CDCl3; HSQC, HMBC): δ = 23.2 (–, C(8)), 28.2 (+, 6 C, 
C(13)), 31.7 (–, C(7)), 53.3 (–, C(9)), 55.8 (–, 2 C, C(10)), 66.1 (–, C(5)), 81.0 (Cquat, 2 C, 
C(12)), 128.1 (+, C(1)), 128.2 (+, 2 C, C(2)), 128.5 (+, 2 C, C(3)), 136.2 (Cquat, C(4)), 
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170.6 (Cquat, 2 C, C(11)), 173.5 (Cquat, C(6)). – IR [cm-1]: ν~ = 3447, 2976, 2934, 1738, 
1156. – MS (CI-MS, NH3): m/z (%) = 422 (100) [MH+]. – Elemental analysis calcd. (%) 
for C22H33NO6 (421.54): C 64.84, H 8.16, N 3.44; found C 64.97, H 8.53, N 3.32. 
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(Bis-tert-butoxycarbonylmethyl-amino)-acetic acid (93): 
Literature known compound BRNr: 7547231 but improved synthesis 
90 (0.20 g, 0.50 mmol) was dissolved in EtOH (25 mL), to which two drops acetic acid 
and a spatula tip 10 % Pd/C were added. The reaction mixture was stirred 18 h in an 
autoclave under 10 bar H2 pressure. The suspension was filtered using celite and the filtrate 
concentrated under reduced pressure. 93 (0.47 mmol, 0.14 g, 93 %) was isolated as a 
colourless solid without further purification. 
mp 88-89 °C. – 1H-NMR (300 MHz; [D6]-Acetone): δ = 1.36-1.44 (m, 18 H, CH3), 1.47-
1.50 (m, 2 H, CH2-COOH), 3.47-3.54 (m, 4 H, CH2-COOtBu), 10.35 (bs, 1 H, COOH). – 
13C-NMR (75 MHz; [D6]-Acetone): δ = 28.3 (+, 6 C, CH3), 57.4 (–, 2 C, CH2-COOtBu), 
57.6 (–, CH2-COOH), 81.9 (Cquat, 2 C, CBoc), 171.7 (Cquat, 2 C, COOtBu), 171.7 (Cquat, 
COOH). – IR (KBr) [cm-1]: ν~ = 2984, 2936, 1747, 1370, 1223, 1155, 995. – MS (-ESI, 
DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 362 (100) [M+Ac-], 302 (85) [M − H+]. – 
C14H25NO6 (303.36). 
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3-(Bis-tert-butoxycarbonylmethyl-amino)-propionic acid (94): 
91 (0.40 g, 1.0 mmol) was dissolved in EtOH (25 mL) and mixed with a spatula tip 10 % 
Pd/C. The reaction mixture was stirred for 12 h in an autoclave under 10 bar H2 pressure. 
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The suspension was filtered using celite and the filtrate concentrated under reduced 
pressure. 94 (1.0 mmol, 0.32 g, 100 %) was isolated as a colourless crystalline solid. 
mp 60-61 °C. – 1H-NMR (300 MHz; CDCl3): δ = 1.48 (s, 18 H, CH3), 2.51 (t, 3J = 6.2 Hz, 
2 H, N-CH2), 3.09 (t, 3J = 6.3 Hz, 2 H, CH2-COOH), 3.50 (s, 4 H, CH2-COOtBu). – 13C-
NMR (75 MHz; CDCl3): δ = 28.1 (+, 6 C, CH3), 31.5 (–, CH2), 49.8 (–, CH2), 55.3 (–, 2 C, 
CH2), 82.5 (Cquat, 2 C, C-Boc), 169.3 (Cquat, 2 C, COOtBu), 173.2 (Cquat, COOH). – IR 
(KBr) [cm-1]: ν~ = 2980, 2932, 2534, 1735, 1706, 1370, 1158. – MS (CI-MS, NH3): m/z 
(%) = 318 (100) [MH+]. – C16H29NO6 (317.39).  
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4-(Bis-tert-butoxycarbonylmethyl-amino)-butyric acid (95): 
92 (0.40 g, 1.0 mmol) was dissolved in MeOH (25 mL) and mixed with a spatula tip 10% 
Pd/C. The reaction mixture was stirred for12 h in an autoclave under 10 bar H2 pressure. 
The suspension was filtered using celite and the filtrate concentrated under reduced 
pressure. 95 (0.9 mmol, 0.29 g, 93 %) was isolated as a colourless oil without further 
purification. 
1H-NMR (300 MHz; CDCl3): δ = 1.46 (s, 18 H, CH3), 1.82 (quin, 2 H, 3J = 6.7 Hz, CH2), 
2.51 (t, 3J = 6.7 Hz, 2 H, N-CH2), 2.88 (t, 3J = 6.7 Hz, 2 H, CH2-COOH), 3.52 (s, 4 H, 
CH2-COOtBu). – 13C-NMR (75 MHz; CDCl3): δ = 22.0 (–, CH2), 28.1 (+, 6 C, CH3), 33.0 
(–, CH2), 53.8 (–, CH2), 55.1 (–, 2 C, CH2), 82.1 (Cquat, 2 C, C-Boc), 169.1 (Cquat, 2 C, 
COOtBu), 177.0 (Cquat, COOH). – IR [cm-1]: ν~ = 2978, 2621, 1732, 1251, 1158, 843. – MS 
(CI-MS, NH3): m/z (%) = 332 (100) [MH+]. – Elemental analysis calcd. (%) for C16H29NO6 
(331.41) + MeOH: C 56.34, H 9.18, N 3.86; found C 55.92, H 9.18, N 3.86. 
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[Benzyloxycarbonylmethyl-(2-tert-butoxycarbonylamino-ethyl)-amino]-acetic acid benzyl 
ester (97): 
Mono-Boc-Ethylendiamine (0.50 g, 3.1 mmol) was dissolved in DMF (15 mL). 
Benzylbromoacetate (1.08 mL, 6.9 mmol), K2CO3 (1.90 g, 13.7 mmol), and a spatula tip of 
KI were added. The suspension was stirred at r.t. for 6 h and then at 60 °C for 2 days and 
monitored by TLC (EtOAc). After filtration the filtrate was mixed with water (30 mL) and 
extracted with EtOAc. The organic layers were dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was purified using column chromatography on silica 
gel (EtOAc, Rf = 0.80) yielding 97 (2.7 mmol, 1.24 g, 87 %) as a colourless oil. 
1H-NMR (300 MHz; CDCl3): δ = 1.43 (s, 9 H, CH3), 2.73 (t, 3J = 5.4 Hz, 2 H, CH2), 3.17-
3.22 (m, 2 H, CH2), 3.44 (s, 4 H, CH2), 5.03 (bs, 1 H, NH), 5.16 (s, 4 H, CH2-Ph), 7.27-
7.40 (m, 10 H, H-Ar). – 13C-NMR (75 MHz; CDCl3): δ = 28.5 (+,3 C, CH3), 38.4 (–, CH2), 
53.6 (–, 2 C, CH2), 66.5 (–, 2 C, CH2-Ph), 79.0 (Cquat, C-Boc), 128.3 (+, 4 C, C-Ar), 128.3 
(+, 2 C, C-Ar), 128.6 (+, 4 C, C-Ar), 135.5 (Cquat, 2 C, C-Ar), 156.2 (Cquat, COON), 171.3 
(Cquat, 2 C, COOBzl). – IR [cm-1]: ν~ = 3396, 3034, 2974, 1742, 1709, 1169, 740, 698. – 
MS (CI, NH3): m/z (%) = 457 (100) [MH+]. – Elemental analysis calcd. (%) for 
C25H32N2O6 (456.54): C 65.77, H 7.07, N 6.14; found C 65.46, H 7.02, N 6.23. 
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[(2-tert-Butoxycarbonylamino-ethyl)-methoxycarbonylmethyl-amino]-acetic acid methyl 
ester (98): 
Mono-Boc-Ethylendiamine (0.50 g, 3.1 mmol) was dissolved in MeCN (40 mL). Methyl-
bromoacetate (0.64 mL, 6.9 mmol), K2CO3 (1.90 g, 13.7 mmol), and a spatula tip of KI 
were added. The suspension was stirred at r.t. for 6 h and then at 60 °C for 2 days and 
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monitored by TLC (EtOAc). After filtration the filtrate was mixed with water (30 mL) and 
extracted with EtOAc. The organic layers were dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was purified using column chromatography on silica 
gel (PE:EtOAc 1:1, Rf = 0.40) yielding 98 (1.8 mmol, 1.06 g, 63 %) as a colourless solid. 
mp 73-74 °C. – 1H-NMR (300 MHz; CDCl3): δ = 1.44 (s, 9 H, CH3), 2.84 (t, 3J = 5.6 Hz, 
2 H, N-CH2), 3.13-3.18 (m, 2 H, NH-CH2), 3.54 (s, 4 H, N-CH2), 3.71 (s, 6 H, O-CH3), 
5.50 (bs, 1 H, NH). – 13C-NMR (75 MHz; CDCl3): δ = 28.4 (+, 3 C, CH3), 51.6 (+, 2 C, 
CH3), 53.5 (–, CH2), 54.9 (–, 2 C, CH2), 60.7 (–, CH2), 78.9 (Cquat, C-Boc), 156.1 (Cquat, 
2 C, COOMe), 171.8 (Cquat, COON). – IR (KBr) [cm-1]: ν~ = 3358, 2977, 2872, 1739, 
1699, 1524, 861, 581. – MS (ESI, CH2Cl2/MeOH + 10 mmol/L NH4Ac): m/z (%) = 647 (2) 
[2 M + K+], 631 (8) [2 M + Na+], 609 (11) [2 M + H+], 343 (9) [MK+], 327 (20) [M + Na+], 
305 (100) [MH+], 249 (50) [MH+ – C4H8], 205 (21) [MH+ – Boc]. – Elemental analysis 
calcd. (%) for C13H24N2O6 (304.35): C 51.31, H 7.95, N 9.20; found C 51.04, H 7.30, N 
8.93. 
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[(2-tert-Butoxycarbonylamino-ethyl)-ethoxycarbonylmethyl-amino]-acetic acid ethyl ester 
(99): 
Literature known compound BRNr: 7651262viii but improved synthesis 
Mono-Boc-Ethylendiamine (0.50 g, 3.1 mmol) was dissolved in MeCN (40 mL). Ethyl-
bromoacetate (0.76 mL, 6.9 mmol), K2CO3 (1.90 g, 13.7 mmol), and a spatula tip of KI 
were added. The suspension was stirred at r.t. for 6 h and then at 60 °C for 2 days and 
monitored via TLC (EtOAc). After filtration the filtrate was mixed with water (30 mL) and 
extracted with EtOAc. The organic layers were dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was purified using column chromatography on silica 
gel (EtOAc, Rf = 0.72) yielding 99 (2.2 mmol, 0.74 g, 72 %) as a colourless solid. 
1H-NMR (300 MHz; CDCl3): δ = 1.27 (t, 3J = 7.1 Hz, 6 H, CH3), 1.44 (s, 9 H, CH3-Boc), 
2.84 (t, 3J = 5.3 Hz, 2 H, CH2), 3.13-3.18 (m, 2 H, CH2), 3.52 (s, 4 H, CH2), 4.17 (q, 3J = 
7.1 Hz, 4 H, O-CH2). – C15H28N2O6 (332.4). 
                                                 
viii Hamachi, I.; Matsugi, T.; Shinkai, S. Tet. Lett. 1996, 37, 9233. 
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[(2-Amino-ethyl)-benzyloxycarbonylmethyl-amino]-acetic acid benzyl ester di-hydrogen-
chloride (100): 
97 (1.24 g, 2.7 mmol) was dissolved in Et2O (10 mL) and HCl/Et2O was added to the 
solution under ice cooling. After 30 min the Et2O is evaporated and the product dried under 
high vacuum. 100 (2.7 mmol, 1.16 g, 99 %) is a colourless very hygroscopic solid. 
1H-NMR (300 MHz; [D6]-DMSO): δ = 2.84-2.95 (m, 4 H, CH2), 3.69 (s, 4 H, N-CH2), 
5.13 (s, 4 H, CH2-Ph), 7.31-7.42 (m, 10 H, H-Ar), 7.80 (bs, 3 H, NH3+). – 13C-NMR 
(75 MHz; [D6]-DMSO): δ = 36.7 (–, CH2), 51.2 (–, CH2), 54.7(–, 2 C, CH2), 65.6 (–, 2 C, 
CH2), 127.9 (+, 4 C, C-Ar), 128.0 (+, 2 C, C-Ar), 128.3 (+, 4 C, C-Ar), 135.7 (Cquat, 2 C, 
C-Ar), 170.9 (Cquat, 2 C, COOBzl). – MS (ESI, H2O/MeOH + 10 mmol/L NH4Ac): m/z 
(%) = 577 (100) [MH+], 521 (65) [MH+ − C4H8]. – C20H26N2O4Cl2 (429.34). 
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[(2-Amino-ethyl)-methoxycarbonylmethyl-amino]-acetic acid methyl ester di-hydrogen-
chloride (101): 
98 (0.68 g, 2.2 mmol) was dissolved in Et2O (10 mL) and HCl/Et2O was added to the 
solution under ice cooling. After 30 min the Et2O is evaporated and the product dried under 
high vacuum. 101 (2.0 mmol, 542 mg, 88 %) is a colourless very hygroscopic solid. 
mp 83-85 °C. – 1H-NMR (300 MHz; [D6]-DMSO): δ = 2.83-2.93 (m, 4 H, CH2), 3.61 (s, 
10 H, O-CH3 + CH2), 7.89 (bs, 3 H, NH3+). – 13C-NMR (75 MHz; [D6]-DMSO): δ = 36.4 
(–, CH2), 51.2 (–, CH2), 51.5 (+, 2 C, CH3), 54.4 (–, 2 C, CH2-N), 171.0 (Cquat, 2 C, 
COOMe). – IR (KBr) [cm-1]: ν~ = 3420, 3303, 2959, 2537 1745, 1709, 1252. – MS (CI, 
NH3): m/z (%) = 457 (100) [MH+]. – C25H32N2O6 (456.54). 
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{Benzyloxycarbonylmethyl-[2-(2-tert-butoxycarbonylamino-acetylamino)-ethyl]-amino}-
acetic acid benzyl ester (102): 
Boc-Gly-OH (207 mg, 1.2 mmol), DIPEA (0.37 mL, 2.2 mmol), EDC (0.23 mL, 
1.3 mmol), and HOBt (176 mg, 1.3 mmol) were dissolved in DCM (10 mL) under ice 
cooling. 100 (100 mg, 0.2 mmol) dissolved in a little DCM was added slowly via syringe. 
The reaction was allowed to warm to r.t.. The reaction progress was monitored by TLC 
(EtOAc). After completion the solution was mixed with water (25 mL) and extracted with 
DCM. The combined organic layers were washed with brine and dried over Na2SO4. The 
solvent was evaporated and the product purified using column chromatography on silica 
gel (EtOAc, Rf = 0.48) yielding 102 (0.15 mmol, 76 mg, 64 %) as a colourless oil. 
1H-NMR (300 MHz; CDCl3): δ = 1.40 (s, 9 H, CH3), 2.85 (t, 3J = 5.5 Hz, 2 H, CH2), 3.20-
3.25 (m, 2 H, CH2), 3.52 (s, 4 H, N-CH2), 3.81 (d, 3J = 5.2 Hz, 2 H, CH2-Gly), 5.09 (s, 4 H, 
CH2-Ph), 5.19 (bs, 1 H, NH), 7.30-7.35 (m, 10 H, H-Ar). – 13C-NMR (75 MHz; CDCl3): 
δ = 28.4 (+, 3 C CH3), 37.3 (–, CH2), 43.9 (–, CH2-Gly), 52.8 (–, CH2), 66.7 (–, 2 C, CH2), 
79.7 (Cquat, C-Boc), 128.3 (+, 4 C, C-Ar), 128.5 (+, 2 C, C-Ar), 128.7 (+, 4 C, C-Ar), 135.4 
(Cquat, 2 C, C-Ar), 155.8 (Cquat, COON), 169.3 (Cquat, CONR), 171.5 (Cquat, 2 C, COOBzl). 
– IR (KBr) [cm-1]: ν~ = 3253, 3032, 2969, 1732, 1580. – MS (ESI, CH2Cl2/MeOH + 
10 mmol/L NH4Ac): m/z (%) = 536 (13) [MNa+], 514 (100) [MH+]. – Elemental analysis 
calcd. (%) for C27H35N3O7 (513.59) + EtOH: C 62.24, H 7.38, N 7.51; found C 62.01, H 
7.36, N 7.93. 
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{[2-(2-Amino-acetylamino)-ethyl]-benzyloxycarbonylmethyl-amino}-acetic 
 acid benzyl ester di-hydrogenchloride (103): 
102 (76 mg, 0.15 mmol) was dissolved in Et2O (10 mL) and HCl/Et2O was added to the 
solution under ice cooling. After 150 min the Et2O is evaporated and the product dried 
under high vacuum. 103 (0.14 mmol, 66 mg, 90 %) is a yellowish very hygroscopic solid. 
1H-NMR (300 MHz; [D6]-DMSO): δ = 2.96 (t, 3J = 6.4 Hz, 2 H, CH2), 3.27-3.33 (m, 2 H, 
CH2), 3.47-3.53 (m, 2 H, CH2-Gly), 3.85 (s, 4 H, N-CH2), 5.14 (s, 4 H, CH2-Ph), 7.31-7.41 
(m, 10 H, H-Ar), 8.21 (bs, 3 H, NH3+), 8.51 (t, 3J = 5.3 Hz 1 H, NH). – 13C-NMR 
(75 MHz; [D6]-DMSO): δ = 35.7 (–, CH2), 39.8 (–, CH2), 53.3 (–, CH2), 54.1 (–, 2 C, 
CH2), 66.2 (–, 2 C, CH2), 128.0 (+, 4 C, C-Ar), 128.2 (+, 4 C, C-Ar), 128.4 (+, 2 C, C-Ar), 
135.4 (Cquat, 2 C, C-Ar), 166.1 (Cquat, CONH), 168.5 (Cquat, 2 C, COOBzl). – IR (KBr) 
[cm-1]: ν~ = 3252, 3030, 2954, 1732, 1570. – MS (ESI, H2O/MeOH + 10 mmol/L NH4Ac): 
m/z (%) = 414 (100) [MH+]. – C22H29N3O5Cl (486.40). 
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[Benzyloxycarbonylmethyl-(4-tert-butoxycarbonylamino-butyl)-amino]-acetic acid-benzyl-
ester (105): 
Mono-Boc-diaminobutane (0.20 g, 1.1 mmol) was dissolved in MeCN (20 mL). 
Benzylbromoacetate (0.37 mL, 2.3 mmol), K2CO3 (0.64 g, 4.7 mmol) and a spatula tip of 
KI were added. The suspension was stirred at r.t. for 6 h and then at 60 °C for 2 days and 
monitored by TLC (EtOAc). After filtration the filtrate was mixed with water (30 mL) and 
extracted with EtOAc. The organic layers were dried over Na2SO4 and concentrated under 
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reduced pressure. The crude product was purified using column chromatography on silica 
gel (PE:EtOAc 1:1, Rf = 0.54) yielding 105 (0.8 mmol, 356 mg, 71 %) as a colourless oil. 
1H-NMR (600 MHz; CDCl3): δ = 1.39-1.46 (m, 11 H, CH2 + CH3-Boc), 1.60-1.65 (m, 2 H, 
CH2), 2.65-2.70 (m, 2 H, CH2), 2.97-3.09 (m, 2 H, CH2), 3.55 (s, 4 H, N-CH2), 4.52 (bs, 
1 H, NH), 5.09 (s, 4 H, CH2-Ph), 7.25-7.35 (m, 10 H, H-Ar). – 13C-NMR (75 MHz; 
CDCl3): δ = 25.2 (–, CH2), 27.4 (–, CH2), 28.4 (+, 3 C, CH3), 40.3 (–, CH2), 53.9 (–, CH2), 
55.0 (–, 2 C, CH2), 66.3 (–, 2 C, CH2), 79.0 (Cquat, C-Boc), 128.1 (+, 4 C, C-Ar), 128.4 (+, 
2 C, C-Ar), 128.6 (+, 4 C, C-Ar), 135.6 (Cquat, 2 C, C-Ar), 156.0 (Cquat, COON), 171.1 
(Cquat, 2 C, COOBzl). – IR (KBr) [cm-1]: ν~ = 3250, 3032, 2962, 1730, 1581, 876. – MS 
(ESI, H2O/MeCN): m/z (%) = 507 (11) [MNa+], 485 (100) [MH+], 429 (36) [MH+ − C4H8]. 
– Elemental analysis calcd. (%) for C27H36N2O6 (484.60): C 66.92, H 7.49, N 5.78; found 
C 66.53, H 7.04, N 5.49. 
 
N
O
O
O O
NH2
*2HCl
 
 
[(4-Amino-butyl)-benzyloxycarbonylmethyl-amino]-acetic acid benzyl ester di-hydrogen-
chloride (106): 
105 (125 mg, 0.26 mmol) was dissolved in Et2O (10 mL) and HCl/Et2O was added to the 
solution under ice cooling. After 60 min the Et2O is evaporated and the product dried under 
high vacuum. 106 (0.25, 114 mg, 96 %) is a colourless hygroscopic solid. 
mp 63-65 °C. – 1H-NMR (300 MHz; [D6]-DMSO): δ = 1.57-1.59 (m, 4 H, CH2) 2.74-2.75 
(m, 2 H, CH2), 2.91-3.05 (m, 2 H, CH2), 3.99 (m, 4 H, N-CH2), 5.17 (s, 4 H, CH2-Ph), 
7.31-7.42 (m, 10 H, H-Ar), 8.06 (bs, 3 H, NH3+). – 13C-NMR (75 MHz; [D6]-DMSO): δ = 
23.9 (–, CH2), 37.9 (–, CH2), 53.9 (–, 2 C, CH2), 54.5 (–, CH2), 64.8 (–, CH2), 66.6 (–, 2 C, 
CH2), 128.1 (+, 4 C, C-Ar), 128.2 (+, 4 C, C-Ar), 128.4 (+, 2 C, C-Ar), 135.2 (Cquat, 2 C, 
C-Ar), 167.2 (Cquat, 2 C, COOBzl). – IR (KBr) [cm-1]: ν~ = 3252, 3025, 2952, 1734, 1593. 
– MS (ESI, MeOH + 10 mmol/L NH4Ac): m/z (%) = 385 (100) [MH+]. – Elemental 
analysis calcd. (%) for C22H30N2O4Cl2 (457.40) + H2O: C 55.68, H 6.80, N 5.91; found C 
55.65, H 6.98, N 5.80. 
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{Benzyloxycarbonylmethyl-[4-(2-tert-butoxycarbonylamino-acetylamino)-butyl]-amino}-
acetic acid benzyl ester (107): 
Boc-Gly-OH (0.10 g, 0.4 mmol), DIPEA (0.15 mL, 0.9 mmol), EDC (0.09 mL, 0.5 mmol), 
and HOBt (66 mg, 0.5 mmol) were dissolved in DCM (15 mL) under ice cooling. 106 
(0.10 g, 0.2 mmol) dissolved in a little DCM was added slowly via syringe. The reaction 
was allowed to warm to r.t.. The reaction progress was monitored by TLC (EtOAc). After 
completion the solution was mixed with water (25 mL) and extracted with DCM. The 
combined organic layers were washed with brine and dried over Na2SO4. The solvent was 
evaporated and the crude product purified using column chromatography on silica gel 
(EtOAc, Rf = 0.56) yielding 107 (0.15 mmol, 81 mg, 68 %) as a colourless hygroscopic oil. 
1H-NMR (600 MHz; CDCl3): δ = 1.45 (s, 9 H, CH3), 1.46-1.57 (m, 4 H, CH2), 2.72 (t, 3J = 
6.5 Hz, 2 H, CH2), 3.23-3.26 (m, 2 H, CH2), 3.59 (s, 4 H, N-CH2), 3.76 (d, 3J = 5.3 Hz, 
2 H, CH2-Gly), 5.14 (s 4 H, CH2-Ph), 5.31 (bs, 1 H, NHB), 6.54 (m, 1 H, NHA), 7.32-7.38 
(m, 10 H, H-Ar). – 13C-NMR (150 MHz; CDCl3; HSQC): δ = 25.2 (–, C(7)), 26.9 (–, 
C(8)), 28.3 (+, 3 C, C(1)), 39.1 (–, C(6)),  53.9 (–, C(9)), 55.1 (–, 2 C, C(10)), 66.4 (–, 2 C, 
C(12)), 80.0 (Cquat, C(2)), 128.3 (+, 4 C, C-Ar), 128.4 (+, 2 C, C-Ar), 128.6 (+, 4 C, C-Ar), 
135.6 (Cquat, 2 C, C(13)), 169.3 (Cquat, C(5)), 171.1 (Cquat, 2 C, C(11)). – IR (KBr) [cm-1]: 
ν~ = 3242, 3030, 2969, 1730, 1658, 1580. – MS (ESI, CH2Cl2/MeOH + 10 mmol/l NH4Ac): 
m/z (%) = 564 (21) [MNa+], 542 (100) [MH+]. – Elemental analysis calcd. (%) for 
C29H39N3O7 (541.28) + H2O: C 62.24, H 7.38, N 7.51; found C 61.59, H 7.19, N 7.42. 
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Nα-Bis(2-ethoxy-2-oxoethyl)-L-lysine methylester (109): 
Literature known compoundix but improved procedure. 
H-Lys(Z)-OMe⋅HCl (1.12 g, 3.4 mmol) was dissolved in MeCN (25 mL). After addition of 
K2CO3 (9.40 g, 68.0 mmol) the suspension was stirred at r.t. over night. Ethyl-
bromoacetate (3.79 mL, 34.0 mmol) was added and the reaction mixture was refluxed over 
night. The suspension was filtered and the obtained filtrate concentrated under reduced 
pressure. The crude product was purified using column chromatography on silica gel (PE 
→ PE:EtOAc 2:1, Rf = 0.2) yielding Z-protected 109 (3.2 mmol, 1.47 g, 93 %) as a 
colourless oil. This oil was dissolved in EtOH (25 mL), mixed with a spatula tip 10 % 
Pd/C and stirred for 10 h in an autoclave under 10 bar H2 atmosphere yielding 109 
(3.2 mmol, 1.06 g, 100 %) as a colourless oil. 
1H-NMR (300 MHz; [D6]-Acetone): δ = 1.22 (t, 3J = 7.1 Hz, 6 H, CH3), 1.31-1.64 (m, 4 H, 
CH2), 1.65-1.75 (m, 2 H, CH2), 3.16-3.29 (m, 2 H, CH2), 3.47 (t, 3J = 7.3 Hz, 1 H, CH), 
3.60-3.68 (m, 7 H, CH2 + O-CH3), 4.09 (q, 3J = 7.1 Hz, 4 H, O-CH2). – 13C-NMR 
(75 MHz; [D6]-Acetone): δ = 14.2 (+, CH3), 22.9 (–, CH2), 29.3 (–, CH2), 29.9 (–, CH2), 
40.8 (–, CH2), 51.4 (+, CH3), 52.6 (–, 2 C, CH2), 60.6 (–, 2 C, CH2), 64.5 (+, CH), 156.4 
(Cquat, COOMe), 171.4 (Cquat, 2 C, COOEt). – MS (ESI, MeOH + 10 mmol/L NH4Ac): m/z 
(%) = 355 (17) [MNa+], 333 (100) [MH+]. – C15H38N2O6 (332.19). 
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2-(Bis-ethoxycarbonylmethyl-amino-)-6-(2-tert-butoxycarbonylamino-acetylamino)-
hexanic acid methylester (Boc-Gly-NTAL-OMe/Et)(110): 
Boc-Gly-OH (0.21 g, 1.2 mmol), DIPEA (0.37 mL, 2.2 mmol), EDC (0.23 mL, 1.3 mmol) 
and HOBt (0.18 g, 1.3 mmol) were dissolved in DCM under ice cooling 109 (0.37 g, 
1.1 mmol) dissolved in few DCM was added slowly via syringe. The reaction was allowed 
                                                 
ix Hart, B.R.; Shea, K.J. J. Am. Chem. Soc. 2001, 123, 2072. 
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to warm to r.t.. The reaction progress was monitored by TLC (EtOAc). After completion 
the solution was mixed with water (25 mL) and extracted with DCM. The combined 
organic layers were washed with brine and dried over Na2SO4. The solvent was evaporated 
and the crude product purification using column chromatography on silica gel (EtOAc, 
Rf = 0.36) yielding 110 (0.4 mmol, 188 mg, 71 %) as a colourless oil. 
1H-NMR (400 MHz; CDCl3): δ = 1.28 (t, 3J = 7.1 Hz, 6 H, COSY: H(16)), 1.47 (s, 9 H, 
COSY: H(1)), 1.48-1.67 (m, 4 H, COSY: H(7), H(8)), 1.70-1.74 (m, 2 H, COSY: H(9)), 
3.28-3.31 (m, 2 H, COSY: H(6)), 3.45 (t, 3J = 7.6 Hz, 1 H, COSY: H(10)), 3.61 (s, 2 H, 
COSY: H(13)), 3.62 (s, 2 H, COSY: H(17)), 3.71 (s, 3 H, COSY: H(12)), 3.81-3.85 (m, 
2 H, COSY: H(4)), 4.17 (q, 3J = 7.1 Hz, 4 H, COSY: H(15)), 5.42 (bs, 1 H, COSY: H(A)), 
6.51 (bs, 1 H, COSY: H(B)). – 13C-NMR (100 MHz; CDCl3; HSQC): δ = 14.2 (+, 2 C, 
C(16), C(20)), 22.5 (–, C(8)), 28.2 (–, C(7)), 28.3 (+, 3 C, C(1)), 29.3 (–, C(9)), 39.1 (–, 
C(6)), 44.2 (–, C(4)), 51.4 (+, C(12)), 52.7 (–, 2 C, C(13), C(17)), 60.7 (–, 2 C, C(15), 
C(19)), 64.1 (+, C(10)), 79.9 (Cquat, C(2)), 156.0 (Cquat, C(3)), 169.5 (Cquat, C(5)), 171.5 
(Cquat, 2 C, C(14), C(18)), 173.3 (Cquat, C(11)). – IR [cm-1]: ν~ = 3362, 2981, 2938, 2251, 
1740, 1670, 1166. – MS (ESI, H2O/MeCN): m/z (%) = 528 (9) [MK+], 512 (36) [MNa+], 
490 (100) [MH+], 434 (77) [MH+ − C4H8], 390 (13) [MH+- Boc]. – HRMS (C22H39N3O9): 
calcd. 489.2686, found 489.2680 ± 0.01 ppm. 
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6-(2-Amino-acetylamino)-2-(bis-ethoxycarbonylmethyl-amino)-hexanoic acid methyl ester 
hydrogenchloride (111): 
110 (0.38 g, 0.8 mmol) was dissolved in Et2O (10 mL) and HCl/Et2O was added to the 
solution under ice cooling. After 60 min the Et2O is evaporated and the product dried under 
high vacuum. 111 (0.8 mmol, 332 mg, 100 %) is a colourless hygroscopic solid. 
mp 73-74 °C. – 1H-NMR (400 MHz; [D6]-DMSO; COSY): δ = 1.18 (t, 3J = 7.3 Hz, 6 H, 
H13), 1.23-1.50 (m, 4 H, H4 + H5), 1.57-1.60 (m, 2 H, H6), 3.05-3.11 (m, 2 H, H3), 3.39 (t, 
3J = 7.5 Hz, 1 H, H7), 3.41-3.52 (m, 2 H, H1), 3.52-3.77 (m, 7 H, H9 + H10), 4.05 (q, 3J = 
7.0 Hz, 4 H, H12), 8.12 (bs, 3 H, HA), 8.40 (t, 3J = 5.4 Hz, 1 H, HB). – 13C-NMR (100 MHz; 
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[D6]-DMSO; HSQC, HMQC): δ = 14.0 (+, 2 C, C(13)), 22.6 (–, C(5)), 28.4 (–, C(4)), 29.2 
(–, C(6)), 38.5 (–, C(3)), 39.8 (–, C(1)), 51.0 (+, C(9)), 52.1 (–, 2 C, C(10)), 59.8 (–, 2 C, 
C(12)), 63.7 (+, C(7)), 165.5 (Cquat, C(2)), 170.8 (Cquat, 2 C, C(11)), 172.3 (Cquat, C(8)). – 
IR (KBr) [cm-1]: ν~ = 3226, 3074, 2951, 1744, 1680, 1218, 1025. – MS (ESI, MeOH + 
10 mmol/L NH4Ac): m/z (%) = 412 (33) [MNa+], 390 (100) [MH+]. – Elemental analysis 
calcd. (%) for C17H32N3O7Cl (425.91) + H2O: (M + H2O) C 46.00, H 7.72, N 9.47; found 
C 46.05, H 7.37, N 9.42. 
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Boc-Gly-NTAL-OLi (112): 
110 (0.11 g, 0.22 mmol) and LiOH⋅H2O (27.8 mg, 0.66 mmol) were dissolved in 25 % 
water/acetone (10 mL). The mixture was stirred at r.t. for 12 h. The remaining acetone was 
evaporated and the remaining solution freeze dried. The resulting solid was redissolved in 
water and extracted with DCM. The aqueous solution was freeze dried again yielding 112 
(0.22 mmol, 96 mg, 100 %) as a colourless solid.  
mp 97-99 °C. – 1H-NMR (300 MHz; D2O): δ = 1.30-1.65 (m, 15 H, CH3 + CH3), 2.86-3.10 
(m, 7 H, CH + CH2 + N-CH2), 3.56-3.59 (m, 2 H, CH2-Gly). – 13C-NMR (75 MHz; D2O; 
HMQC): δ = 24.3 (–, CH2), 27.5 (+, 3 C, CH3), 28.1 (–, CH2), 28.4 (–, CH2), 39.0 (–, CH2), 
39.0 (–, CH2), 43.4 (–, CH2), 56.8 (–, 2 C, CH2), 68.0 (+, CH), 81.5 (Cquat, C-Boc), 172.3 
(Cquat, CONH), 181.0 (Cquat, 2C, COO-), 182.3 (Cquat, COO-). – IR (KBr) [cm-1]: ν~ = 3354, 
2969, 1739, 1539, 1512. – MS (ESI, H2O/MeOH + 10 mmol/L NH4Ac): m/z (%) = 285 
(100) [A3- – Boc – Gly + NH4+ + 2 H+ Li+], 420 (50) [A3- + 4 H+], 426 (71) [A3- + 3 H+ + 
Li+], 432 (30) [A3- + 2 H+ +2 Li+]. – C17H26Li3N3O9 (437.23). 
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Li[Ni(Boc-Gly-NTAL)(H2O)2] (113): 
112 (122 mg, 0.28 mmol) and NiCO3⋅2Ni(OH)2⋅4H2O (35 mg, 0.09 mmol) were dissolved 
in water (20 mL). The solution was stirred 30 min at r.t. and 30 min at 60 °C. The resulting 
suspension was filtered and the filtrate freeze dried. The product 113 (0.28 mmol, 145 mg, 
100 %) could be obtained as a green-blue solid after recrystallisation in EtOH/water. 
IR (KBr) [cm-1]: ν~ = 3253, 3032, 2969, 1732, 1580. – MS (ESI(−), H2O/MeOH): m/z 
(%) = 474 (100) [A- − 2 Η2Ο]. – C17H30LiN3NiO11 (518.07). 
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3,5-Bis-[(bis-benzyloxycarbonylmethylamino)-methyl]-benzoic acid methylester (117): 
3,5-Bis-(bromomethyl)-benzoic acid methylester (1.00 g, 3.1 mmol), iminodiacetic acid-
di-benzylester (1.92 g, 6.2 mmol), and K2CO3 (1.72 g, 12.4 mmol) were dissolved in 
MeCN (50 mL). The suspension was stirred at 60 °C for 2 d. The remaining solid was 
filtered off and the filtrate acidified with 1N HCl. The mixture was separated between 
water and EtOAc. The organic layers were dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was purified using column chromatography on silica 
gel. (PE:EtOAc = 5:1, Rf = 0.4).The product 117 (1.1 mmol, 0.89 g, 36 %) is a yellow oil. 
1H-NMR (300 MHz; CDCl3): δ = 3.59 (s, 8 H, N-CH2), 3.87 (s, 3 H, O-CH3), 3.93 (s, 4 H, 
CH2-Ar), 5.12 (s, 8 H, CH2-Ph), 7.27-7.38 (m, 20 H, Ph), 7.57 (s, 1 H, H(4)-Ar), 7.94 (d, 
4J = 1.5 Hz, 2 H, H(2)-Ar + H(6)-Ar). – 13C-NMR (75 MHz; CDCl3): δ = 52.1 (+, O-CH3), 
54.3 (–, 4 C, CH2), 57.4 (–, 2 C, CH2), 66.2 (–, 4 C, CH2), 128.2 (+, 8 C, C-Ar), 128.3 (+, 
4 C, C-Ar), 128.6 (+, 8 C, C-Ar), 129.3 (+, 2 C, C-Ar), 130.6 (Cquat, C(1)), 134.2 (+, C-Ar), 
 186
135.7 (Cquat, C-Ar), 138.9 (Cquat, 4 C, C-Ar), 167.0 (Cquat, Ar-COOCH3), 170.8 (Cquat, 4 C, 
COOBn). – IR [cm-1]: ν~ = 3463, 3065, 3034, 2951, 1734, 1605, 1002. – MS (ESI, 
CH2Cl2/MeOH + 10 mmol/L NH4Ac): m/z (%) = 787 (100) [MH+] – C46H46N2O10 
(786.89). 
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3,5-Bis-[(bis-tert-butoxycarbonylamino)-methyl]-benzoic acid methylester (118):  
3,5-Bis-(bromomethyl)-benzoic acid methylester (0.50 g, 1.6 mmol), iminodiacetic acid-
di-tert-butylester (0.76 g, 3.1 mmol), and K2CO3 (0.86 g, 6.2 mmol) were dissolved in 
MeCN (50 mL). The suspension was stirred at 60 °C for 2 d. The remaining solid was 
filtered off and the filtrate acidified with 1N HCl. The mixture was separated between 
water and EtOAc. The organic layers were dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was purified using column chromatography on silica 
gel. (PE:EtOAc = 5:1, Rf = 0.4).The product 118 (0.8 mmol, 0.55 g, 54 %) is a yellow 
solid. 
1H-NMR (300 MHz; CDCl3): δ = 1.41 (s, 36 H, CH3), 3.36 (s, 8 H, CH2), 3.83 (s, 3 H, 
OCH3), 3.88 (s, 4 H, CH2-Ar), 7.56 (s, 1 H, H(4)-Ar), 7.91 (d, 4J = 1.4 Hz, 2 H, H (2)-Ar + 
H(6)-Ar). – 13C-NMR (150 MHz; CDCl3): δ = 28.2 (+, 12 C, CH3), 51.9 (+, CH3), 55.2 (–, 
4 C, CH2), 57.1 (–, 2 C,CH2), 81.0 (Cquat, 4 C, C-Boc), 129.2 (+, 2 C, C(2) + C(6)), 130.4 
(Cquat, C(1)), 134.3 (+, C(4)), 139.2 (Cquat, 2 C, C(3)+C(5)), 167.2 (Cquat, COOCH3), 170.4 
(Cquat, 4 C, COOtBu). – IR (KBr) [cm-1]: ν~ = 3368, 2979, 2932, 1740, 1369. – UV/Vis 
(MeCN) λmax [nm] (lg ε): 282 (3.150). – MS (ESI, CH2Cl2/MeOH + 10 mmol/L NH4Ac): 
m/z (%) = 651 (100) [MH+], 595 (6) [MH+− C4H8]. – C34H54N2O10 (650.82). 
 
 187
OO
N
N
N
N
N
N
H 6
H2
H
4
 
 
3,5-Bis-[(bis-pyridine-2-ylmethyl-amino)-methyl]-benzoic acid methylester (119): 
3,5-Bis-(bromomethyl)-benzoic acid methylester (0.50 g, 1.6 mmol), BPA (0.93 g, 
4.7 mmol), and K2CO3 (1.29 g, 9.3 mmol) were dissolved in MeCN (50 mL). The 
suspension was stirred at 60 °C for 2 d. The remaining solid was filtered off and the filtrate 
acidified with 1N HCl. The mixture was separated between water and EtOAc. The organic 
layers were dried over Na2SO4 and concentrated under reduced pressure. The product 119 
(1.2 mmol, 0.67 g, 77 %) is a yellow solid. 
mp 75-77 °C. 1H-NMR (300 MHz; [D6]-Acetone): δ = 3.65-4.14 (m, 15 H, OCH3, NCH2), 
7.11-7.30 (m, 4 H, H-Py), 7.46-7.55 (m, 1 H, H-Ar), 7.59-7.78 (m, 8 H, H- Py), 7.89-7.96 
(m, 2 H, H-Ar), 8.41-8.57 (m, 4 H, H-Py). – 13C-NMR (75 MHz; [D6]-Acetone): δ = 52.3 
(+, CH3), 58.8 (–, 2 C, CH2), 60.6 (–, 4 C, CH2), 122.9 (+, C-Ar), 123.6 (+, 2 C, C-Ar), 
129.4 (+, 4 C, C-Py), 131.1 (Cquat, C-Ar), 134.7 (+, 4 C, C-Py), 137.2 (+, 4 C, C-Py), 139.2 
(Cquat, 2 C, C-Ar), 140.9 (Cquat, 4 C, C-Py), 149.8 (+, 4 C, C-Py), 160.5 (Cquat, COOCH3). – 
MS (EI, 70 eV): m/z (%) = 558 (3) [M+•], 527 (3) [M+•- •O-CH3], 466 (100) [M+•- •CH2-
Py]. – C34H34N6O2 (558.69). 
 
O
O
N
NN
N
boc
boc
boc
N
NN
N
boc
boc
boc  
 
3,5-Bis-(tri-Boc-Cyc-aminomethyl)-benzoic acid methylester (120): 
Tri-Boc-Cyc (1.00 g, 2.1 mmol), K2CO3 (1.17 g, 8.5 mmol) and a spatula tip of KI were 
dissolved in MeCN (40 mL).3,5-Bis(bromomethyl)-benzoic acid methylester (0.32 g, 
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1.0 mmol) was added in little portions over a period of 15 min. The suspension was stirred 
at 60 °C for 2 d. The remaining solid was filtered off and the filtrate acidified with 1N HCl. 
The mixture was separated between water and EtOAc. The organic layers were dried over 
Na2SO4 and concentrated under reduced pressure. The crude product was purified using 
column chromatography on silica gel. (PE:EtOAc = 1:1, Rf = 0.74). 120 (1.7 mmol, 1.93 g, 
83 %) is a colourless solid. 
mp 107-110 °C. – 1H-NMR (300 MHz; CDCl3): δ = 1.25-1.47 (m, 54 H, CH3), 2.60-2.69 
(m, 8 H, CH2-Cyc), 3.27-3.80 (m, 24 H, CH2-Cyc), 3.78-3.81 (m, 4 H, CH2-Ph), 3.88 (s, 
3 H, O-CH3), 7.27 (s, 1 H, H-Ar), 7.84 (bs, 2 H, H-Ar). – 13C-NMR (75 MHz; CDCl3): δ = 
28.4 (+, 12 C, CH3), 28.7 (+, 6 C, CH3), 48.0 (–, 4 C, CH2), 49.8 (–, 4 C, CH2), 52.0 (+, 
CH3), 54.0 (–, 4 C, CH2), 55.4 (–, 4 C, CH2), 56.2 (–, 2 C, CH2), 79.4 (Cquat, 4 C, C-Boc), 
79.5 (Cquat, 2 C, C-Boc), 124.1 (+, C-Ar), 125.2 (+, 2 C, C-Ar), 130.0 (Cquat, C-Ar), 130.3 
(Cquat, 2 C, C-Ar), 155.7 (Cquat, 4 C, NCOOtBu), 156.1 (Cquat, 2 C, NCOOtBu), 166.5 (Cquat, 
COOMe). – IR (KBr) [cm-1]: ν~ = 3013, 2976, 2932, 1690, 1169, 772. – MS (ESI, 
DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 1106 (100) [MH+]. – C56H96N8O14 
(1105.43). 
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3,5-Bis-(tri-Boc-Cyc-aminomethyl)-benzoic acid (121): 
120 (0.30 g, 0.3 mmol) and LiOH⋅H2O (0.13 g, 0.3 mmol) were dissolved in water/acetone 
= 3:1 (25 mL). The solution was stirred at r.t for 12 h. The remaining acetone was 
evaporated. The aqueous solution was neutralised with saturated ammonium chloride 
solution and extracted with DCM. The organic layers were dried over Na2SO4 and 
concentrated. The crude product was purified using column chromatography on silica 
(EtOAc → MeOH:EtOAc = 5:1, Rf = 0.34). 121 (0.26 mmol, 0.28 g, 86 %) is a colourless 
solid. 
mp 136-138 °C. – 1H-NMR (300 MHz; CDCl3): δ = 1.19-1.49 (m, 54 H, CH3), 2.39-2.68 
(m, 8 H, CH2-Cyc), 3.12-3.81 (m, 28 H, CH2-Cyc + CH2-Ph) 7.15 (bs, 1 H, H-Ar), 8.79 
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(bs, 2 H, H-Ar). – 13C-NMR (75 MHz; CDCl3): δ = 28.3 (+, 12 C, CH3), 28.6 (+, 6 C, 
CH3), 48.2 (–, 4 C, CH2), 49.8 (–, 4 C, CH2), 54.1 (–, 4 C, CH2), 55.5 (–, 4 C, CH2), 56.1 
(-, 2 C, CH2), 79.4 (Cquat, 4 C, C-Boc), 79.5 (Cquat, 2 C, C-Boc), 124.1 (+, C-Ar), 125.2 (+, 
2 C, C-Ar), 130.0 (Cquat, C-Ar), 130.3 (Cquat, C-Ar), 155.7 (Cquat, 4 C, NCOOtBu), 156.1 
(Cquat, 2 C, NCOOtBu), 166.5 (Cquat, COOH). – IR (KBr) [cm-1]: ν~ = 3473, 2977, 2933, 
2821, 1685, 1251, 1167, 773. – MS (ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 
1092 (52) [MH+], 547 (100) [M + 2 H+]. – C55H94N8O14 (1091.41). 
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[Zn2(bis-(Cyc-methyl)-benzoic acid methylester)(OH)](ClO4)3 (122): 
120 (0.62 g, 0.6 mmol) was dissolved in few DCM and mixed with TFA (3.6 mL, 
47 mmol). The solution was stirred over night at r.t.. After evaporation of the solvents the 
completion of the reaction was controlled via 1H-NMR. The resulting triflate salt was 
dissolved in water and freeze dried. The obtained solid was dissolved in EtOH and 
neutralised with NaHCO3. In EtOH (5 mL) predissolved zinc(II) perchlorate hexahydrate 
(0.22 g, 0.6 mmol) was added to the reaction mixture. The resulting suspension was 
refluxed over night. Insoluble particles were filtered off and the filtrate concentrated. The 
resulting crude product was recrystallised in water/MeCN. 122 (0.53 g, 0.56 mmol, 93 %) 
is obtained as colourless needles. 
mp > 200 °C. – 1H-NMR (300 MHz; CDCl3): δ = 2.52-2.87 (m, 16 H, CH2-Cyc), 2.89-3.05 
(m, 8 H, CH2-Cyc), 3.09-3.21 (m, 4 H, CH2-Ph), 3.22-3.49 (m, 4 H, CH2-Ph), 3.85 (s, 2 H, 
CH2-Ar), 3.91 (s, 3 H, O-CH3), 4.01 (s, 2 H, CH2-Ar), 7.42 (s, 1 H, H-Ar), 7.95 (d, 3J = 
6.8 Hz, 2 H, H-Ar). – 13C-NMR (75 MHz; CD3CN): δ = 47.5 (–, 4 C, CH2), 48.9 (–, 4 C, 
CH2), 51.4 (+, CH3), 53.6 (–, 4 C, CH2), 55.7 (–, 4 C, CH2), 55.9 (–, 2 C, CH2), 123.8 (+, 
2 C, C-Ar), 124.1 (+, C-Ar), 130.4 (Cquat, 2 C, C-Ar), 130.2 (Cquat, C-Ar), 166.5 (Cquat, 
COOMe). – IR (KBr) [cm-1]: ν~ = 3005, 2986, 2966, 2930, 1734, 1169. – MS (ESI, 
MeCN): m/z (%) = 431 (100) [K4+ + 2 TFA-]. – C26H49N8O15Cl3Zn2 (946.10). 
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Nε-Benzyloxycarbonyl-Nα-bis(2-ethoxy-2-oxoethyl)-L-lysine-benzylester (123): 
H-Lys(Z)-OBzl⋅HCl (1.26 g, 3.4 mmol), K2CO3 (9.40 g, 68.0 mmol) were dissolved in 
MeCN (25 mL) and stirred for 8 h. Ethylbromoacetate (3.8 mL, 34.0 mmol) was added and 
the suspension refluxed for 18 h. The suspension was filtered and the solution 
concentrated. The resulting crude product was purified using column chromatography on 
silica gel (PE → PE:EtOAc = 1:1, Rf = 0.51). 123 (3.0 mmol, 1.64 g, 89 %) is a yellow 
liquid. 
1H-NMR (300 MHz; CDCl3): δ = 1.21 (t, 3J = 7.1 Hz, 6 H, CH3), 1.39-1.58 (m, 2 H, CH2), 
1.64-1.76 (m, 4 H, CH2), 3.08-3.22 (m, 2 H, CH2), 3.46 (t, 3J = 7.5 Hz, 1 H, CH), 3.62 (s, 
4 H, N-CH2), 4.10 (q, 3J = 7.1 Hz, 4 H, O-CH2), 4.91 (bs, 1 H, NH), 5.05-5.12 (m, 4 H, 
CH2-Ph), 7.28-7.39 (m, 10 H, H-Ar). – C29H38N2O8 (542.63). 
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6-Amino-2-(bis-ethoxycarbonylmethylamino)-hexanic acid (124): 
123 (0.80 g, 1.5 mmol) and a spatula tip of 10 % Pd/C were suspended in EtOH (25 mL). 
The reaction mixture was stirred over night in a autoclave under 10 bar H2 atmosphere. 
After hydrogenolysis the suspension was filtered over celite and concentrated under 
reduced pressure. The crude product was dissolved in water and washed with DCM and 
EtOAc. The aqueous solution was freeze dried. 124 (1.4 mmol, 0.46 g, 98 %) was isolated 
as a colourless solid. 
mp 141-142 °C. – 1H-NMR (400 MHz; D2O): δ = 1.18 (t, 3J = 7.2 Hz, 6 H, COSY: H(10)), 
1.20-1.39 (m, 2 H, COSY: H(3)), 1.50-1.65 (m, 4 H, COSY: H(2) + H(4)), 2.92 (t, 3J = 
7.4 Hz, 2 H, COSY: H(1)), 3.17 (dd, 3J = 5.8, 9.1 Hz, 1 H, COSY: H(5)), 3.42 (d, 2J = 
17.5 Hz, 2 H, COSY: H(7)), 3.60 (d, 2J = 17.5 Hz, 2 H, COSY: H(7)), 4.10 (q, 3J = 7.3 Hz, 
4 H, COSY: H(9)). – 13C-NMR (100 MHz; D2O; HSQC, HMQC): δ = 13.3 (+, 2 C, 
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C(10)), 22.7 (–, C(3)), 26.6 (–, C(2)), 29.8 (–, C(4)), 39.3 (–, C(1)), 53.9 (–, 2 C, C(7)), 
61.9 (–, 2 C, C(9)), 68.2 (+, C(5)), 173.7 (Cquat, 2 C, C(8)), 179.6 (Cquat, C(6)). – IR (KBr) 
[cm-1]: ν~ = 3430, 2940, 1744, 1561, 1397. – MS (ESI, H2O/MeOH + 10 mmol/L NH4Ac): 
m/z (%) = 319 (100) [MH+]. – Elemental analysis calcd. (%) for C14H26N2O6 (318.37): C 
52.82, H 8.23, N 8.80; found C 52.40, H 7.91, N 8.61. 
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2-(Bis-ethoxycarbonylmethyl-amino)-6-tert-butoxycarbonylamino-hexanoic acid (125): 
124 (0.50 g, 1.6 mmol) and NEt3 (0.3 mL, 2.1 mmol) were dissolved in MeOH (25 mL). 
The solution was cooled in an ice bath and was drop wise mixed with Boc2O (0.41 g, 
1.88 mmol) dissolved in DCM. The mixture was allowed to warm to r.t. and stirred over 
night. The solution was concentrated and purified using column chromatography (EtOAC 
→ EtOAC:MeOH = 5:1, Rf (EE) = 0.3). The resulting product 125 (0.45 g, 1.1 mmol, 
67 %) is a colourless solid. 
mp 71-74 °C. – 1H-NMR (400 MHz; CDCl3; HSQC): δ = 1.22 (t, 3J = 7.1 Hz, 6 H, H(13)), 
1.37-1.49 (m, 11 H, H(1) + H(6)), 1.52-1.80 (m, 2 H, H(7)), 3.05-3.07 (m, 2 H, H(4)), 3.28 
(t, 3J = 7.1 Hz, 1 H, H(8)), 3.50 + 3.60 (2s, 4 H, H(10)), 5.47 (q, 3J = 7.1 Hz, 4 H, H(12)), 
4.60 (bs, 1 H, HA), 10.71 (bs, 1 H, HB). – 13C-NMR (100 MHz; CDCl3; HSQC): δ = 14.1 
(+, 2 C, C(13)), 23.9 (–, C(6)), 28.4 (+, 3 C, C(1)), 28.7 (–, C(5)), 29.8 (–, C(7)), 40.2 (–, 
C(4)), 53.4 (–, C(10)), 61.2 (–, 2 C, C(12)), 66.1 (+, C(8)), 67.0 (–, 2 C, C(10)), 78.9 (Cquat, 
C(2)), 156.0 (Cquat, C(3)), 172.4 (Cquat, 2 C, C(11)), 176.0 (Cquat, C(9)). – IR (KBr) [cm-1]: 
ν~ = 3320, 2967, 2945, 1732, 1624, 1555. – MS (ESI, H2O/MeOH + 10 mmol/L NH4Ac): 
m/z (%) = 441 (39) [MNa+], 419 (100) [MH+], 363 (53) [MH+ - C4H8]. – C19H34N2O8 
(418.49). 
 
SPRS Protocol: 
• Loading: 
The resin was suspended in DMF. Four equivalents (based on resin substitution) of 
the carboxylic acid and 4 equivalents of PyBOP (based on resin substitution) were 
dissolved in DMF. This mixture was added to the resin. Eight equivalents (based on 
resin substitution) of DIPEA were added and the mixture was shaken for 18 h. 
 192
• Capping 
The resin was preswelled in DMF (15 min) and DCM (10 min). After removal of 
the solvents the resin was mixed with a solution of Ac2O (47 µL, 0.5 mmol) and 
pyridine (81 µL, 1.0 mmol) in DCM (2 mL). The solution was removed after 
15 min and the resin washed with DCM and DMF. The acetylation step was 
repeated twice. 
• Boc-Deprotection 
The resin was preswelled in DCM (2 mL). The deprotection was performed using a 
mixture of TFA (4 mL), anisole (0.2 mL) and DCM (1 mL) and a reaction time of 
15 min. The deprotection step was repeated for three times. After completion the 
resin was washed with DCM and dried. 
• Coupling 
The Boc-AA (0.5 mmol), HOBt (68 mg, 0.5 mmol) and HBTU (186 mg, 
0.49 mmol) were dissolved in DMF (2 mL). After addition of DIPEA (171 µL, 
1.0 mmol) the coupling mixture was added to the resin (preswollen in DMF). The 
resin filtered off after 1 h and the coupling step repeated for three times. The 
completion of the coupling step was monitored using the Kaiser test. The resin was 
washed with DCM and DMF and dried. 
• Ester Cleavage 
The resin was preswelled in water/DMF and mixed with 1 M LiOH. The 
deprotection was repeated three times. The resin was washed with water/DMF. 
• Complexation 
The resin was preswelled in water/MeCN and mixed with a Ni(II)-solution (NiCl2 
and Ni(OAc)2). After 1 h the complexation was repeated. The resin was washed 
several times with water, DMF, MeCN and DCM. Additionally the resin was 
extracted with water using a soxlet apparatus. After drying of the resin the Ni(II) 
loading was determined gravimetrically (97 % Ni(II)-loading).  
• Activation of safety-catch-resin  
The resin was mixed with NMP (8 mL/g resin). DIPEA (5 eq.) and iodoacetonitrile 
(23.5 eq.) were added and stirred for 24 h at r.t.. 
• Cleavage 
The resin was filled in a syringe and washed with DMSO and THF. The resin was 
preswelled in THF and mixed for 20 h with 2 N NaOH (10 mL/500 mg resin). 
Filtration and washing of the resin delivers the free acid. The Ni(II)-NTA complex 
was obtained after freeze drying. 
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Kaiser test:  
Preparation of the following solutions: 
Sol-1: 5 g of Ninhydrin in 100 mL of EtOH. Sol-2: 80 g of liquefied phenol in 20 mL of 
EtOH. Sol-3: 2 mL of a 0.001 M aqueous solution of KCN in 98 mL of pyridine. 
Place a few resin beads in a glass vial and rinse several times with EtOH. Add two drops of 
each of the solutions above. Mix well and heat to 120 oC for 4-6 min. Positive test is 
indicated by blue/purple resin beads. Negative test is indicated by pale yellow/brown 
colour. 
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Z-L-Tyr[Ac-(Tri-Boc-Cyc)]-OMe (127) 
Z-L-Tyr-OMe (0.15 g, 0.5 mmol), 126 (0.32 g, 0.6 mmol), and K2CO3 (0.12 g, 0.9 mmol) 
were suspended in MeCN (25 mL). After refluxing for 12 h the mixture was filtered. 
Concentration of the filtrate delivered the crude product which was purified using column 
chromatography on silica gel (PE:EtOAc = 2:3, Rf = 0.33). 127 (0.32 g, 0.4 mmol, 76 %) is 
a colourless solid. 
mp 93-96 °C. – 1H-NMR (300 MHz; CDCl3): δ = 1.32-1.42 (m, 27 H, Boc-CH3), 2.93-3.01 
(m, 2 H, CH2), 3.25-3.56 (m, 16 H, CH2-Cyc), 3.64 (s, 3 H, O-CH3), 4.49-4.59 (m, 3 H, 
CH2-Ar + CH), 5.02 (s, 2 H, CH2-Ar), 5.18 (d, 3J = 8.2 Hz, 1 H, NH), 6.78 (d, 3J = 8.5 Hz, 
2 H, H-Ar), 6.92 (d, 3J = 8.5 Hz, 2 H, H-Ar), 7.22-7.30 (m, 5 H, H-Ar). – 13C-NMR 
(75 MHz; CDCl3): δ = 28.4 (+, 3 C, CH3), 28.5 (+, 3 C, CH3), 28.5 (+, 3 C, CH3), 37.2 (–, 
CH2) 49.7 (–, 4 C, CH2), 49.9 (–, 2 C, CH2), 50.4 (–, 2 C, CH2), 51.4 (–, CH2), 52.3 (+, 
CH3), 54.9 (+, CH), 66.9 (–, CH2), 80.3 (Cquat, C-Boc), 80.4 (Cquat, C-Boc), 80.5 (Cquat, C-
Boc), 115.0 (+, 2 C, C-Ar), 128.1 (+, 2 C, C-Ar), 128.2 (+, C-Ar), 128.5 (+, C-Ar), 128.7 
(Cquat, C-Ar), 130.3 (+, 2 C, C-Ar), 136.2 (Cquat, 2 C, C-Ar), 155.6 (Cquat, NCOOtBu), 157.1 
(Cquat, NCOOtBu), 157.3 (Cquat, NCOOtBu), 168.6 (Cquat, COOMe), 171.1 (Cquat, COOR), 
172.0 (Cquat, CONH). – MS (ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 859 (57) 
[M+NH4+], 843 (28) [MH+], 742 (100) [MH+ - Boc]. – C43H63N5O12 (842.01). 
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[Zn(Z-L-Tyr(Ac-Cyc)-OMe)](ClO4)2 (128): 
127 (0.15 g, 0.2 mmol) was dissolved in TFA (5 mL) and stirred at r.t. over night. 1H-
NMR-control showed completion of the Boc-deprotection. TFA was removed under 
reduced pressure. The resulting slurry was dissolved in water and freeze dried. The triflate 
salt was dissolved in water and neutralised with NaHCO3. This solution was mixed with 
Zn(ClO4)2⋅6 H2O (75 mg, 0.2 mmol). After 1 h warming to 40 °C the insoluble particles 
were filtered off and the filtrate concentrated. 128 (0.12 g, 0.2 mmol, 100 %) was obtained 
as a colourless solid after crystallisation in water/MeCN. 
mp > 200 °C. – MS (ESI, H2O/MeOH + 10 mmol/L NH4Ac): m/z (%) = 664 (75) [K2+ + 
Ac-], 590 (100) [K2+ - Me]. – IR (KBr) [cm-1]: ν~ = 3204, 3007, 2986, 2966, 1734, 1716, 
1655, 1320, 1169, 837. – C28H39N5O6Zn (605.22). 
 
General procedure for the generation of organozinc reagents 130a and 130b. 
The Rieke zinc was prepared from ZnCl2 using a catalytic amount of naphthalene: To a 
Schlenk tube charged with finely divided lithium (1% Na) (3.0 mmol), naphthalene 
(0.3 mmol) and anhydrous THF (2 mL) (distilled from benzophenone-sodium ketyl under 
N2) or DME (in case of Z-p-Me-Phe-OtBu 131) under argon a solution of anhydrous zinc 
chloride (1.5 mmol in 2 mL of THF or DME (in case of Z-p-Me-Phe-OtBu 131)) was 
transferred via syringe. The mixture was stirred vigorously until all lithium was consumed 
(30 min). To the Rieke zinc suspension under argon a solution of iodoalanine (1.28 mmol) 
in DME (3 mL) (in case of Z-p-Me-Phe-OtBu 131) or THF was added via syringe. The 
exothermic reaction was completed in 5 min (the end of reaction is indicated when the 
black zinc disappeared). The mixture was stirred for additional 30 min. 
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10-(p-Iodo-benzyl)-1,4,7,10-tetraaza cyclododecane-1,4,7-tricarbonic acid-tri-tert-
butylester (136): 
p-Iodobenzylbromide (0.5 g, 1.7 mmol) was dissolved in MeCN (35 mL). Trifold-Boc 
protected cyclen (1.03 g, 2.2 mmol) and K2CO3 (1.21 g 8.8 mmol) were added, and after 
completion of the reaction the reaction mixture was filtered and concentrated. The crude 
product was purified by chromatography on silica gel (PE:DCM = 5:1 → EtOAc, 
Rf (EtOAc) = 0.84) giving 136 (1.58 mmol, 1.09 g, 93 %) as a colourless solid. 
mp = 75-77 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.25-1.56 (m, 27H), 2.39-2.78 (m, 
4H), 3.11-3.73 (m, 14H), 7.00 (d, 3J = 8.2 Hz, 2H), 7.61 (d, 3J = 8.2 Hz, 2H). – 13C-NMR 
(75 MHz, CDCl3): δ = 28.5 (+, 6 C, CH3), 28.7 (+, 3 C, CH3), 47.9 (–, 2 C, CH2), 50.0 (–, 
2 C, CH2), 54.8 (–, 2 C, CH2), 55.5(–, 2 C, CH2), 56.7(–, CH2), 79.5 (Cquat, 3 C, C-Boc), 
92.8 (Cquat, C-Ar), 132.2 (+, 2 C, C-Ar), 136.7 (Cquat, C-Ar), 137.2 (+, 2 C, C-Ar), 155.4 
(Cquat, NCOOtBu), 155.7 (Cquat, NCOOtBu), 156.1 (Cquat, NCOOtBu). – MS 
(ESI/DCM/MeOH + 10 mmol/L NH4OAc): m/z = 689 [(M+H)+]. – C30H49IN4O6 (688.65). 
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[(4-Iodo-benzyl)-methoxycarbonylmethyl-amino]-acetic acid methylester (137): 
Dimethyl iminodiacetate hydrochloride (0.87 g, 4.4 mmol) and NaH (60 % suspension) 
(0.18 g, 4.4 mmol) were dissolved in MeCN (35 mL) and stirred for 5 min. K2CO3 (2.42 g, 
17.5 mmol) and p-iodobenzylbromide (1.00 g, 3.4 mmol) were added to this suspension. 
After completion of the reaction the mixture was filtered and concentrated. The crude 
product was purified by chromatography on silica gel (PE:DCM = 5:1 → EtOAc, 
Rf = 0.44) yielding 137 (3.1 mmol, 1.49 g, 90 %) as a colourless oil. 
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1H-NMR (300 MHz, CDCl3): δ = 3.52 (s, 4H), 3.68 (s, 6H), 3.84 (s, 2H), 7.13 (d, 3J = 
8.2 Hz, 2H), 7.62 (d, 3J = 8.2 Hz, 2H). – 13C-NMR (75 MHz, CDCl3): δ = 51.6 (+, 2 C, 
CH3), 54.1 (–, 2 C, CH2), 57.3 (–, CH2), 92.9 (Cquat, C-Ar), 130.7 (+, 2 C, C-Ar), 137.2 
(Cquat, C-Ar), 137.8 (+, 2 C, C-Ar), 171.5 (Cquat, 2 C, COOMe). – MS (CI/NH3): m/z = 378 
[(M+H)+]. – C13H16INO4 (377.18). 
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Z-p-Me-Phe-OtBu (131):  
A Schlenk flask was charged with p-iodotoluene (0.34 g, 1.5 mmol), Pd2(dba)3 (40 mg, 
2.5 mol%), P(o-tol)3 (47 mg, 10 mol%), CuBr⋅DMS (32 mg, 0.1 eq) and DME (4 mL). At 
-10 °C a solution of the organozinc derivate of Z-I-Ala-OtBu (1.2 mmol) in DME (4 mL) 
was added. The reaction mixture was slowly allowed to warm to r.t. over night. The 
reaction mixture was concentrated under argon and the solvent was removed in vacuum. 
EtOAc was added and the organic phase was washed twice with water and brine, the 
combined organic layers were dried over MgSO4 and concentrated. The crude resulting oil 
was purified by chromatography on silica gel (PE:EtOAc = 4:1, Rf = 0.28) affording 131 
(0.79 mmol, 0.31 g, 66 %) as a colourless solid. 
mp = 51-52 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.41 (s, 9H), 2.31 (s, 3H), 3.04 (d, 3J = 
5.5 Hz, 2H), 4.51 (dt, 3J = 5.9, 8.1 Hz, 1H),  5.10 (s, 2H), 5.21 (d, 3J = 8.2 Hz, 1H), 7.00-
7.11 (m, 4H), 7.30-7.39 (m, 5H). – 13C-NMR (75 MHz, CDCl3): δ = 21.1 (+, CH3), 28.0 
(+, 3 C, CH3), 37.9 (–, CH2), 52.2 (+, CH), 66.8 (–, CH2), 82.3 (Cquat, C), 128.1 (+, 3 C, C-
Ar), 128.5 (+, 2 C, C-Ar), 129.1 (+, 2 C, C-Ar), 129.4 (+, 2 C, C-Ar), 132.9 (Cquat, C-Ar), 
136.4 (Cquat, C-Ar), 136.5 (Cquat, C-Ar), 143.4 (+, C-Ar), 155.6 (Cquat, COOBzl), 170.7 
(Cquat, COOtBu). – MS (ESI/ DCM/MeOH + 10 mmol/L NH4OAc): m/z = 756 
[(2M+NH4)+], 387 [(M+NH4)+], 370 [(M+H)+]. – Elemental anal. calcd. (%) for 
C22H27NO4 (369.46): C 71.52, H 7.37, N 3.79; found C 71.60, H 7.14, N 3.60. 
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Z-p-NH2-Phe-OtBu (132):  
A Schlenk flask was charged with p-iodoaniline (0.34 g, 1.5 mmol), Pd2(dba)3 (40 mg, 
2.5 mol%), P(o-tol)3 (47 mg, 10 mol%), CuBr⋅DMS (32 mg, 0.1 eq), and DME (4 mL). At 
-10 °C a solution of the organozinc derivate of Z-I-Ala-OtBu (1.2 mmol) in DME (4 mL) 
was added. The reaction mixture was slowly allowed to warm to r.t. over night. The 
reaction mixture was concentrated under argon and the solvent was removed under 
vacuum. EtOAc was added and the organic phase was washed twice with water and brine. 
The collected organic layers were dried over MgSO4 and concentrated. The crude resulting 
oil was purified via chromatography on silica gel (PE:EtOAc = 3:2, Rf = 0.2) affording the 
pure product 132 (0.88 mmol, 0.35 g, 73 %) as a glass. 
1H-NMR (300 MHz, CDCl3): δ = 1.37 (s, 9H), 2.92 (d, 3J = 5.8 Hz, 2H), 3.56 (bs, 2H), 
4.41 (dt, 3J = 5.9, 8.1 Hz, 1H),  5.05 (s, 2H), 5.15 (d, 3J = 8.0 Hz, 1H), 6.54 (d, 3J = 8.2 Hz, 
2H), 6.87 (d, 3J = 8.2 Hz, 2H), 7.25-7.35 (m, 5H). – 13C-NMR (75 MHz, CDCl3): δ = 28.0 
(+, 3 C, CH3), 37.5 (–, CH2), 55.3 (+, CH), 66.8 (–, CH2), 82.1 (Cquat, C), 115.2 (+, 2 C, C-
Ar), 125.8 (Cquat, C-Ar), 128.1 (+, 3 C, C-Ar), 128.5 (+, 2 C, C-Ar), 128.6 (Cquat, C-Ar), 
130.4 (+, 2 C, C-Ar), 136.5 (Cquat, C-Ar), 146.3 (Cquat, C-Ar), 155.7 (Cquat, COOBzl), 170.8 
(Cquat, COOtBu). – MS (ESI DCM/MeOH + 10 mmol/L NH4OAc): m/z = 388 [(M+NH4)+], 
371 [(M+H)+]. – Elemental anal. calcd. (%) for C21H26N2O4 (370.45): C 68.09, H 7.07, N 
7.56; found C 68.23, H 7.20, N 7.38. 
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Z-p-Boc-NH-L-Phe-OMe (133):  
A Schlenk flask was charged with (4-Iodo-phenyl)-carbamic acid tert-butylester (0.38 g, 
1.2 mmol), Pd2(dba)3 (40 mg, 2.5 mol%), P(o-tol)3 (47 mg, 10 mol%), CuBr⋅DMS (32 mg, 
0.1 eq), HMPT (2 mL), and THF (2 mL). At –10 °C a solution of the organozinc derivate 
of Z-I-L-Ala-OMe (1.1 mmol) in THF (2 mL) was added. The reaction mixture was slowly 
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allowed to warm to r.t. over night. The reaction mixture was concentrated under argon and 
the solvent was removed under vacuum. EtOAc was added and the organic phase was 
washed twice with water and brine. The collected organic layers were dried over MgSO4 
and concentrated. The crude resulting oil was purified via chromatography on silica gel 
(PE:EtOAc = 2:1, Rf = 0.2) affording the pure product 133 (0.83 mmol, 0.39 g, 75 %) as a 
solid. 
mp = 65-67 °C. – [α]20D = + 3.0 (c 0.5 in CHCl3). – 1H-NMR (300 MHz, CDCl3): δ = 1.51 
(s, 9H), 2.97-3.13 (m, 2H), 3.71 (s, 3H), 4.57-4.68 (m, 1H), 5.09 (s, 2H), 5.21 (d, 3J = 
8.2 Hz, 1H), 7.00 (d, 3J = 8.5 Hz, 2H), 7.27 (d, 3J = 8.2 Hz, 2H), 7.30-7.44 (m, 5H), 7.30-
7.39 (m, 5H). – 13C-NMR (75 MHz, CDCl3): δ = 28.3 (+, 3 C, CH3), 37.5 (–, CH2), 52.4 
(+, CH3), 54.8 (+, CH), 67.0 (–, CH2), 80.6 (Cquat, C), 118.6 (+, 2 C, C-Ar), 128.1 (+, 3 C, 
C-Ar), 128.2 (+, C-Ar), 128.6 (+, 2 C. C-Ar), 129.9 (+, 2 C, C-Ar), 130.1 (Cquat, C-Ar), 
136.2 (Cquat, C-Ar), 137.4 (Cquat, C-Ar), 152.7 (Cquat, COOBzl), 155.6 (Cquat, NCOOtBu), 
172.0 (Cquat, COOMe). – MS (ESI DCM/MeOH + 10 mmol/L NH4OAc): m/z = 446 
[(M+NH4)+], 429 [(M+H)+], 373 [(M+H-C4H8)+], 329 [(M+H-Boc)+]. – Elemental anal. 
calcd. (%) for C23H28N2O6 (428.49): C 64.47, H 6.59, N 6.54; found C 64.30, H 6.27, N 
6.19. 
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Z-p-Me(IDA-OMe)-Phe-OtBu (134):  
A Schlenk flask was charged with 137 (0.30 g, 1.2 mmol), Pd2(dba)3 (40 mg, 2.5 mol%), 
P(o-tol)3 (47 mg, 10 mol%), CuBr⋅DMS (32 mg, 0.1 eq), HMPT (2 mL), and THF (2 mL). 
At -10 °C a solution of the organozinc derivate of Z-I-Ala-OtBu (1.2 mmol) in THF (4 mL) 
was added. The reaction mixture was slowly allowed to warm to r.t. over night. The 
reaction mixture was concentrated under argon and the solvent was removed under 
vacuum. EtOAc was added and the organic phase was washed twice with water and brine. 
The collected organic layers were dried over MgSO4 and concentrated. The crude resulting 
oil was purified via chromatography on silica gel (PE:EtOAc = 7:3, Rf = 0.18) affording 
the pure product 134 (0.78 mmol, 0.41 g, 65 %) as a glass. 
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[α]20D = + 14.6 (c 0.5 in CHCl3). 1H-NMR (600 MHz, CDCl3, HSQC): δ = 1.42 (s, 9H, 
H(13)), 3.09 (d, 3J = 5.7 Hz, 2H, H(9)), 3.57 (s, 4H, H(3)), 3.72 (s, 6H, H(1)), 3.91 (s, 2H, 
H(4)), 4.51-4.57 (m, 1H, H(10)), 5.12 (s, 2H, H(15)), 5.25 (d, 3J = 7.7 Hz, 1H, NH), 7.13 
(d, 3J = 7.5 Hz, 2H, H(6)), 7.31 (d, 3J = 7.6 Hz, 2H, H(7)), 7.32-7.40 (m, 5H, H(17-19)). – 
13C-NMR (150 MHz, CDCl3, HSQC): δ = 27.9 (+, 3 C, C(13)), 38.1 (–, C(9)), 51.5 (+, 2 
C, C(1)), 53.9 (–, C(3)), 55.2 (+, C(10)), 60.4 (–, C(4)), 66.8 (–, C(15)), 82.3 (Cquat, C(12)), 
128.1 (+, 2 C, C(17)), 128.2 (+, C(19)), 128.5 (+, 2 C, C(7)), 129.1 (+, 2 C, C(18)), 129.6 
(+, 2 C, C(6)), 135.3 (Cquat, C(8)), 136.0 (Cquat, C(16)), 136.4 (Cquat, C(5)), 155.6 (Cquat, 
C(14)), 170.5 (Cquat, C(11), 171.5 (Cquat, 2 C, C(2)). – MS (ESI DCM/MeOH + 10 mmol/L 
NH4OAc): m/z = 529 [(M+H)+], 473 [(M+H-C4H8)+]. – Elemental anal. calcd. (%) for 
C28H36N2O8 (528.61): C 63.62, H 6.86, N 5.30; found C 63.79, H 6.91, N 5.20. 
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Z-p-Me(3-Boc-Cyc)-L-Phe-OMe (135):  
A Schlenk flask was charged with 136 (0.19 g, 0.28 mmol), Pd2(dba)3 (10 mg, 2.5 mol%), 
P(o-tol)3 (12 mg, 10 mol%), CuBr⋅DMS (8 mg, 0.1 eq), HMPT (2 mL), and THF (2 mL). 
At -10 °C a solution of the organozinc derivate of Z-I-L-Ala-OMe (0.35 mmol) in of THF 
(2 mL) was added. The reaction mixture was slowly allowed to warm to r.t. over night. The 
reaction mixture was concentrated under argon and the solvent was removed under 
vacuum. EtOAc was added and the organic phase was washed twice with water and brine. 
The collected organic layers were dried over MgSO4 and concentrated. The crude resulting 
oil was purified via chromatography on silica gel (PE:EtOAc = 3:2, Rf = 0.16) affording 
the pure product 135 (0.30 mmol, 0.19 g, 86 %) as a solid. 
mp = 56-57 °C. – [α]20D = + 40.4 (c 0.5 in CHCl3). – 1H-NMR (CDCl3, 300 MHz): δ = 
1.42 (s, 9H), 1.47 (s, 18H), 2.53-2.79 (m, 4H), 3.03-3.11 (m, 2 H), 3.11-3.50 (m, 8H), 3.57 
(bs, 4H), 3.69 (s, 3H), 4.57-4.70 (m, 1H), 5.08 (s, 2H), 5.21 (d, 3J = 7.7 Hz, 1H), 7.02 (d, 
3J = 8.0 Hz, 2H), 7.16 (d, 3J = 8.0 Hz, 2H), 7.30-7.44 (m, 5H), 7.30-7.38 (m, 5H). – 13C-
NMR (75 MHz, CDCl3): δ = 28.5 (+, 6 C, CH3), 28.7 (+, 3 C, CH3), 37.9 (–, CH2), 47.3 (–, 
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2 C, CH2), 48.9 (–, 2 C, CH2), 49.5 (–, 2 C, CH2), 50.0 (–, 2 C, CH2), 52.3 (+, CH3), 54.8 
(+, CH), 56.9 (–, CH2), 67.0 (–, CH2), 79.3 (Cquat, 2 C, C-Boc), 79.4 (Cquat, C-Boc), 128.1 
(+, 2 C, C-Ar), 128.2 (+, C-Ar), 128.6 (+, 2 C, C-Ar), 129.1 (+, 2 C, C-Ar), 130.3 (Cquat, C-
Ar), 130.6 (+, C-Ar), 134.7 (Cquat, C-Ar), 136.7 (Cquat, 2 C, C-Ar), 155.6 (Cquat, NCOOtBu), 
155.8 (Cquat, NCOOtBu), 156.1 (Cquat, COOBzl), 171.9 (Cquat, COOME). – HR-MS 
(EI/70 eV): m/z = calcd. for C42H63N5O10 797.4575; found 797.4559 ± 0.62 ppm. 
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3. Enhanced Peptide β-Sheet Affinity by Metal to Ligand 
Coordinationi
This chapter deals with the application of a C-terminal NTA recognition unit which is 
bound to MOPAS (= methoxy-pyrrole amino acids) units.ii These MOPAS building blocks 
bind to oligoamides inducing a β-sheet conformation. The resulting receptor oligopeptide 
was used to bind a pentapeptide. Within the receptor-peptide assembly the peptide 
backbone was forced to adapt a β-sheet conformation. The induced secondary structure of 
the peptide was examined by NMR-techniques.iii  
 
i Kruppa, M.; Bonauer, C.; Michlova, V.; König, B, J. Org. Chem. 2005, Web Release 
Date: 25.05.2005. 
ii MOPAS building blocks were synthesised by C. Bonauer. 
iii NMR measurements were performed by V. Michlova. 
3.1 Introduction 
Intramolecular processes are typically more favourable than intermolecular processes.1 
This includes the formation of weak reversible interactions such as hydrogen bonds. 
Recent studies on hydrogen bonding patterns complementary to peptide β-sheet structures2 
by Nowick,3 Gellman,4 and others5 have taken advantage of this.6 The peptide and its 
complementary binding sites are covalently linked by a turn structure allowing intra-
molecular hydrogen bond formation.7 The selective binding of amino acid side chain 
functional groups, such as carboxyl-, ammonium-, phosphate- or imidazole-groups is an 
alternative way of peptide binding, which has been thoroughly investigated.8 Schmuck et 
al.9 recently reported the combination of a carboxyl-binding pyrrole guanidinium group 
with pyrazoles, which provides hydrogen bond donor and acceptor sites complementary to 
a peptide structure.10 We report here a compound, which combines strong intermolecular 
coordination, with hydrogen bonds to create a synthetic peptide binding site. The concept 
is illustrated using a histidine-coordinating nitrilotriacetic acid (NTA) complex11 and 
methoxy pyrrole amino acids (MOPAS) with peptide β-sheet binding ability. After 
complex formation the subsequent process of peptide backbone binding becomes 
intramolecular, facilitating hydrogen bond formation and control of the small peptide 
conformation in DMSO. 
 
 
,  Donor and acceptor of strong interactions; ,  Donor and acceptor of weak interactions
Figure 92. Schematic illustration of a binding process combining strong metal to ligand 
coordination and weaker interactions.
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3.2 Results and Discussion 
Scheme 49 shows the synthesis of the peptide binding complex 142. Compound 138,12 
obtained from lysine methyl ester, was coupled to activated ester 139, which we have 
reported recently.5 After Boc-deprotection a second MOPAS unit was introduced, again 
using compound 139. Cleavage of the methyl/ethyl-ester under basic conditions generated 
the NTA ligand, from which the zinc complex 142 was obtained in good yield. 
Scheme 49. Synthesis of complex 142 
 
NH2
N
O
O
O O
O
O
N
H
O
O
O N
H
N
N N
Boc
N
O
O
O O
O
O
N
H
O
N
H
O
N
H O
O
N
O
O
O O
O
O
N
H
O
N
H
O
N
H
N
H
O
O
N
H O
O
Zn
O
O
OH2O
H2O N
O
O
O
N
H
O
N
H
O
N
H
O
N
H
O
N
H O
O
n
 
Li
+
+
-
138 139
140-Boc
141
142
DIPEA,
DCM, 
RT, 12 h, 
60 %
1) HCl/Et2O 
2) Boc-MOPAS-OBt (139), 
    DIPEA, DCM
1) LiOH×H2O,
    H2O/acetone (3/1)
2) 2 ZnCO3×3 Zn(OH)2,
74 %
87 %
 
 
 204
Although Ni(II) or Cu(II) NTA complexes show higher affinities to N-terminal histidine, 
Zn(II) was chosen as metal ion for complex formation to obtain a diamagnetic compound, 
which allows spectroscopic investigation of the supramolecular structure with a bound 
peptide. The affinity of the Zn(II)-NTA complex to N-terminal histidine in DMSO13 is still 
sufficiently high (K > 104 L/mol) to ensure complete complex formation in a millimolar 
solution, which is necessary for NMR investigations. Pentapeptide H2N-His-Leu-Leu-Val-
Phe-OMe14 was used to investigate the binding properties of 142. The NMR spectra of 
142⋅H2N-His-Leu-Leu-Val-Phe-OMe (c = 2.22⋅10-2 mol/L), obtained by dissolving 
equimolar amounts of the receptor and the pentapeptide in DMSO [D6], shows a single set 
of resonances, which were structurally assigned. The temperature dependence of the 
chemical shifts confirmed the expected hydrogen bond interaction of the MOPAS amide 
NH to methoxy groups, which should keep the structure planar.15  
Table 24. Temperature dependence of NH Signal shifts 
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Figure 93. Hydrogen bonds as suggested from temperature 
dependence of chemical shifts (blue dotted lines). Red hydrogen bonds 
are expected, but without reference value for temperature dependence 
of chemical shift of hydrogen bound pyrrole NH no support can be 
derived from the experiment. 
 
 [ppb/K] 
NH A -4.1 
NH B -4.6* 
NH C -2.3 
NH D -5.4* 
NH E -2.3 
NH F -1.1 
NH G -5.4 
NH H -4.0 
NH I -2.8 
NH J -4.1 
NH K -5.6 
* For NH B and NH D pyrrole hydrogen atoms, which are expected to form intrastrand hydrogen bonds to 
the pentapeptide, and for NH F imidazole hydrogen atom no reference values are known. So no conclusions 
can be derived from the temperature dependence. 
 
A small ppb/K value for one of the central peptide amide protons indicates a possible 
hydrogen bond to a MOPAS carbonyl group. 2D NOESY spectra (see experimental 
section) revealed four intrastrand contacts, which are indicated in figure 94.16 This proves 
strong interactions between the bound pentapeptide and the MOPAS units. 
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Figure 94. Spectroscopically detected interactions of 142 and H N-His-Leu-Leu-Val-Phe-
OMe in DMSO solution. Red dotted lines: Hydrogen bonding suggested from temperature 
dependence of chemical shift. Red arrows: Intrastrand NOE contacts. Green arrows: 
Intramolecular distances within the pentapeptide used for the determination of its 
conformation. 
2
The interactions of the conformationally restricted MOPAS units with the bound 
pentapeptide induce a conformational preference of the peptide. To show this, 
intramolecular distances of the bound pentapeptide were derived from integrated NOESY 
spectra and used as constrains to calculate the solution structure of the pentapeptide bound 
to MOPAS complex 142 (see experimental section). Figure 95 shows the resulting 
pentapeptide structures, which have a β-sheet like conformation.17 Distances of the derived 
structure correspond well with the experimental NOE values (see table 25).18 As control 
experiments an equimolar mixture of the ligand of 142 without NTA-unit and the 
pentapeptide were investigated under identical conditions (see experimental section). No 
crosspeaks indicating close interactions between the peptide and the MOPAS units could 
be detected. Intramolecular NOE´s within the peptide were of low intensity, again showing 
a flexible conformation.19
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Figure 95. Structure of H2N-His-Leu-Leu-Val-Phe-OMe bound to 142. Top: Overlaid 
structures from MD simulation; bottom: Minimized average structure. 
Table 25. Distances within the assembly of H2N-His-Leu-Leu-Val-Phe-OMe and 142 
Interacting 
protons 
distance from NOE 
[Å] 
distance of average 
structure 
NH G – 24´ 2.8 2.5 
NH H – 24´ 2.1 2.3 
NH H – 19´ 2.8 2.9 
NH I – 19´ 2.1 2.2 
NH I – 14´ 2.8 2.9 
NH J – 14´ 2.0 2.2 
NH J – 10´ 2.9 3.0 
NH K – 10´ 2.1 2.2 
NH K – 3´ 2.8 3.0 
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3.3 Conclusion 
Mallik and Srivastava20 recently reported the significantly enhanced binding affinity of an 
inhibitor of carbonic anhydrase II by attaching a metal complex tether, which interacts 
with surface-exposed histidine residues. Our experiments have now shown that by 
combining a Zn-NTA tether with a heterocyclic peptide β-sheet binder, it is possible to 
restrict the conformation of a small flexible pentapeptide in DMSO solution. 
Intermolecular interactions of the MOPAS units with the pentapeptide in DMSO would be 
too weak to induce a conformational preference. The principle of “two-prong” binders is 
applicable to other peptide receptors, which suffer from competing solvent interactions. 
Exchanging Zn(II) in 142 by Cu(II) or Ni(II) leads to peptide-binding compounds with an 
affinity to H2N-His-Leu-Leu-Val-Phe-OMe in the lower micromolar range21 under 
aqueous physiological conditions. Other amino acid residues than imidazole can be 
targeted using other transition metal ion conjugates.22 This allows selective recognition 
and conformational control of small peptides in biological environment. 
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F. J. Am. Chem. Soc. 1998, 120, 3536. (f) Baldini, L.; Wilson, A.J.; Hong, J.; Hamilton, 
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Angew. Chem. Int. Ed. 2002, 41, 117. (i) Jasper, C.; Schrader, T.; Panitzky, J.; Klärner, 
F.-G. Angew. Chem. Int. Ed. 2002, 41, 1355. (k) Malinovski, V.; Tumir, L.; Piantanida, 
I.; Zinic, M.; Schneider, H.-J. Eur. J. Org. Chem. 2002, 3785. 
9 Schmuck, C.; Geiger, L. J. Am. Chem. Soc. 2004, 126, 8898. 
10Other examples of combined use of different reversible interaction: Ligand to metal 
coordination and ionic interaction: (a) Wright, A.T.; Anslyn, E.V. Org. Lett. 2004, 6, 
1341. Ligand to metal coordination and hydrogen bonding: (b) Tobey, S.L.; Anslyn, E.V. 
J. Am. Chem. Soc. 2003, 125, 14807. Guanidinium ion and boronic acid: (c) Wiskur, 
S.L.; Lavigne, J.J.; Metzger, A.; Tobey, S.L.; Lynch, V; Anslyn, E.V. Chem. Eur. J. 
2004, 10, 3792. (d) Tobey, S.L.; Anslyn, E.V. J. Am. Chem. Soc. 2003, 125, 14807. (e) 
Shirin, Z.; Hammes, B.S.; Young, V.G.; Borovik, A.S. J. Am. Chem. Soc. 2000, 122, 
1836. (f) MacBeth, E.C.; Hammes, B.S.; Young, V.G.; Borovik, A.S. Inorg. Chem. 2001, 
40, 4733. 
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3.4 Experimental Section 
3.4.1 Instruments and general techniques  
See experimental section of chapter 1 (page 131). 
 
3.4.2 Synthesis 
Compounds 138iv and Boc-MOPAS-OBt (139)v were prepared as previously reported. 
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Et/Me-NTA-MOPAS-BOC (140-Boc):  
Boc-MOPAS-OBt (72 mg, 0.18 mmol) was dissolved in DCM (15 mL). After the solution 
was cooled to 0 °C, 138 (55 mg, 0.15 mmol) and DIPEA (0.07 mL, 0.4 mmol) were added. 
The ice bath was removed and the reaction mixture was stirred for 24 h. The resulting 
product was extracted twice with 5% aqueous KHSO4 (25 mL), once with water (25 mL) 
and twice with 0.5 M aqueous NaHCO3 (25 mL) solution. After drying over Na2SO4, 
evaporation of the solvent and subsequent column chromatography on silica (EtOAc, Rf = 
0.64) gave 140-Boc (0.09 mmol, 54 mg, 60 %) as a yellow oil. 
1H-NMR (400 MHz, CDCl3, COSY): δ = 1.18 (t, 3J = 7.2 Hz, 6 H; H(22)), 1.29-1.50 (m, 
11 H; H(1) + H(14)), 1.51-1.60 (m, 2 H; H(13)), 1.62-1.74 (m, 2 H; H(15)), 2.01 (s, 3 H; 
H(7)), 3.30-3.38 (m, 2 H; H(12)), 3.37 (t, 3J = 7.4 Hz, 1 H; H(16)), 3.54-3.59 (m, 4 H; 
H(19)), 3.61 (s, 3 H; H(18)), 3.79 (s, 3 H; H(9)), 4.07 (q, 3J = 7.2 Hz, 4 H; H(21)), 4.11-
4.20 (m, 2 H; H(4)), 5.74-5.84 (m, 1 H; HA), 6.91-7.01 (m, 1 H; HC), 10.25 (bs, 1 H; HB). – 
13C-NMR (150 MHz, CDCl3, HSQC, HMBC): δ = 8.1 (+, C(7)), 14.2 (+, 2 C, C(22)), 23.4 
(–, C(14)),  28.4 (+, C(1)), 29.6 (–, C(3)), 30.2 (–, C(15)), 35.4 (–, C(4)), 38.8 (–, C(11)), 
51.4 (+, C(18)), 52.6 (–, 2 C, C(19)), 60.5 (–, 2 C, C(21)), 61.4 (–, C(9)), 64.7 (+, C(16)), 
79.2 (Cquat, C(2)), 107.9 (Cquat, C(6)), 112.4 (Cquat, C(10)), 128.7 (Cquat, C(5)), 147.0 (Cquat, 
C(8)), 155.9 (Cquat, C(3)), 161.5 (Cquat, C(11)), 171.3 (Cquat, 2 C, C(20)), 173.0 (Cquat, 
                                                 
iv Hart, B.R.; Shea, K.J. J. Am. Chem. Soc. 2001, 123, 2072. 
v Bonauer, C.; Zabel, M.; König, B. Org. Lett. 2004, 9, 1349. 
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C(17)). – IR (KBr) [cm-1]: ν~ = 3426, 3074, 2951, 1744, 1680, 1534, 1218, 1025. – MS 
(ESI, H2O/MeOH + 10 mmol/L NH4Ac): m/z (%) = 637 (12) [MK+], 621 (22) [MNa+], 599 
(100) [MH+] – Elemental analysis calcd (%) for C28H46N4O10 (598.7): C 56.17, H 7.74, N 
9.36; found C 55.68, H 7.66, N 9.27. 
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Et/Me-NTA-MOPAS-NH2⋅HCl (140-H):  
Compound 140-Boc (81 mg, 0.14 mmol) was dissolved in Et2O (5 mL) and cooled to 0 °C 
in ice. To deprotect the Boc-group HCl saturated Et2O was added drop wise until the 
product started to precipitate. The ice bath was removed and the reaction progress 
monitored by TLC (EtOAc). After 90 min the solvent was evaporated. Compound 140-H 
(0.14 mmol, 75 mg, 100 %) was isolated as a very hygroscopic colourless solid. 
mp 81-83 °C. – 1H-NMR (400 MHz, [D6]-DMSO, COSY, HMBC, HSQC): δ = 1.17 (t, 
3J = 7.1 Hz, 6 H; H(19)), 1.21-1.41 (m, 2 H; H(11)), 1.49 (m, 2 H; H(10)), 1.60 (m, 2 H; 
H(12)), 2.01 (s, 3 H; H(4)), 3.23 (m, 2 H; H(9)), 3.39 (m, 1 H; H(13)), 3.50-3.65 (m, 7 H; 
H(16), H(15)), 3.75 (s, 3 H; H(6)), 3.88 (m, 2 H; H(1)), 4.04 (q, 3J = 7.1 Hz, 4 H; H(18)), 
6.35 (bs, 6 H), 7.14 (m, 1 H; HC), 8.29 (m, 3 H; HA), 10.93 (s, 1 H; HB). – 13C-NMR 
(100 MHz, [D6]-DMSO, HMBC, HSQC): δ = 7.7 (+, C(4)), 13.9 (+, 2 C, C(19)), 22.6 (–, 
C(11)), 29.1 (–, C(10)), 29.3 (–, C(12)), 33.1 (–, C(1)), 37.9 (–, C(9)), 51.0 (+, C(15)), 52.1 
(–, 2 C, C(16)), 59.8 (–, 2 C, C(18)), 61.3 (+, C(6)), 63.7 (+, C(13)), 110.1 (Cquat, C(3)), 
113.8 (Cquat, C(7)), 121.8 (Cquat, C(2)), 145.7 (Cquat, C(5)), 159.5 (Cquat, C(8)), 170.7 (Cquat, 
C(8)), 170.7 (Cquat, 2 C, C(17)), 172.3 (Cquat, C(14)). – IR (KBr) [cm-1]: ν~ = 3429, 3010, 
2928, 1744, 1631, 1547, 1227. – MS (ESI, CH2Cl2/MeOH + 10 mmol/L NH4Ac): m/z (%) 
= 521 (64) [MNa+], 499 (100) [MH+]. – Elemental analysis calcd. (%) for C23H39N4O8Cl 
(534.25) + H2O: C 49.98, H 7.48, N 10.14; found C 49.92, H 7.37, N 10.08. 
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Et/Me-NTA-MOPAS-MOPAS-Boc (141):  
Compound 140-H (0.14 g, 0.27 mmol) was dissolved in DCM (15 mL). After the solution 
was cooled to 0 °C Boc-MOPAS-OBt (0.16 g, 0.40 mmol) and DIPEA (0.12 mL, 
0.7 mmol) were added. The ice bath was removed and the reaction mixture was stirred for 
24 h. The resulting product was extracted twice with 5% aqueous KHSO4 (25 mL), once 
with water (25 mL) and twice with 0.5 M aqueous NaHCO3 (25 mL) solution. After drying 
over Na2SO4, the solvent was evaporated in vacuum and column chromatography on silica 
gel (PE:EtOAc = 1:1, Rf (EtOAc) = 0.60) yielded 141 (0.20 mmol, 153 mg, 74 %) as a 
slightly yellow oil. 
1H-NMR (400 MHz, CDCl3, COSY): δ = 1.23 (t, 3J = 7.0 Hz, 6 H; H(30)), 1.34-1.55 (m, 
11 H; H(1) + H(22)), 1.57-1.67 (m, 2 H; H(21)), 1.72-1.86 (m, 2 H; H(23)), 2.00 (s, 3 H; 
H(7)), 2.13 (s, 3 H; H(15)), 3.38-3.47 (m, 3 H; H(24) + H(20)), 3.61 (s, 3 H; H(17)), 3.62 
(s, 4 H; H(27)), 3.65 (s, 3 H; H(26)), 3.88 (s, 3 H; H(9)), 4.12 (q, 3J = 7.0 Hz, 4 H; H(29)), 
4.19 (d, 3J = 5.6 Hz, 2 H; H(12)), 4.72 (d, 3J = 4.8 Hz, 2 H; H(4)), 6.14-6.21 (m, 1 H; HC), 
6.96 (t, 3J = 4.9 Hz, 1 H; HA), 7.12 (t, 3J = 5.7 Hz, 1 H; HE), 11.1 (bs, 1 H; HB), 11.46 (bs, 
1 H; HD). – 13C-NMR (100 MHz, CDCl3, HSQC + HMBC): δ = 7.9 (+, C(7)), 8.2 (+, 
C(15)), 14.2 (+, 2 C, C(30)), 23.4 (–, C(22)), 28.4 (+, C(1)), 29.5 (–, C(21)), 30.3 (–, 
C(23)), 34.3 (–, C(4)), 35.3 (–, C(12)), 38.8 (–, C(20)), 51.4 (+, C(26)), 52.6 (–, 2 C, 
C(27)), 60.5 (–, 2 C, C(29)), 61.2 (+, C(17)), 61.4 (+, C(9)), 64.7 (+, C(24)), 78.9 (Cquat, 
C(2)), 107.6 (Cquat, C(6)), 108.3 (Cquat, C(14)), 112.2 (Cquat, C(10) + C(18)), 128.0 (Cquat, 
C(13)), 129.1 (Cquat, C(5)), 147.1 (Cquat, C(16)), 147.5 (Cquat, C(8)), 155.8 (Cquat, C(11)), 
160.8 (Cquat, C(3)), 161.9 (Cquat, C(19)), 171.3 (Cquat, 2 C, C(28)), 173.0 (Cquat, C(25)). – IR 
(KBr) [cm-1]: ν~ = 3425, 3032, 2960, 1731, 1679, 1580, 1012. – MS (ESI, CH2Cl2/MeOH + 
10 mmol/L NH4Ac): m/z (%) = 803 (15) [MK+], 787 (43) [MNa+], 766 (100) [MH+]. 
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Li[Zn(NTA-MOPAS-MOPAS-Boc)(H2O)2] (142): 
To a solution of 141 (0.12 g, 0.15 mmol) in 25% water/acetone (20 mL) was added 
LiOH⋅H2O (19 mg, 0.45 mmol). The reaction mixture was stirred for 12 h at r.t., acetone 
was removed in vacuum and the remaining solvent lyophilised. The crude carboxylate and 
basic zinc carbonate (27 mg, 0.05 mmol) were dissolved in water (20 mL). After stirring 
for 30 min at r.t. the suspension was heated to 60 °C for 1 d. Insoluble particles were 
filtered off and the filtrate was lyophilised. The raw product was suspended in ethanol 
followed by the addition of ether. The precipitated material was separated from solution by 
centrifugation to give 142 (0.13 mmol, 103 mg, 86 %), as a colorless solid. 
mp > 200 °C. – MS (ESI, H2O/MeOH + 10 mmol/l NH4Ac): m/z (%) = 755 (100) [M-
2H2O]-, 757 (100) [MH2-2H2O] +. – IR (KBr) [cm-1]: ν~ = 3384, 2972, 2932, 1701, 1624, 
1537. FAB NI-LSIMS (MeOH/glycerine) HRMS (C31H45N6O12Zn [A- + 2H+]+) calcd. 
757.2387; found 757.2381+/- 0.0015. 
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3.4.3 Structure determination 
Preparation of the assembly: 
The MOPAS receptor (142) and the pentapeptide were mixed in a molar ratio 1:1 and 
dissolved in approx. 0.7 mL of [D6]-DMSO to reach a concentration of 22 mmol/L. The 
NMR experiments were performed in a tube with an inside diameter of 5 mm. To remove 
oxygen the sample was degassed in three freeze-thaw cycles in liquid nitrogen. 
 
Assignment of resonance signals 
Complete 1H and 13C resonance assignments were done using conventional 2D techniques 
(COSY, HMQC and HMBC experiments). 
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Figure 96. Numbering of 142-His-Leu-Leu-Val-Phe-OMe used for NMR assignments. 
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Figure 97. 1H NMR spectrum of 142-His-Leu-Leu-Val-Phe-OMe in [D6]-DMSO. 
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142-His-Leu-Leu-Val-Phe-OMe: 1H NMR (600 MHz; [D6]-DMSO; COSY): δ = 0.77 (m, 
6H, H(22´)), 0.79/0.84 (m, 6H, H(12´)), 0.82 (m, 6H, H(17´)), 1.28 (m, 2H, H(23)), 1.35 (s, 
9H, H(1)), 1.42 (m, 2H, H(15´)), 1.45 (m, 2H, H(20´)), 1.47 (q, 2H, H(21)), 1.48 (m, 2H, 
H(21´)), 1.55 (d, 2H, H(16´)), 1.58 (m, 2H, H(24)), 1.77 (m, 2H, H(22)), 1.88 (m, 1H, 
H(11´)), 1.9 (s, 3H, H(7)), 1.99 (s, 3H, H(15)), 2.59/2.85 (dd, 2H, H(25´)), 2.92/2.99 (dd, 
2H, H(4´)), 2.78/3.08 (m, 2H, H(26)), 2.7/3.17 (m, 2H, H(28)), 3.23 (m, 2H, H(20)), 3.38 
(m, 1H, H(24´)), 3.53 (s, 3H, H(1´)), 3.70 (s, 3H, H(17)), 3.73 (s, 3H, H(9)), 3.99 (d, 2H, 
H(4)), 4.14 (d, 1H, H(10´)), 4.27 (d, 2H, H(12)), 4.29 (m, 1H, H(19´)), 4.30 (m, 1H, 
H(14´)), 4.45 (q, 1H, H(3´)), 6.48/6.67 (bs, 1H, HG), 6.89 (bs, 1H, HF), 6.96 (bs, 1H, HA), 
7.06 (bs, 1H, HE), 7.18 (d, 1H, H(6´)), 7.22 (m, 1H, H(8´)), 7.24 (d, 1H, H(7´)), 7.39 (bs, 
1H, HC,), 7.47 (m, 1H, H(27´)), 7.54 (bs, 1H, HJ),  7.61 (m, 1H, H(28´)), 8.07 (bs, 1H, HI), 
8.30 (bs, 1H, HH), 8.38 (d, 1H, HK), 10.45 (s, 1H, HB), 10.54 (s, 1H, HD). 13C-NMR 
(150 MHz; [D6]-DMSO; HMQC + HMBC): δ =  7.4 (C(7)), 7.6 (C(15)), 17.8 + 18.8 
(C(12´)), 21.4 (C(17´)), 21.7 (C(22´)), 23.9 (C(21´)), 23.9 (C(16´)), 25.5 (C(23)), 25.6 
(C(24)), 27.9 (C(1)), 29.6 (C(21)), 26.3 (C(22)), 30.5 (C(11´)), 33.0 (C(12)), 36.8 (C(4´)), 
36.8 (C(25´)), 37.8 (C(20)),   34.9 (C(4)), 40.1 (C(15´)), 40.8 (C(20´)), 50.3 (C(19´)), 50.7 
(C(14´)),  51.5 (C(1´)), 53.1 (C(3´)), 54.6 (C(24´)), 56.5 (C(26)),  56.8 (C(28)),  56.9 
(C(10´)),  61.5 (C(9)), 61.6 (C(17)), 78.2 (C(2)), 107.4 (C(6)), 107.6 (Cquat, C(14)), 125.7 
(Cquat, C(7´)), 127.2 (Cquat, C(6´)),  127.3 (Cquat, C(8´)), 128.0 (Cquat, C(27´)), 128.4 (Cquat, 
C(5´)), 128.4 (Cquat, C(13)), 128.7 (Cquat, C(5)), 129.1 (Cquat, C(18)), 134.9 (Cquat, C(28´)), 
126.6 (Cquat, C(26´)), 146.3 (Cquat, C(16)), 146.8 (Cquat, C(8)), 155.7 (Cquat, C(3)), 159.9 
(Cquat, C(11)), 171.2 (Cquat, C(9´)), 171.6 (Cquat, C(27)), 171.9 (Cquat, C(29)), 172.2 (Cquat, 
C(2´)), 174.2 (Cquat, C(18´)),  179.6 (Cquat, C(13´)), 182.1 (Cquat, C(23´)), 211.4 (Cquat, C(25)). 
 
Temperature dependence of chemical shifts 
 
Temperature dependence of chemical shifts was measured to identify possible hydrogen 
bonds. The 1H-NMR spectra were recorded at various temperatures on a Bruker DRX-600 
spectrometer. Table 26 shows the determined chemical shift values (Hz) for each NH 
group of the examined compound in the range of 285 - 325 K. 
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Table 26. Determined 1H resonance chemical shift in Hz for NH protons at various 
temperatures in [D6]-DMSO 
NH[Hz] / 
T[K] 
285 290 295 300 305 310 315 320 325 
NH A 4214.63 4202.44 4190.05 4177.77 4165.03 4151.79 4139.81 4126.57 4113.96 
NH B 6502.40 6488.74 6474.66 6460.99 6448.6 6434.09 6420.22 6405.3 6390.17 
NH C 4458.44 4451.08 4443.52 4435.62 4429.22 4421.14 4415.56 4408.42 4401.90 
NH D 6382.60 6366.84 6349.81 6332.22 6317.45 6300.63 6285.08 6268.69 6253.13 
NH E 4261.71 4255.83 4247.00 4240.68 4233.97 4226.19 4218.42 4212.53 4205.39 
NH F 4136.66 4133.93 4131.19 4128.19 4125.31 4121.74 4118.12 4113.98 4109.40 
NH G 4043.13 4028.21 4012.23 3996.66 3977.77 3961.37 3946.03 3928.58 3912.40 
NH H 4997.54 4988.08 4972.74 4960.53 4948.36 4935.96 4924.40 4912.21 4902.54 
NH I 4869.96 4863.66 4854.41 4846.95 4838.23 4828.98 4820.78 4811.32 4802.08 
NH J 4566.05 4549.87 4538.94 4524.64 4509.30 4495.07 4488.70 4476.09 4465.37 
NH K 5076.36 5062.91 5044.81 5028.06 5008.26 4991.87 4977.78 4958.66 4943.74 
 
The resonance values from table 26 were used to calculate the temperature dependence of 
the chemical shift. The measured values were plotted and fitted in EXCEL using a linear 
correlation function. The obtained coefficient in Hz/K is converted into the corresponding 
values in ppb/K (see table 24). These values are used to estimate the possibility of 
hydrogen bonds, using the following boundaries:  
Hydrogen bond very likely less than -2 ppb/K 
Intermediate range -2 to -3 ppb/K 
No hydrogen bonding more than -4 ppb/K 
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Figure 98. 1H-NMR spectra in [D6]-DMSO at different temperatures. 
NMR NOE experiments 
1D-NOE measurements in [D6]-DMSO were performed at 300 K on a Bruker DRX-600 
spectrometer with working frequency 600.13 MHz. The difference NOE experiment with 
selective excitation using the modified DPFGSE pulse sequence (q3 gaussian cascade 
Double Pulsed Field Gradient Spin Echo) has been used. For every proton, which has been 
irradiated a series of 5 experiments with different mixing times (from 10 ms to 1 s) and 
with a relaxation delay of 2 s were acquired. An exponential window function with 4 Hz 
line broadening was applied before the Fourier transformation (FT) and a baseline 
correction was conducted after the FT.  
2D-NOESY experiments with a mixing time of 500 ms were performed for structural 
calculations. Signal overlap restricts the number of observable intrastrand contacts. At least 
four NOE interactions between the bound peptide and the MOPAS heterocycles can be 
clearly detected. The measurements have been repeated with mixing times of 100, 200, 
300, 400 and 500 ms giving the same structural parameter for the intramolecular distances. 
Cross peaks from intermolecular interactions are best seen at 500 ms. 
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Figure 99. NOESY spectrum at 300 K with mixing time 500ms. Interactions between the 
pentapeptide and the 142 units are labelled. 
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Figure 100. Interactions between the pentapeptide and the MOPAS units as detected by 
the NOESY spectrum. 
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Structure of the bound pentapeptide unit 
The intramolecular cross peaks of the bound pentapeptide in the 2D NOESY spectrum 
were integrated to obtain the distancesvi describing the structure of the pentapeptide. The 
value of the integral of the methylene hydrogens (number 25´) was used as the reference 
distance for these calculations. The value of the integral intensity is 293.85. Table 27 
summarises the derived distances within the bound peptide. The distances were calculated 
using the following standard and known equations.  
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Table 27. Intramolecular distances for the bound pentapeptide derived from the integrals 
of NOE crosspeak intensity 
Interacting protons Intensity Distance [Å] 
NH G – 24´ 21.82 2.79 
NH H – 24´ 105.4 2.07 
NH H – 19´ 77.59 2.85 
NH I – 19´ 19.83 2.24 
NH I – 14´ 18.2 2.78 
NH J – 14´ 76.69 2.08 
NH J – 10´ 13.2 2.93 
NH K – 10´ 72.34 2.21 
NH K – 3´ 13.95 2.90 
 
The distances were used as constrains to calculate the molecular structure of the 
pentapeptide (Hyperchem, NH-CH distance constrains as in Table S2; force field MM+). A 
subsequent MD simulation at 300 K for 10 ps and 10 times for 10 ps with 0.001 ps step 
size gave 10 structures, which are shown as overlay in figure 95, top. The average structure 
from these ten conformers was again energy minimised with MM+ to give the structure 
shown in figure 95, bottom. 
 
                                                 
vi Neuhaus, D.; Williamson, M.P. The Nuclear Overhauser Effect in Structural and 
Conformational Analysis, Wiley-VCH, New York, 2nd Ed, 2000. 
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Measurements in the absence of the Zn-NTA-unit 
To prove the importance of the complex for the intermolecular interactions NMR 
measurements of mixtures of Boc-MOPAS-MOPAS-OEtv and the pentapeptide were done. 
In the absence of the Zn(II)-NTA complex two tautomeric forms of the histidine residue 
were observed, while in the presence of the Zn(II)-NTA complex only one was present. 
The second tautomer was observable in the proton spectrum (figure 102). All signals were 
less broad in comparison to 142-His-Leu-Leu-Val-Phe-OMe, which indicated that both 
parts do not interact and show unrestricted motion on the NMR time scale. 
 
The 2D-NOESY experiment (figure 103) for a mixture of Boc-MOPAS-MOPAS-OEt and 
His-Leu-Leu-Val-Phe-OMe showed different dynamic behaviour of the pentapeptide and 
the MOPAS unit. The intramolecular cross peaks in the 2D-NOESY spectrum are due to 
fast movement of very low intensity. No cross peaks, which indicate interstrand 
interactions were observed. Strong chemical exchange is observed for all NH groups in the 
2D-NOESY spectrum. 
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Figure 101. Boc-MOPAS-MOPAS-OEt.
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Figure 102. 1H-NMR spectrum of Boc-MOPAS-MOPAS-OEt and His-Leu-Leu-Val-Phe-
OMe measured under identical conditions as before. 
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Figure 103. NOESY spectrum of Boc-MOPAS-MOPAS-OEt and His-Leu-Leu-Val-Phe-
OMe measured at 300 K with a mixing time of 500 ms. 
3JNHHα coupling constants: 
Phe: 3JNHHα = 6.88  
Val: 3JNHHα = 6.59  
Leu: 3JNHCα = 6.86  
Leu: 3JNHHα = 5.69 
 
Cα/Hα coupling constants: 
Phe: 137 Hz 
Val: 140 Hz 
Leu: 136 Hz 
Leu: 138 Hz 
His: 137 Hz 
 
 
Parameters of the NMR experiments 
 
1H-NMR spectra 
Spectral width: 14 kHz 
Size: 16k of data points 
Relaxation period: 2 s 
Number of pass: 32 
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1D 1H-DPFGSE-NOE 
Spectral width: 14 kHz 
Size: 16k of data points 
Mixing time: 100 to 1000 ms 
Length of gaussian cascade: 79.2 ms 
Relaxation period: 2 s 
Number of pass: 4 – 6k 
 
1H-1H NOESY 
Spectral width: 14 kHz for both domains 
Size: 512 (f1) and 2k (f2) of data points 
Mixing time: 500 ms 
 
Relaxation period: 2 s 
Number of pass: 32 
 
 
Calculation of the pentapeptide structure: 
2D-NOESY spectrum at 300 K was measured for the calculation of the distances. The 
apodization function cos2(x) was applied on the measured data. After Fourier 
transformation in both domains the phase shift was corrected in the spectrum and the 
baseline was corrected using the multinominal of fifth degree.  
 
Example of microcalorimetrical titration 
Titration of nickel complex of Ni(II)-142 with pentapeptide in buffered aqueous solution 
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Figure 104. Microcalorimetrical titration of Ni(II)-142 (c = 0.1 mM) with analysed 
pentapeptide (c = 1 mM) in DMSO (T = 293 K). 
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4. A Luminescent Receptor with Imidazole and 
Ammonium Ion Affinity for Peptide Binding in Aqueous 
Solutioni  
This chapter deals with the application of a C-terminal IDA recognition building block. 
The free amine is linked to a precursor of a fluorescenting crown ether by a double SN2 
reaction.ii The available ditopic receptor was used to bind to small peptides containing a 
terminal histidine in aqueous buffered solutions.iii In a final screening, the receptor proved 
the selectivity to bind histidine among all natural amino acids exclusively. 
 
i Kruppa, M.; Mandl, C.; Miltschitzky, S.; König, B. J. Am. Chem. Soc. 2005, 127, 3362. 
ii Precursor 145 and crown ether 148 were synthesised by C. Mandl. 
iii Microcalorimetric measurements were carried out by S. Miltschitzky. 
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4.1 Introduction 
Ammonium ions are present in many compounds of biological or pharmaceutical interest, 
ranging from simple amino acids, neurotransmitters, amino sugars to peptides and proteins. 
The classic hosts for the ammonium ion binding1 are crown ethers of appropriate size, 
however high binding affinities are only observed in organic solvents, such as methanol.2 
At physiological conditions in water or DMSO as solvent, the binding constants are usually 
smaller than logK = 2. A more favourable intramolecular hydrogen bond formation 
between crown ether and ammonium ion3 is achieved by combining it with a stronger ionic 
or reversible covalent intermolecular interaction creating di- or polytopic receptors.4 
Recent examples used the combination of crown ethers with boronic acids5 to bind 
glucoseamine, with guanidinium6,7 ammonium and non-polar groups8 to bind amino 
acids.9, ,10 11 Reversible coordination to metal complexes can provide high affinity and 
selectivity in aqueous solution, but it has not been used to amplify crown ether – 
ammonium ion binding.12 We report here the preparation and peptide binding properties of 
the luminescent crown ether13 147 which contains a pendant copper(II) imino diacetic acid 
(Cu(II)-IDA) complex.14,   15
 
4.2 Results and Discussion 
The Cu(II)-IDA motif is well known for its binding ability to imidazole and histidine. 
16, , , , ,17 18 19 20 21 To combine this property with the ammonium ion affinity of a crown ether, 
amine 144 was allowed to react with bis-tosylate 145 followed by deprotection to give the 
aza crown 146 (scheme 50). The phthalic-ester moiety of 146 allows one to monitor the 
binding of an ammonium ion to the crown ether by an increase in its emission intensity 
(excitation: λ = 305 nm; detection: λ ≈ 377 nm). Upon addition of Cu(II) ions a stable 
complex (147) is formed with the IDA ligand. Compound 148 was prepared for 
comparison from 145 by reaction with mono-Boc-protected 1,2-ethylenediamine to 
investigate the response of the crown ether emission to an ammonium ion binding. 
Scheme 50. Synthesis of luminescent benzocrown ethers 146, 147 and 148 
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To investigate the photophysical properties of the crown ether part, absorption and 
emission spectra of compound 148 were recorded in methanol and their response to the 
presence of ammonium ions tested. Upon excitation at the absorption maximum around 
λmax = 268 nm an emission with a maximum at 385 nm was observed. The quantum yield 
of Φ = 0.09 is rather low.22 Upon addition of KSCN or n-BuNH3Cl, the emission intensity 
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increases significantly by a factor of 2.2 or 3.7, respectively. Table 28 summarises the 
binding constants derived from the titration data. 
Table 28. Binding affinities and emission response of compound 148 in methanol to the 
addition of potassium or ammonium ions 
guest K [M-1] logK Imax/Io
KSCN 4790 3.68 2.22 
n-BuNH3Cl 178 2.25 3.68 
 
As expected, no response of the emission properties is observed for 14723 or 148 if treated 
with KSCN or n-BuNH3Cl in buffered aqueous solution (50 mM HEPES, pH 7.5, c =              
10-5 mol/L, up to 1000 equiv. ammonium ion), even with a large excess of the salts. The 
aqueous solvent competes with the crown ether for the cation binding and the ammonium - 
crown ether interaction is intercepted. The situation changes if the dipeptide His-Lys-OMe 
is added to a solution of 147. Coordination of the N-terminal histidine to the Cu(II)-IDA 
complex24 of 147 makes the crown ether - ammonium ion binding intramolecularly and 
much more favourable. Titration of 147 with His-Lys-OMe in HEPES buffer (50 mM, pH 
7.5)25 resulted in a 1:1 complex (scheme 51) as shown by a Job’s plot analysis (figure 105). 
With a binding constant of logK = 4.22 ± 0.05 compound 147 binds the ammonium group 
of His-Lys-OMe with high affinity in buffered water. Calorimetric titrations confirmed the 
strong interaction of 147 and His-Lys-OMe. Calorimetric titrations confirmed the strong 
interactions of 147 and His-Lys-OMe. The emission intensity change of 147 in the 
presence of His-Lys-OMe can even be observed with the naked eye (figure 106). No 
emission response is detected under the same conditions with the N-terminal acylated 
dipeptide Ac-His-Lys-OMe, which proves the importance of an N-terminal histidine for the 
overall binding process. 
Scheme 51. Proposed mode of binding of luminescent crown ether 147 and His-Lys-OMe 
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Figure 105. Emission titration of 147 (c = 10-5 mol/L) with His-Lys-OMe in buffered 
aqueous solution (50 mM HEPES, pH 7.5). Insert: Job´s plot analysis. 
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(I)        (II)     (III)    
 
 compound 147 
  N-terminal histidine          ammonium ion 
      (I)             (III) 
Figure 106. Schematic binding process and emission intensity changes of solutions of 147 
in buffered water in the presence of His-Lys-OMe. 
Surprisingly, using His-OMe as an added guest molecule, nearly the same enhancement of 
emission intensity is observed as with His-Lys-OMe. Job´s plot analysis shows a 
stoichiometry of 2:1 for the His-OMe – 147 aggregate (figures 107 and 108). The 
coordination chemistry of the Cu(II)- IDA complex provides a likely rationale for this 
observation: After the binding of one His-OMe to Cu(II)-IDA, one coordination site 
remains, which can accommodate the imidazole moiety of a second His-OMe while its 
ammonium group is bound by the crown ether, leading to an increased emission 
intensity.26 The overall binding constant of His-OMe to 147 was determined to be logK = 
3.8 ± 0.1. The binding motif allows the selective detection of N-terminal His groups, which 
is illustrated by the binding of the tripeptide H-His-Gly-Gly-OH. This peptide binds to 147 
with the same 2:1 stoichiometry as observed for histidine and an overall affinity of logK = 
3.71 ± 0.05. 
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Figure 107. Proposed structure of the assembly of two His-OMe with 147. 
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Figure 109. Response of the emission intensity of 147 to the presence of 20 natural α-
amino acids in aqueous buffered solution (50 mM HEPES, pH 7.5). 
Side chain functionalities of amino acids, such as Lys, Cys, Ser or Met are known to 
coordinate to the Cu(II)-IDA complex, but only this interaction alone does not trigger the 
emission response. The interaction of the ammonium group with the benzo crown, which 
only becomes possible intramolecularly,28 is the necessary second process to signal the 
binding event. 
4.3 Conclusion 
The combination of an imidazole coordinating metal complex with a luminescent 
ammonium-binding crown ether results in a simple synthetic receptor with high affinity in 
buffered water for molecules bearing both functional groups. The emission response is 
triggered by the weak ammonium ion binding which only becomes possible 
intramolecularly within the assembly. Only the presence of an ammonium group, even in 
large excess, does not trigger an optical output. Binding selectivities, which are different 
from the present one, may be accomplished by other combinations of strongly coordinating 
metal complexes and binding sites of weak affinity. 
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4.4 Experimental Section 
4.4.1 Instruments and general techniques 
See experimental section of chapter 1 (page 131) 
4.4.2 Synthesis 
N-Z-1,6-diamino-hexane (143)iv, 4,5-bis-(2-{2-[2-(toluol-4-sulfonyloxy)-ethoxy]-ethoxy}-
ethoxy)-phthalic acid dimethylester (145)v  
N
O
O
O O
NH2
 
tert-Butyl-[(6-aminohexyl)-tert-butoxycarbonylmethylamino]-acetate (144):  
143 (0.21 g, 4.9 mmol) was dissolved in MeCN (20 mL) and mixed with tert-butyl 
bromoacetate (1.56 mL, 10.6 mmol), K2CO3 (2.92 g, 21.1 mmol) and a spatula tip of 
potassium iodide. The suspension was stirred 2 days at 60 °C and monitored by TLC 
(EtOAc). The mixture was filtered, diluted with water (20 mL) and extracted twice with 
EtOAc. After drying over Na2SO4 the organic solvents were evaporated to yield the crude 
product. Purification using column chromatography on silica gel (EtOAc, Rf = 0.9) gave 
the Z-protected IDA-intermediate as a colourless oil. 
To deprotect the Z-group, the oil was dissolved in EtOH (25 mL) and mixed with a spatula 
tip of 10% Pd/C. Hydrogenolytical cleavage was performed in an autoclave at 10 bar H2 
pressure for 12 h at r.t.. After filtration, the ethanol was evaporated to yield 144 (4.3 mmol, 
1.46 g, 87 %) as a colourless oil. 
1H-NMR (300 MHz; CDCl3): δ = 1.24-1.29 (m, 4 H, CH2), 1.38-1.49 (m, 20 H, CH3-Boc + 
CH2), 2.62-2.69 (m, 4 H, CH2), 3.16-3.18 (m, 2 H, CH2), 3.40 (s, 4 H, N-CH2), 4.82 ppm 
(bs, 1 H, NH). – 13C-NMR (75 MHz; CDCl3): δ = 26.6 (–, CH2), 26.8 (–, CH2), 27.8 (–, 
CH2), 28.2 (+, 6 C, CH3), 40.9 (–, CH2), 54.0 (–, CH2), 55.9 (–, 2 C, CH2), 66.6 (–, CH2), 
80.9 (Cquat, 2 C, C-Boc), 170.8 ppm (Cquat, 2 C, COOtBu). – IR [cm-1]: ν~ = 2930, 1740, 
1714, 1209. – MS (CI-MS, NH3): m/z (%) = 345 (100) [MH+]. – HRMS (C18H36N2O4+•): 
                                                 
iv Atwell, G. J.; Denny, W. A. Synthesis 1984, 12, 1032. 
v Mandl, C.P.; König, B. J. Org. Chem. 2005, 70, 670. 
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calcd. 344.2675, found 344.2671 ± 0.72 ppm. – Elemental analysis calcd. (%) for 
C18H36N2O4 (344.27) + EtOAc: C 58.36, H 9.97, N 6.93; found C 58.29, H 9.92, N 6.98. 
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14-[6-(Bis-carboxymethyl-amino)-hexyl]-6,7,9,10,13,14,15,16,18,19,21,22-dodecahydro-
12H-5,8,11,17,20,23-hexaoxa-14-aza-benzocyclohenicosene-2,3-dicarboxylic acetic acid 
dimethylester ditriflate (146):  
Compound 144 (0.3 g, 0.9 mmol) was dissolved in MeCN (14 mL) and mixed with 145 
(0.67 g, 0.8 mmol), K2CO3 (1.29 g, 9.3 mmol) and KI (0.14 g, 0.9 mmol). The suspension 
was refluxed for 2 d and the reaction progress monitored by TLC (CHCl3:MeOH = 6:1). 
After cooling to r.t. the mixture was filtered over celite, washed with MeCN and CHCl3 
and the filtrate was evaporated to dryness. Purification using column chromatography on 
silica gel (CHCl3 : MeOH = 20:1 → 15:1, Rf (CHCl3:MeOH = 6:1) = 0.33) gave bis-tert-
butyl protected 146 as a light yellow oil. This diester was dissolved in TFA (5 mL) and 
stirred for 2 h at r.t.. After evaporating the TFA, the slurry was suspended in Et2O and 
decanted. Compound 146 (0.5 mmol, 0.44 g, 65 %) is a colourless hygroscopic solid. 
mp 38-40 °C. – 1H- NMR (600 MHz; D2O; COSY, HSQC): δ = 0.93-0.98 (m, 2 H, H(15)), 
1.01-1.04 (m, 2 H, H(14)), 1.41-1.46 (m, 4 H, H(13), H(16)), 2.99-3.02 (m, 2 H, H(12)), 
3.07-3.10 (m, 2 H, H(17)), 3.23-3.27 (m, 2 H, H(11)), 3.29-3.33 (m, 2 H, H(11)), 3.58-3.63 
(m, 6 H, H(10), H(8/9)), 3.66-3.74 (m, 6 H, H(8/9)), 3.78 (s, 6 H, H(1)), 3.77-3.80 (m, 2 H, 
H(7)), 3.86-3.89 (m, 2 H, H(7)), 4.05 (s, 4 H, H(18)), 4.05-4.08 (m, 2 H, H(6)), 4.17-4.20 
(m, 2 H, H(6)), 7.18 (s, 2 H, H(4)). – 13C- NMR (100 MHz; D2O; HSQC, HMBC): δ = 
22.6 + 23.0 (–, 2 C, C(14), C(15)), 25.0 & 25.1 (–, 2 C, C(13), C(16)), 53.2 (–, C(12)), 53.2 
(+, 2 C, C(1)), 53.7 (–, 2 C, C(11)), 54.4 (–, 2 C, C(18)), 56.4 (–, C(17)), 63.7 (–, 2 C, 
C(10)), 68.2 (–, 2 C, C(6)), 68.9 (–, 2 C, C(7)), 69.8 (–, 4 C, C(8), C(9)), 112.6 (+, 2 C, 
C(4)), 124.7 (Cquat, 2 C, C(3)), 149.6 (Cquat, 2 C, C(5)), 168.1 (Cquat, 2 C, C(2)), 169.3 
(Cquat, 2 C, C(19)) [TFA signals are not listed]. – IR (KBr) [cm-1]: ν~ = 3450, 2930, 2890, 
1732, 1294, 1196 – MS ((-)ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 685 (100) 
[M – H+]. – HRMS (C32H51N2O14+): calcd. 687.3339, found 687.3340 ± 0.64 ppm. 
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H-His-Lys-OMe ⋅ 3 TFA 
H-Lys(Boc)-OMe⋅HCl (0.25 g, 0.8 mmol) was dissolved in DCM (15 mL) and DIPEA 
(0.43 mL, 2.5 mmol) added under nitrogen atmosphere. Boc-His(Boc)-
OH⋅dicyclohexylamine (0.49 g, 0.9 mmol), EDC (0.18 mL, 1.0 mol) and HOBt (0.14 g, 
1.0 mmol) were added and the reaction was monitored by TLC (EtOAc). After 12 h the 
solution was mixed with water (15 mL), diluted with DCM (20 mL) and extracted twice 
with brine (20 mL). The combined organic layers were dried over Na2SO4 and the solvent 
evaporated. The crude product was purified using column chromatography on silica gel 
(EtOAc, Rf = 0.4) resulting in a colourless solid. The protected dipeptide was dissolved in a 
small amount of DCM and mixed with TFA (1.46 mL, 18.9 mmol). After 12 h the mixture 
was evaporated to dryness and completion of the reaction controlled by 1H-NMR. The 
triflate salt was redissolved in water, washed with DCM and lyophilised. H-His-Lys-
OMe⋅3TFA (0.29 g, 0.5 mmol, 58 %) is a colourless, hygroscopic solid. 
mp 62-63 °C. – 1H-NMR (600 MHz; [D6]-DMSO): δ = 1.16-1.18 (m, 2 H, COSY: H(3)), 
1.34-1.59 (m, 2 H, HSQC: H(2)), 1.60-1.76 (m, 2 H, COSY: H(4)), 2.76 (m, 2 H, COSY: 
H(1)), 3.19 (2 x dd, 2J = 15.4 Hz,  3J = 7.2 Hz, 2 H, COSY: H(10)), 3.62 (s, 3 H, HSQC: 
H(7)), 4.22 (t, 3J = 6.9 Hz, 1 H, COSY: H(9)), 4.29 (dt, 3J = 5.4, 7.8 Hz, 1 H, COSY: 
H(5)), 7.41 (s, 1 H, HMBC: H(12)), 7.90 (bs, 3 H, HMBC: HA), 8.11-8.80 (bs, 1 H, 
HMBC: HD), 8.92 (d, 3J = 7.3 Hz, 1 H, HMBC: HB), 8.98 (s, 1 H, HMBC: H(13)), 13.50-
15.45 ppm (bs, 2 H, HC). – 13C-NMR (150 MHz; [D6]-DMSO; HSQC, HMQC): δ = 22.0 
(–, C(3)), 26.4 (–, C(10)), 26.5 (–, C(2)), 30.4 (–, C(4)), 38.4 (–, C(1)), 51.2 (+, C(9)), 52.0 
(+, C(5)),  52.1 (+, C(7)), 117.8 (+, C(12)), 127.2 (Cquat, C(11)), 134.3 (+, C(13)), 167.5 
(Cquat, C(8)), 171.7 ppm (Cquat, C(6)) [TFA signals are not listed]. – IR (KBr) [cm-1]: ν~ = 
3431, 3123, 3049 2965, 1676, 1204, 1135, 723. – MS (ESI, H2O/MeOH + 10 mmol/L 
NH4Ac): m/z (%) = 298 (100) [MH+], 170 (10) [M + 2H+ + MeCN]. – Elemental analysis 
calcd. (%) for C19H26N5O9F9 (639.16) + H2O: C 34.71, H 4.29, N 10.65; found: C 34.17, H 
4.28, N 10.55. 
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Ac-His-Lys-OMe ⋅ 2 TFA 
H-Lys(Boc)-OMe⋅HCl (0.25 g, 0.8 mmol) was dissolved in DCM (15 mL) and DIPEA 
(0.43 mL, 2.5 mmol) added under nitrogen atmosphere. Ac-His(1-Trt)-OH (0.4 g, 
0.9 mmol), EDC (0.18 mL, 1.0 mol) and HOBt (0.14 g, 1.0 mmol) were added thereafter 
and the reaction was monitored by TLC (EtOAc). After 12 h the solution was mixed with 
water (15 mL), diluted with DCM (20 mL) and extracted twice with brine (20 mL). The 
combined organic layers were dried over Na2SO4 and the solution evaporated. The crude 
product was purified using column chromatography on silica gel (EtOAc → EtOAc/MeOH 
= 1/1, Rf (EtOAc) = 0.1) resulting in a colourless solid. The protected dipeptide was 
dissolved in a small amount of DCM and mixed with TFA (1.06 mL, 13.7 mmol). After 
12 h the mixture was evaporated to dryness and completion of the reaction was controlled 
by 1H-NMR. The triflate salt was redissolved in water, washed with DCM and lyophilised. 
Ac-His-Lys-OMe⋅2TFA (0.42 g, 0.7 mmol, 93 %) is a colourless, hygroscopic solid. 
1H-NMR (600 MHz; [D6]-DMSO): δ = 1.28-1.41 (m, 2 H, COSY: H(3)), 1.45-1.58 (m, 
2 H, HSQC: H(2)), 1.59-1.78 (m, 2 H, COSY: H(4)), 1.83 (s, 3 H, HSQC: H(15)), 2.70-
2.82 (m, 2 H, COSY: H(1)), 2.85-3.11 (2 x dd, 2J = 14.9 Hz,  3J = 5.5 Hz, 2 H, COSY: 
H(10)), 3.62 (s, 3 H, HSQC: H(7)), 4.17-4.28 (m, 1 H, COSY: H(9)), 4.57-4.67 (m, 1 H, 
COSY: H(5)), 7.31 (s, 1 H, HMBC: H(12)), 7.81 (bs, 3 H, HMBC: HA), 8.23 (d, 3J = 
7.9 Hz, 1 H, HMBC: HD) 8.41 (d, 3J = 7.5 Hz, 1 H, HMBC: HB), 8.94-8.98 (m, 1 H, 
HMBC: H(13)), 14.01-14.73 (bs, 2 H, HC). – 13C-NMR (150 MHz; [D6]-DMSO; HSQC, 
HMQC): δ = 22.1 (–, C(3)), 22.4 (+, C(15)), 26.3 (–,  C(2)), 27.0 (–, C(10)), 30.0 (–, C(4)), 
38.4 (–, C(1)), 51.3 (+, C(5)), 51.7 (+, C(9)), 51.8 (+, C(7)), 116.6 (+, C(12)), 129.3 (Cquat, 
C(11)), 133.6 (+, C(13)), 169.4 (Cquat, C(14)), 170.3 (Cquat, C(8)), 172.1 (Cquat, C(6)). – IR 
(KBr) [cm-1]: ν~ = 3431, 3122, 3050 2965, 2913, 1676, 1204, 1130. – MS (ESI, 
H2O/MeCN): m/z (%) = 340 (100) [MH+].  
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[Cu(146)(H2O)3] (147) 
To a solution of the diacid 146 (90 mg, 0.1 mmol) in water (5 mL), CuCl2 (13 mg, 
0.1 mmol) in MeOH (10 mL) was added. Stirring was continued at r.t. for 2 h. The solvent 
was evaporated and the residue dissolved in a small amount of water. MeOH was added 
until a precipitate had formed and the solid was removed by filtration. MeOH was 
evaporated and the crude product was recrystallised from methanol yielding compound 
147 (73 mg, 0.09 mmol, 86 %) as a blue solid. 
mp > 200 °C. – MS (ESI, MeOH + 10 mmol/L NH4Ac): m/z (%) = 847 (34) [MH+ + 
2 MeCN + H2O], 830 (50) [MH+ + 2 MeCN], 825 (65) [MH+ + H2O + HAc], 808 (35) 
[MH+ + HAc], 748 (100) [MH+].  
 
Spectra and emission titration in methanol 
Procedure: 
The cuvette with 2.5 mL of receptor 147 in HEPES buffer was titrated stepwise with small 
amounts of the analyte solution.  
 
Cary Eclipse Spectrometer 
Spectrometer setup: 
Excitation wavelength λ = 305 nm 
Detection wavelength λ = 377 – 380 nm 
Temperature: T = 298 K 
 
Titration conditions: 
Solvent: 50 mM HEPES buffer, pH 7.5, 
Starting volume: 2.5 mL 
c (receptor) = 5.04⋅10-5 M 
c (analyte) = 1.1 – 1.2⋅10-2 M 
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Figure 110. Absorption spectra of compound 148 in methanol. 
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Figure 111. Emission spectra of compound 148 in methanol (excitation at 270 nm). 
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Figure 112. Change in emission intensity of compound 148 at 384 nm upon titration with 
KSCN or nBuNH3Cl in methanol. 
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Figure 113. Fluorescence titration of 147 vs. H-His-Gly-Gly-OH in HEPES buffer (logK = 
3.7 ± 0.05). 
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Figure 114. Job`s plot analysis of 147 - H-His-Gly-Gly-OH binding. 
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5. Receptor for Protein Surfaces with Affinity to Histidine 
and phosphorylated Amino acids 
High binding constants under physiological conditions turn metal complexes into essential 
components of peptide receptor molecules (see previous chapters). The possibility to boost 
weaker molecule interactions (like hydrogen bonds) by metal complex support was 
demonstrated in chapter 3 and chapter 4. The maximal binding constant (K = 104 - 105 M-1) 
reached by these polytopic receptors were equivalent with the binding constants of the 
corresponding pure metal complexes. The incorporation of several metal complexes in one 
receptor molecule might lead to increased binding affinities. 
For this purpose a histidine recognition unit ( ) is combined with a phosphate binder ( ). 
The new receptor molecule ( ) which combines both affinities should bind in a superior 
way to a peptide ( ) containing phosphate ( ) and histidine ( ). As all binding events are 
reversible (scheme 52) a receptor mixture in the presence of this peptide should lead to the 
formation of one main assembly of peptide and receptor molecule. 
Scheme 52. Schematic depiction of a binding experiment 
 
 
In a first synthesis the C-terminal NTA recognition unit 109 was linked with bis-cyclen 
receptor 149.i Using a nucleophilic aromatic substitution reaction the cyclen functionalised 
                                                 
i Subat, M. PhD Thesis, University of Regensburg. 
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triazin was bound to the primary amine in good yields giving 150. This Boc- and ester-
protected precursor 150 was stepwise deprotected and used for metal complexations 
yielding the Zn(II)-complexes 151 and 152 in moderate yields. 
Scheme 53. Synthesis of the Zn(II)-complexes 151 and 152 
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The metal complexes 151 and 152 are presently used by Grauerii to determine the binding 
ability to histidine and phosphorylated peptides. 
 
                                                 
ii Grauer, A. Diploma Thesis, University of Regensburg, ongoing. 
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5.1 Experimental Part 
5.1.1 Instruments and general techniques 
See experimental section chapter 1 (page 131) 
5.1.2 Synthesis 
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Bis-(tri-Boc-cyc)-triazin-NTAL-OEt/Me (150): 
149iii (0.60 g, 0.57 mmol), 109 (0.20 g, 0.6 mmol) and K2CO3 (1.44 g, 1.2 mmol) were 
dissolved in dioxan (20 mL). The mixture was heated to 95 °C and stirred for 3 days. The 
suspension was filtered and the filtrate concentrated under reduced pressure. The crude 
product was purified using column chromatography on silica gel (EtOAc, Rf = 0.8) 
yielding 150 (0.52 mmol, 700 mg, 92 %) as a colourless solid.  
mp 48-49 °C. – 1H-NMR (600 MHz; CDCl3; COSY, HMBC, HSQC): δ = 1.25 (t, 3J = 
7.2 Hz, 6 H, H(1)), 1.28-1.51 (m, 56 H, H(9) + H(18) + H(23)), 1.52-1.54 (m, 2 H, H(11)), 
1.66-1.73 (m, 2 H, H(8)), 3.33-3.59 (m, 35 H, H(10) + H(14) + H(15) + H(19) + H(20) + 
H(5)), 3.63 (d, 3J = 4.8 Hz, 4 H, H(4)), 3.67 (s, 3 H, H(7)), 4.13 (q, 3J = 7.1 Hz, 4 H, H(2)), 
4.74 (bs, 1 H, NH). – 13C-NMR (150 MHz; CDCl3; HMBC, HSQC): δ = 14.2 (+, 2 C, 
C(1)), 23.4 (–, C(9)), 28.5 (+, 18 C, C(18) + C(23)), 29.6 (–, C(11)), 30.3 (–, C(8)), 40.9 (-, 
C(10)), 49.2-51.3 (–, 16 C, C(14) + C(15) + C(19) + C(20)), 51.4 (+, C(7)), 52.8 (–, 2 C, 
C(4)), 60.3 (–, 2 C, C(2)), 64.8 (+, C(5)), 80.0 (Cquat, 4 C, C(17)), 80.2 (Cquat, 2 C, C(22), 
156.3 (Cquat, 6 C, C(16) + C(21)), 164.7 (Cquat, 2 C, C(13)), 168.0 (Cquat, C(12)),171.4 
(Cquat, 2 C, C(3)), 172.9 (Cquat, C(6)). – IR (KBr) [cm-1]: ν~ = 3341, 2980, 2940, 1741, 
1687, 1165, 730. – MS (ESI, MeCN/MeOH): m/z (%) = 1353 (100) [MH+], 677 (32) 
[M+2H+], 649 (23) [M-C4H8+2H+], 627 (20) [M+2H+-Boc]. – C64H113N13O18 (1351.80). 
                                                 
iii Subat, M. PhD Thesis, University of Regensburg. 
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[Zn2( Bis-cyc-triazin-NTAL-OEt/Me)(OH)](ClO4)3 (151): 
150 (0.13 g, 0.1 mmol) was dissolved in TFA (10 mL) and stirred at r.t.. The reaction 
progress was monitored by 1H-NMR. After all Boc protons disappeared the reaction 
mixture was evaporated. The obtained triflate was dissolved in water and freeze dried. The 
residue was redissolved in water (10 mL) and neutralised with NaHCO3 followed by the 
addition of Zn(ClO4)2⋅6H2O (75 mg, 0.2 mmol). The mixture was refluxed over night. 
Undissolved particles were filtered off and the filtrate freeze dried. Crystallisation in 
MeOH yielded 151 (0.08 mmol, 96 mg, 53 %) as a colourless solid. 
mp > 200 °C. – IR (KBr) [cm-1]: ν~ = 3249, 3242, 2993, 2977, 2944, 1732, 1714, 1687, 
1570, 1084, 623. – MS (ESI, MeCN/H2O): m/z (%) = 485 (100) [K4++OH-+ClO4-]. – 
C34Cl3H66N13O19Zn2 (1193.22). 
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[Zn2( Bis-cyc-triazin-NTAL)(OH)(H2O)2](ClO4)2 (152): 
150 (0.25 g, 0.18 mmol) was dissolved in TFA (10 mL) and stirred at r.t.. The reaction 
progress was monitored by 1H-NMR. After all Boc protons disappeared the reaction 
mixture was evaporated. The obtained triflate was dissolved in water and freeze dried. The 
residue was redissolved in water (10 mL) and neutralised with LiOH. To this neutral 
solution LiOH⋅H2O (25 mg, 0.6 mmol) was added and the mixture refluxed for 2 d. The 
mixture was freeze dried, redissolved in water (10 mL) and Zn(ClO4)2⋅6H2O (0.22 g, 
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0.6 mmol) was added. The mixture was refluxed over night. Undissolved particles were 
filtered off and the filtrate freeze dried. Crystallisation in MeOH yielded 152 (0.12 mmol, 
135 mg, 67 %) as a colourless solid. 
mp > 200 °C. – IR (KBr) [cm-1]: ν~ = 3249, 3242, 2993, 2977, 2944, 1687, 1570, 1084, 
623. – MS (ESI, MeCN/H2O): m/z (%) = 443 (100) [K3++OH-]. – C29Cl2H57N13O17Zn3 
(1121.12). 
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C. Appendix 
Abbreviations 
Ar  Aryl 
BOC  tert-Butoxycarbonyl 
BPA  Bis-(2-picolyl)-amine 
Bzl  Benzyl 
c  Concentration 
CI  Chemical Ionisation 
d  Day(s) 
DCM  Dichloromethane 
DIPEA Diisopropyl-ethyl-amine 
DME  1,2-Dimethoxyethane 
DMF  Dimethylformamide 
DSMO Dimethylsulfoxide 
EDC  N-(3-Dimethylaminopropyl)-N’-ethyl-carbodiiamide 
EI  Electronic Ionisation 
EtOAc  Ethylacetat 
EtOH  Ethanol 
ESI  Electronspray Ionisation 
Et  Ethyl 
FAB  Fast-Atom Bombardement 
FT-IR  Fourier Transformation Infrared 
h  Hour(s) 
HEPES N-2-Hydroxyethylpiperazine-N’-2-ethansulfonic acid 
HMPT  Hexamethyl phosphor acid triamide 
HOBt  1-Hydroxybenzotriazole 
HRMS  High Resolution Mass Spectroscopy 
IDA  Iminodiacetic acid 
IR  Infrared Spectroscopy 
J  Coupling Constant 
K  Molecule cation 
Me  Methyl 
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MeOH  Methanol 
min  minutes 
MOPAS Methoxy-pyrrol-amino acid 
mp  Melting Point 
MS  Mass Spectroscopy 
NMR  Nuclear Magnetic Resonanz Spectroscopy 
NTA  Nitrilotriacetic acid 
PE  Petrol Ether (Hexanes) 
Ph  Phenyl 
Py  Pyridine 
PyBOP (Benzotriazol-1-yloxy)-tripyrrolidinophosphonium-hexfluorophosphate 
Rf  Retention Factor 
r.t.  Room Temperatur 
TEAOH Tetraethylammonium hydroxide 
TEAP  Tetraethylammonium perchloride 
TFA  Trifluoracetic acid 
THF  Tetrahydrofuran 
TLC  Thin Layer Chromatography 
Tos  p-Toluol-sulfonyl 
x  Mole Fraction 
Z  Benzyloxycarbonyl 
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Summary 
Focusing on interactions between Lewis acidic metal complexes and Lewis basic surfaces 
of proteins, I was able to outline the power of this concept by several projects. 
 
An initial screening experiment in chapter 1 was used to find suitable metal complex – 
peptide side chain interactions. Based on potentiometric titration data it was possible to 
prove substrate-metal-complex interactions in aqueous solution. In addition to already 
known interactions of M(II)-IDA/M(II)-NTA and imidazole binding of imidazole to M(II)-
cyclen was discovered. Cd(II)-cyclen showed imidazole binding and Zn(II)-cyclen binds to 
imidazole and phosphate. The newly identified metal complex to amino acid side chain 
functional group interactions, and the excluded interactions, may help to develop and 
optimise new IMAC polymers for protein purification. 
 
To simplify the synthesis of a desired peptide receptor, a building block receptor synthesis 
was developed in chapter 2. The synthesis of C- and N-terminal receptor building blocks 
could be achieved by simple SN2 reactions of mono protected diamines and amino acids. 
The ligation of these building blocks was optimised using the active ester formed out of 
EDC/HOBt. Furthermore the synthesis of bidentate recognition units possessing an 
additional carboxylate for receptor ligation yielded the new receptor precursors 117, 118, 
119 and 120. The Zn(II) complex 122 synthesised by Boc-deprotection of 120 showed high 
affinity towards phenylphosphate which was examined by 31P-NMR and 
microcalorimetrical titration. 
In a first attempt a solid phase receptor synthesis was performed using a safety-catch resin. 
The resulting Ni(II)-NTA complex showed good affinities towards a pentapeptide 
containing a terminal histidine.  
To create binding sites in the side chains of natural amino acids the functionalisation of 
tyrosine was used for cyclen ligation. The scope of the Negishi cross coupling reaction of 
organozinc compounds derived from chiral amino acids was extended to electron rich 
iodoanilines as coupling reagents. This now allows the direct modification of serine into 
phenylalanine derivatives bearing metal ion chelating ligand in their side chain.  
 
The experiments in chapter 3 demonstrated that it is possible to restrict the conformation of 
a small flexible pentapeptide in DMSO solution by combining a Zn-NTA tether with a 
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heterocyclic peptide β-sheet binder. Intermolecular interactions of the MOPAS units with 
the pentapeptide in DMSO would be too weak to induce a conformational preference. The 
principle of “two-prong” binders is applicable to other peptide receptors, which suffer from 
competing solvent interactions. Exchanging Zn(II) in 142 by Cu(II) or Ni(II) leads to 
peptide-binding compounds with an affinity to H2N-His-Leu-Leu-Val-Phe-OMe in the 
lower micromolar range under aqueous physiological conditions. 
 
Chapter 4 showed that the combination of an imidazole coordinating metal complex with a 
luminescent ammonium-binding crown ether resulted in a simple synthetic receptor with 
high affinity in buffered water for molecules bearing both functional groups. The emission 
response was triggered by the weak ammonium ion binding which only becomes possible 
intramolecularly within the assembly. The presence of just an ammonium group, even in 
large excess, does not trigger an optical output. 
 
The final project, discussed in chapter 5, combined two different metal complexes within 
one receptor molecule. Targeting a terminal histidine and a phosphorylated serine or 
thyrosine, these receptors should be able to bind phosphorylated peptides containing 
terminal histidines with very high affinities. 
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